Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Spontaneous
Pregnancy complications in acquired thrombotic thrombocytopenic purpura: a case¿control study.
Acquired Immunodeficiency Syndrome
von Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura.
Acute Chest Syndrome
Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.
Acute Coronary Syndrome
Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.
Acute Coronary Syndrome
VWF, ADAMTS13, and acute coronary syndromes.
Acute Kidney Injury
Absolute immature platelet count helps differentiate thrombotic thrombocytopenic purpura from hypertension-induced thrombotic microangiopathy.
Acute Kidney Injury
Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity.
Acute Kidney Injury
Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity: comment.
Acute Kidney Injury
Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity: reply.
Acute Kidney Injury
ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy.
Acute Kidney Injury
ADAMTS13 inhibits oxidative stress and ameliorates progressive chronic kidney disease following ischaemia/reperfusion injury.
Acute Kidney Injury
Decreased a disintegrin-like and metalloprotease with thrombospondin (ADAMTS)-13 is associated with a poor prognosis in sepsis-induced organ failure*
Acute Kidney Injury
Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure.
Acute Kidney Injury
Hereditary ADAMTS 13 deficiency presenting as recurrent acute kidney injury.
Acute Kidney Injury
High Frequency of Acquired ADAMTS13 Deficiency After Hemolysis in Hemiscorpius Lepturus (Scorpion) Stung Children.
Acute Kidney Injury
Nonsteroidal Anti-inflammatory Drug Induced Thrombotic Thrombocytopenic Purpura.
Acute Kidney Injury
Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure.
Acute Kidney Injury
Renal thrombotic microangiopathy and pulmonary arterial hypertension in a patient with late-onset cobalamin C deficiency.
Acute Kidney Injury
Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure.
Acute Kidney Injury
Thrombotic microangiopathy as first manifestation of acute human immunodeficiency virus infection: a case report and review of the literature.
Acute Lung Injury
ADAMTS-13 regulates neutrophil recruitment in a mouse model of invasive pulmonary aspergillosis.
Acute Lung Injury
[Post-transfusion acute lung injury (Trali) after plasma infusion in a patient having a constitutional thrombotic microangiopathy]
adamts13 endopeptidase deficiency
A case for consideration by apheresis practitioners: Melanoma and PD-1 inhibitor treatment in a patient with multiple relapses of immune thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
A case of severe ADAMTS13 deficiency presenting as thrombotic thrombocytopenic purpura in pregnancy.
adamts13 endopeptidase deficiency
A common origin of the 4143insA ADAMTS13 mutation.
adamts13 endopeptidase deficiency
A first case of congenital TTP on the African continent due to a new homozygous mutation in the catalytic domain of ADAMTS13.
adamts13 endopeptidase deficiency
A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome.
adamts13 endopeptidase deficiency
A modified PLASMIC score including the lactate dehydrogenase/the upper limit of normal ratio more accurately identifies Chinese thrombotic thrombocytopenic purpura patients than the original PLASMIC score.
adamts13 endopeptidase deficiency
A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13.
adamts13 endopeptidase deficiency
A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infection.
adamts13 endopeptidase deficiency
A novel homozygous missense ADAMTS13 mutation Y658C in a patient with recurrent thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B.
adamts13 endopeptidase deficiency
A perspective on the measurement of ADAMTS13 in thrombotic thrombocytopaenic purpura.
adamts13 endopeptidase deficiency
A Rare Cause of Thrombotic Thrombocytopenia Purpura- (TTP-) Like Syndrome, Vitamin B12 Deficiency: Interpretation of Significant Pathological Findings.
adamts13 endopeptidase deficiency
A recombinant human ADAMTS-13: first-in-human study evaluating pharmacokinetics, safety and tolerability in cTTP patients.
adamts13 endopeptidase deficiency
A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19.
adamts13 endopeptidase deficiency
A role for tissue plasminogen activator in thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis.
adamts13 endopeptidase deficiency
Acquired intracoronary ADAMTS13 deficiency and VWF retention at sites of critical coronary stenosis in patients with STEMI.
adamts13 endopeptidase deficiency
Acquired thrombotic thrombocytopenia purpura associated with severe ADAMTS13 deficiency in a 3-year-old boy: a case report and review of the literature.
adamts13 endopeptidase deficiency
Acquired thrombotic thrombocytopenic purpura due to antibody-mediated ADAMTS13 deficiency precipitated by a localized Castleman's disease: A case report.
adamts13 endopeptidase deficiency
Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade.
adamts13 endopeptidase deficiency
Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent.
adamts13 endopeptidase deficiency
Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS 13 assays.
adamts13 endopeptidase deficiency
ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19.
adamts13 endopeptidase deficiency
ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis.
adamts13 endopeptidase deficiency
ADAMTS-13 deficiency following Hemiscorpius lepturus scorpion sting.
adamts13 endopeptidase deficiency
ADAMTS-13 deficiency: can it cause chronic renal failure?
adamts13 endopeptidase deficiency
ADAMTS-13 level in children with severe diarrhea-associated hemolytic uremic syndrome: Unmasking new association.
adamts13 endopeptidase deficiency
ADAMTS13 activity and genetic mutations in Japan.
adamts13 endopeptidase deficiency
ADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus-related thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
ADAMTS13 activity in sickle cell disease.
adamts13 endopeptidase deficiency
ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.
adamts13 endopeptidase deficiency
ADAMTS13 activity is decreased in a septic porcine model. Significance for glomerular thrombus deposition.
adamts13 endopeptidase deficiency
ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
adamts13 endopeptidase deficiency
ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2.
adamts13 endopeptidase deficiency
ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
ADAMTS13 assays and ADAMTS13-deficient mice.
adamts13 endopeptidase deficiency
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.
adamts13 endopeptidase deficiency
ADAMTS13 controls vascular remodeling by modifying VWF reactivity during stroke recovery.
adamts13 endopeptidase deficiency
ADAMTS13 deficiency and immunological abnormalities in patients with systemic sclerosis.
adamts13 endopeptidase deficiency
ADAMTS13 Deficiency and Thrombotic Thrombocytopenic Purpura Associated with Trimethoprim-Sulfamethoxazole.
adamts13 endopeptidase deficiency
ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice.
adamts13 endopeptidase deficiency
ADAMTS13 deficiency in mice does not affect adipose tissue development.
adamts13 endopeptidase deficiency
ADAMTS13 deficiency in severe postpartum HELLP syndrome.
adamts13 endopeptidase deficiency
ADAMTS13 deficiency promotes microthrombosis in a murine model of diet-induced liver steatosis.
adamts13 endopeptidase deficiency
ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes.
adamts13 endopeptidase deficiency
ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria.
adamts13 endopeptidase deficiency
ADAMTS13 Deficiency Worsens Colitis and Exogenous ADAMTS13 Administration Decreases Colitis Severity in Mice.
adamts13 endopeptidase deficiency
ADAMTS13 deficiency, an important cause of thrombocytopenia during pregnancy.
adamts13 endopeptidase deficiency
ADAMTS13 deficiency, despite well-compensated liver functions in patients with noncirrhotic portal hypertension.
adamts13 endopeptidase deficiency
ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13.
adamts13 endopeptidase deficiency
ADAMTS13 gene deletion enhances plasma high-mobility group box1 elevation and neuroinflammation in brain ischemia-reperfusion injury.
adamts13 endopeptidase deficiency
ADAMTS13 Gene Mutations Influence ADAMTS13 Conformation and Disease Age-Onset in the French Cohort of Upshaw-Schulman Syndrome.
adamts13 endopeptidase deficiency
ADAMTS13 maintains cerebrovascular integrity to ameliorate Alzheimer-like pathology.
adamts13 endopeptidase deficiency
ADAMTS13 missense variants associated with defective activity and secretion of ADAMTS13 in a patient with non-cirrhotic portal hypertension.
adamts13 endopeptidase deficiency
ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
ADAMTS13 promotes angiogenesis and modulates VEGF-induced angiogenesis.
adamts13 endopeptidase deficiency
ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice.
adamts13 endopeptidase deficiency
ADAMTS13 Retards Progression of Diabetic Nephropathy by Inhibiting Intrarenal Thrombosis in Mice.
adamts13 endopeptidase deficiency
ADAMTS13 test and/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis.
adamts13 endopeptidase deficiency
ADAMTS13 turns 3.
adamts13 endopeptidase deficiency
ADAMTS13 unbound to larger von Willebrand factor multimers in cryosupernatant: implications for selection of plasma preparations for thrombotic thrombocytopenic purpura treatment.
adamts13 endopeptidase deficiency
ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
ADAMTS13: a new link between thrombosis and inflammation.
adamts13 endopeptidase deficiency
ADAMTS13: origins, applications, and prospects.
adamts13 endopeptidase deficiency
Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice.
adamts13 endopeptidase deficiency
Allosteric activation of ADAMTS13 by von Willebrand factor.
adamts13 endopeptidase deficiency
Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.
adamts13 endopeptidase deficiency
An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Analysis of clinical and laboratory characteristics in 42 patients with thrombotic thrombocytopenic purpura from a single center in China.
adamts13 endopeptidase deficiency
Animal models for thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
adamts13 endopeptidase deficiency
Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Antibody-mediated ADAMTS13 deficiency workup is commonly missed.
adamts13 endopeptidase deficiency
Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.
adamts13 endopeptidase deficiency
Application of PLASMIC score in prediction of ADAMTS13 deficiency in a pediatric case of acquired thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Assessing thrombocytopenia in the intensive care unit: the past, present, and future.
adamts13 endopeptidase deficiency
Assessment of ADAMTS-13 Level in Hospitalized Children with Serious Bacterial Infections as a Possible Prognostic Marker.
adamts13 endopeptidase deficiency
Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management.
adamts13 endopeptidase deficiency
Autosomal recessive inheritance of von Willebrand factor-cleaving protease deficiency.
adamts13 endopeptidase deficiency
Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Bilateral serous retinal detachment as a complication of acquired peripartum thrombotic thrombocytopenic purpura bout.
adamts13 endopeptidase deficiency
Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency.
adamts13 endopeptidase deficiency
Breast Cancer-Associated Thrombotic Microangiopathy.
adamts13 endopeptidase deficiency
Cancer-associated Microangiopathic Hemolytic Anemia with Thrombocytopenia: an important diagnostic consideration.
adamts13 endopeptidase deficiency
Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency.
adamts13 endopeptidase deficiency
Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.
adamts13 endopeptidase deficiency
Characteristics and Outcomes of Patients with Systemic Lupus Erythematosus-associated Thrombotic Microangiopathy, and Their Acquired ADAMTS13 Inhibitor Profiles.
adamts13 endopeptidase deficiency
Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
adamts13 endopeptidase deficiency
Child-onset thrombotic thrombocytopenic purpura caused by p.R498C and p.G259PfsX133 mutations in ADAMTS13.
adamts13 endopeptidase deficiency
Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features.
adamts13 endopeptidase deficiency
Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies.
adamts13 endopeptidase deficiency
Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.
adamts13 endopeptidase deficiency
Clinical and laboratory diagnosis of TTP: an integrated approach.
adamts13 endopeptidase deficiency
Clinical characteristics and outcomes of thrombotic microangiopathy in Malaysia.
adamts13 endopeptidase deficiency
Clinical features and outcomes in patients with thrombotic microangiopathy not associated with severe ADAMTS13 deficiency.
adamts13 endopeptidase deficiency
Clinical features and prognostic factors of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a literature review of 105 cases from 1999 to 2011.
adamts13 endopeptidase deficiency
Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience.
adamts13 endopeptidase deficiency
Clinical insights from observations on ADAMTS13 deficiency in liver cirrhosis.
adamts13 endopeptidase deficiency
Clinical utility of ADAMTS-13 testing in suspected thrombotic microangiopathy: an audit of ADAMTS-13 activity assay requests in routine practice from a tertiary hospital.
adamts13 endopeptidase deficiency
Comparison of Clinical Scoring Systems in the Management of Patients with Microangiopathic Hemolytic Anemia and Thrombocytopenia
adamts13 endopeptidase deficiency
Complement Activation Associated with ADAMTS13 Deficiency in Human and Murine Thrombotic Microangiopathy.
adamts13 endopeptidase deficiency
Complement activation associated with ADAMTS13 deficiency may contribute to the characteristic glomerular manifestations in Upshaw-Schulman syndrome.
adamts13 endopeptidase deficiency
Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies.
adamts13 endopeptidase deficiency
Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies.
adamts13 endopeptidase deficiency
Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement.
adamts13 endopeptidase deficiency
Complete ADAMTS13 remission in a patient with refractory autoimmune-mediated thrombotic thrombocytopenic purpura after infliximab.
adamts13 endopeptidase deficiency
Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Congenital ADAMTS-13 deficiency presenting as life-threatening thrombosis during pregnancy.
adamts13 endopeptidase deficiency
Congenital ADAMTS13 Deficiency: A Rare Mimicker of Immune Thrombocytopenic Purpura.
adamts13 endopeptidase deficiency
Congenital and acquired ADAMTS13 deficiency: Two mechanisms, one patient.
adamts13 endopeptidase deficiency
Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the ADAMTS13 gene.
adamts13 endopeptidase deficiency
Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes.
adamts13 endopeptidase deficiency
Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.
adamts13 endopeptidase deficiency
Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Current concepts in thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Current insight into thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Current insights into thrombotic microangiopathies: Thrombotic thrombocytopenic purpura and pregnancy.
adamts13 endopeptidase deficiency
Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Current management of thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Cyclosporin A impairs the secretion and activity of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat).
adamts13 endopeptidase deficiency
Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature.
adamts13 endopeptidase deficiency
De Novo Mutation of the ADAMTS13 Gene with Mesenteric Ischemia in an Infant with Congenital Thrombotic Thrombocytopenic Purpura.
adamts13 endopeptidase deficiency
Decreased a disintegrin-like and metalloprotease with thrombospondin (ADAMTS)-13 is associated with a poor prognosis in sepsis-induced organ failure*
adamts13 endopeptidase deficiency
Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure.
adamts13 endopeptidase deficiency
Deficiency of ADAMTS-13 in pediatric patients with severe sepsis and impact on in-hospital mortality.
adamts13 endopeptidase deficiency
Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study.
adamts13 endopeptidase deficiency
Development and validation of a multivariable prediction rule for detecting a severe acquired ADAMTS13 activity deficiency in patients with thrombotic microangiopathies.
adamts13 endopeptidase deficiency
Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.
adamts13 endopeptidase deficiency
Development of a severe von Willebrand factor/ADAMTS13 dysbalance during orthotopic liver transplantation.
adamts13 endopeptidase deficiency
Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes.
adamts13 endopeptidase deficiency
Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes.
adamts13 endopeptidase deficiency
Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Difficulties in diagnosing congenital thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Disseminated intravascular coagulation: is it fact or fancy?
adamts13 endopeptidase deficiency
Does corticosteroid treatment cause prolonged recovery and increased total bilirubin level in severe ADAMTS-13-deficient TTP patient?
adamts13 endopeptidase deficiency
Does severe ADAMTS13 deficiency in thrombotic microangiopathy rule out complement-mediated atypical hemolytic uremic syndrome.
adamts13 endopeptidase deficiency
Dynamic changes in absolute immature platelet count suggest the presence of a coexisting immune process in the setting of thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.
adamts13 endopeptidase deficiency
Early response to caplacizumab and rituximab after anaphylaxis to Octaplas plasma in a patient with thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Effects of naturally occurring mutations in CUB-1 domain on synthesis, stability, and activity of ADAMTS-13.
adamts13 endopeptidase deficiency
Efficacy and Safety Profile of Solvent/Detergent Plasma in the Treatment of Acute Thrombotic Thrombocytopenic Purpura: A Single-Center Experience.
adamts13 endopeptidase deficiency
Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis.
adamts13 endopeptidase deficiency
Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.
adamts13 endopeptidase deficiency
Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Evaluating the impact of the ABO blood group on the clinical outcome of thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency.
adamts13 endopeptidase deficiency
Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13).
adamts13 endopeptidase deficiency
Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.
adamts13 endopeptidase deficiency
Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Expression and characterization of recombinant human ADAMTS-13.
adamts13 endopeptidase deficiency
External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment.
adamts13 endopeptidase deficiency
Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins.
adamts13 endopeptidase deficiency
Fatal case of chikungunya and concomitant thrombotic thrombocytopenic purpura in French Guiana during air flight medical evacuation.
adamts13 endopeptidase deficiency
Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin.
adamts13 endopeptidase deficiency
FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients.
adamts13 endopeptidase deficiency
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.
adamts13 endopeptidase deficiency
From humoral rejection to generalized thrombotic microangiopathy--role of acquired ADAMTS13 deficiency in a renal allograft recipient.
adamts13 endopeptidase deficiency
Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura.
adamts13 endopeptidase deficiency
Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease.
adamts13 endopeptidase deficiency
Hematocrit and C-reactive protein predict treatment response times in ADAMTS13-deficient thrombotic microangiopathy.
adamts13 endopeptidase deficiency
Hemolytic uremic syndrome with Mycoplasma pneumoniae infection and membrane cofactor protein mutation case report.
adamts13 endopeptidase deficiency
Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis.
adamts13 endopeptidase deficiency
Hereditary ADAMTS 13 deficiency presenting as recurrent acute kidney injury.
adamts13 endopeptidase deficiency
High Frequency of Acquired ADAMTS13 Deficiency After Hemolysis in Hemiscorpius Lepturus (Scorpion) Stung Children.
adamts13 endopeptidase deficiency
Highly elevated plasma level of von Willebrand factor accelerates the formation of platelet thrombus under high shear stress in plasma with deficient ADAMTS13 activity.
adamts13 endopeptidase deficiency
How I treat patients with thrombotic thrombocytopenic purpura - 2010.
adamts13 endopeptidase deficiency
Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity.
adamts13 endopeptidase deficiency
Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Idiopathic Noncirrhotic Intrahepatic Portal Hypertension is Associated with Sustained ADAMTS13 Deficiency.
adamts13 endopeptidase deficiency
Immature platelet dynamics correlate with ADAMTS13 deficiency and predict therapy response in immune-mediated thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Impact of a multidisciplinary team for the management of thrombotic microangiopathy.
adamts13 endopeptidase deficiency
Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative.
adamts13 endopeptidase deficiency
Implementation of a rapid assay of ADAMTS13 activity was associated with improved 30-day survival rate in patients with acquired primary thrombotic thrombocytopenic purpura who received platelet transfusions.
adamts13 endopeptidase deficiency
In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Increased urinary albumin excretion following recovery from thrombotic thrombocytopenic purpura due to acquired ADAMTS13 deficiency.
adamts13 endopeptidase deficiency
Increased Von Willebrand factor, decreased ADAMTS13 and thrombocytopenia in melioidosis.
adamts13 endopeptidase deficiency
Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis.
adamts13 endopeptidase deficiency
Indicators Differentiating Thrombotic Thrombocytopenic Purpura From Other Thrombotic Microangiopathies in a Canadian Apheresis Referral Center.
adamts13 endopeptidase deficiency
Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor.
adamts13 endopeptidase deficiency
Influence of ADAMTS13 deficiency on venous thrombosis in mice.
adamts13 endopeptidase deficiency
Inherited ADAMTS13 deficiency (Upshaw-Schulman syndrome): a short review.
adamts13 endopeptidase deficiency
Inherited ADAMTS13 deficiency: unique presentation and treatment.
adamts13 endopeptidase deficiency
Inherited ADAMTS13 deficiency: Unique presentation and treatment.
adamts13 endopeptidase deficiency
Inherited Thrombotic Thrombocytopenic Purpura (Upshaw Schulman Syndrome) as Differential Diagnosis to Neonatal Septicaemia with Disseminated Intravascular Coagulation - a Case Series.
adamts13 endopeptidase deficiency
Inherited thrombotic thrombocytopenic purpura in pregnancy.
adamts13 endopeptidase deficiency
Inhibitory anti ADAMTS13 antibodies with a new rapid fully automated CLiA assay.
adamts13 endopeptidase deficiency
Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.
adamts13 endopeptidase deficiency
Insights into 3D Structure of ADAMTS13: A Stepping Stone towards Novel Therapeutic Treatment of Thrombotic Thrombocytopenic Purpura.
adamts13 endopeptidase deficiency
Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis.
adamts13 endopeptidase deficiency
Interferon-? is not elevated in idiopathic thrombotic thrombocytopenic purpura patients.
adamts13 endopeptidase deficiency
Invited commentary to: ADAMTS13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19 by Tiffany Pascreau et al. Letter to the Editors-in-Chief, Thrombosis Research.
adamts13 endopeptidase deficiency
Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No.
adamts13 endopeptidase deficiency
Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency?
adamts13 endopeptidase deficiency
Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13.
adamts13 endopeptidase deficiency
Lessons learned from the Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry.
adamts13 endopeptidase deficiency
Letter by Hugenholtz and Lisman regarding article, "plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy".
adamts13 endopeptidase deficiency
Limited renal prophylaxis in regular plasmatherapy for heritable ADAMTS13 deficiency.
adamts13 endopeptidase deficiency
Link between von Willebrand factor multimers, relapses and coronary microcirculation in patients with thrombotic thrombocytopenic purpura in remission.
adamts13 endopeptidase deficiency
Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Macrovascular thrombosis in critically ill patients with thrombotic micro-angiopathies.
adamts13 endopeptidase deficiency
Malignant Hypertension with Thrombotic Microangiopathy.
adamts13 endopeptidase deficiency
Management of thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Measurement of ADAMTS13 activity and inhibitors.
adamts13 endopeptidase deficiency
Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods.
adamts13 endopeptidase deficiency
Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity.
adamts13 endopeptidase deficiency
Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome.
adamts13 endopeptidase deficiency
Modifier genes for disorders of thrombosis and hemostasis.
adamts13 endopeptidase deficiency
Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation.
adamts13 endopeptidase deficiency
Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency.
adamts13 endopeptidase deficiency
Myocardial infarction is a complication of factor H-associated atypical HUS.
adamts13 endopeptidase deficiency
Neutrophil Protease Cleavage of Von Willebrand Factor in Glomeruli - An Anti-thrombotic Mechanism in the Kidney.
adamts13 endopeptidase deficiency
Non-O blood group thrombotic thrombocytopenic purpura patients take longer to recover as measured by number of therapeutic plasma exchanges needed for platelet recovery.
adamts13 endopeptidase deficiency
Nonsense-mediated mRNA decay in the ADAMTS13 gene caused by a 29-nucleotide deletion.
adamts13 endopeptidase deficiency
Novel ADAMTS13 mutations in an obstetric patient with upshaw-schulman syndrome.
adamts13 endopeptidase deficiency
Novel, semi-automated, 60-min-assay to determine von Willebrand factor cleaving activity of ADAMTS-13.
adamts13 endopeptidase deficiency
Orthotopic liver transplantation (OLTx) in non-cirrhotic portal hypertension secondary to ADAMTS13 deficiency.
adamts13 endopeptidase deficiency
Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports.
adamts13 endopeptidase deficiency
Paradigm shift of childhood thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency.
adamts13 endopeptidase deficiency
Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome.
adamts13 endopeptidase deficiency
Pathogenesis of thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.
adamts13 endopeptidase deficiency
Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
adamts13 endopeptidase deficiency
Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
adamts13 endopeptidase deficiency
Pathophysiology of thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease).
adamts13 endopeptidase deficiency
Pediatric thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort.
adamts13 endopeptidase deficiency
Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency.
adamts13 endopeptidase deficiency
Plasmic score applicability for the diagnosis of thrombotic microangiopathy associated with ADAMTS13-acquired deficiency in a developing country.
adamts13 endopeptidase deficiency
Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy.
adamts13 endopeptidase deficiency
Platelet Reactive Conformation and Multimeric Pattern of von Willebrand Factor in Acquired Thrombotic Thrombocytopenic Purpura During Acute Disease and Remission.
adamts13 endopeptidase deficiency
Platelet rescue by macrophage depletion in obese ADAMTS-13-deficient mice at risk of thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Platelets: thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Porto-pulmonary hypertension exacerbated by platelet transfusion in a patient with ADAMTS13 deficiency.
adamts13 endopeptidase deficiency
Post-partum management in a patient affected by thrombotic thrombocytopenic purpura: case report and review of literature.
adamts13 endopeptidase deficiency
Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review.
adamts13 endopeptidase deficiency
Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience.
adamts13 endopeptidase deficiency
Predictive Value of Schistocytes in Recurrence of Acquired Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency at Discontinuation of Daily Therapeutic Plasma Exchange.
adamts13 endopeptidase deficiency
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Presence of ADAMTS13 activity in a patient with metastatic cancer and thrombotic microangiopathy.
adamts13 endopeptidase deficiency
Presence of anti-ADAMTS13 antibodies in obesity.
adamts13 endopeptidase deficiency
Preserved Expression of mRNA Coding von Willebrand Factor-Cleaving Protease ADAMTS13 by Selenite and Activated Protein C.
adamts13 endopeptidase deficiency
Prevention of relapse in patients with acquired thrombotic thrombocytopenic purpura undergoing elective surgery: a case series.
adamts13 endopeptidase deficiency
Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Recent advances in thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases.
adamts13 endopeptidase deficiency
Refractory thrombotic thrombocytopenic purpura associated with oral contraceptives and factor V Leiden: a case report.
adamts13 endopeptidase deficiency
Refractory thrombotic thrombocytopenic purpura following influenza vaccination.
adamts13 endopeptidase deficiency
Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab.
adamts13 endopeptidase deficiency
Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma.
adamts13 endopeptidase deficiency
Response to letter regarding article, "plasmin cleavage of von willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy".
adamts13 endopeptidase deficiency
Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura.
adamts13 endopeptidase deficiency
Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature.
adamts13 endopeptidase deficiency
Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature.
adamts13 endopeptidase deficiency
Rituximab in a child with autoimmune thrombotic thrombocytopenic purpura refractory to plasma exchange.
adamts13 endopeptidase deficiency
Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan.
adamts13 endopeptidase deficiency
Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib.
adamts13 endopeptidase deficiency
Role of ADAMTS13 in diet-induced liver steatosis.
adamts13 endopeptidase deficiency
Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
adamts13 endopeptidase deficiency
Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Role of CD40 and ADAMTS13 in von Willebrand factor-mediated endothelial cell-platelet-monocyte interaction.
adamts13 endopeptidase deficiency
Schistocytic anaemia, severe thrombocytopenia, and renal dysfunction: thrombotic microangiopathy due to severe acquired ADAMTS-13 deficiency. Case 2.
adamts13 endopeptidase deficiency
Secondary thrombotic microangiopathy with severely reduced ADAMTS13 activity in a patient with Capnocytophaga canimorsus sepsis: a case report.
adamts13 endopeptidase deficiency
Sepsis-Induced Disseminated Intravascular Coagulation With Features of Thrombotic Thrombocytopenic Purpura: a Fatal Fulminant Syndrome.
adamts13 endopeptidase deficiency
Severe ADAMTS-13 deficiency in childhood.
adamts13 endopeptidase deficiency
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.
adamts13 endopeptidase deficiency
Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome.
adamts13 endopeptidase deficiency
Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients.
adamts13 endopeptidase deficiency
Severe Hemolysis and Pulmonary Hypertension in a Neonate With Upshaw-Schulman Syndrome.
adamts13 endopeptidase deficiency
Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure.
adamts13 endopeptidase deficiency
Severe transient ADAMTS13 deficiency in pneumococcal-associated hemolytic uremic syndrome.
adamts13 endopeptidase deficiency
Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice.
adamts13 endopeptidase deficiency
Short- and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: four case reports.
adamts13 endopeptidase deficiency
Silent Thrombotic Thrombocytopenic Purpura: PLASMIC, Lessons Learned, and Current Management Overview.
adamts13 endopeptidase deficiency
Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.
adamts13 endopeptidase deficiency
Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.
adamts13 endopeptidase deficiency
Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Spontaneous recovery in a patient with acquired thrombotic thrombocytopenic purpura (TTP): observation of a 'subclinical' TTP state.
adamts13 endopeptidase deficiency
STEC-HUS, atypical HUS and TTP are all diseases of complement activation.
adamts13 endopeptidase deficiency
Structural and functional correlation of ADAMTS13.
adamts13 endopeptidase deficiency
Successful treatment of neonatal atypical hemolytic uremic syndrome with C5 monoclonal antibody.
adamts13 endopeptidase deficiency
Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: A pediatric report and literature review.
adamts13 endopeptidase deficiency
Survival and relapse in patients with thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.
adamts13 endopeptidase deficiency
Synergistic interactions between interferon-gamma and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis.
adamts13 endopeptidase deficiency
Systemic antithrombotic effects of ADAMTS13.
adamts13 endopeptidase deficiency
Systemic infections mimicking thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies.
adamts13 endopeptidase deficiency
Ten patient stories illustrating the extraordinarily diverse clinical features of patients with thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency.
adamts13 endopeptidase deficiency
The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission.
adamts13 endopeptidase deficiency
The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure?
adamts13 endopeptidase deficiency
The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis.
adamts13 endopeptidase deficiency
The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine.
adamts13 endopeptidase deficiency
The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
The function of ADAMTS13 in thrombogenesis in vivo: insights from mutant mice.
adamts13 endopeptidase deficiency
The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency.
adamts13 endopeptidase deficiency
The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS.
adamts13 endopeptidase deficiency
The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: the Swiss connection.
adamts13 endopeptidase deficiency
The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation.
adamts13 endopeptidase deficiency
The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective.
adamts13 endopeptidase deficiency
The role of ADAMTS-13 in the coagulopathy of sepsis.
adamts13 endopeptidase deficiency
The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
adamts13 endopeptidase deficiency
The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs.
adamts13 endopeptidase deficiency
The thrombotic microangiopathies.
adamts13 endopeptidase deficiency
The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007.
adamts13 endopeptidase deficiency
The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: overview of pathogenesis (Experience of The Oklahoma TTP-HUS Registry, 1989-2007).
adamts13 endopeptidase deficiency
The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange.
adamts13 endopeptidase deficiency
Thrombocytopenia and severe hyperbilirubinemia in the neonatal period secondary to congenital thrombotic thrombocytopenic purpura and ADAMTS13 deficiency.
adamts13 endopeptidase deficiency
Thrombocytopenia in hospitalized patients: approach to the patient with thrombotic microangiopathy.
adamts13 endopeptidase deficiency
Thrombogenesis and thrombotic disorders based on 'two-path unifying theory of hemostasis': philosophical, physiological, and phenotypical interpretation.
adamts13 endopeptidase deficiency
Thrombospondin-1 and ADAMTS13 competitively bind to VWF A2 and A3 domains in vitro.
adamts13 endopeptidase deficiency
Thrombotic microangiopathies: towards a pathophysiology-based classification.
adamts13 endopeptidase deficiency
Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis.
adamts13 endopeptidase deficiency
Thrombotic microangiopathy with acquired deficiency in ADAMTS 13 activity in lung transplant recipients.
adamts13 endopeptidase deficiency
Thrombotic thrombocytopenic purpura and acquired immunodeficiency syndrome diagnosed in pregnancy: Case report.
adamts13 endopeptidase deficiency
Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor.
adamts13 endopeptidase deficiency
Thrombotic thrombocytopenic purpura developed during the conservative treatment of anti-phospholipase A2 receptor antibody-positive idiopathic membranous nephropathy: a case report.
adamts13 endopeptidase deficiency
Thrombotic thrombocytopenic purpura in a patient with rapidly progressive glomerulonephritis with both anti-glomerular basement membrane antibodies and myeloperoxidase anti-neutrophil cytoplasmic antibodies.
adamts13 endopeptidase deficiency
Thrombotic thrombocytopenic purpura in humans and mice.
adamts13 endopeptidase deficiency
Thrombotic thrombocytopenic purpura related to ADAMTS13 deficiency, and successful treatment in a chimpanzee (Pan troglodytes verus).
adamts13 endopeptidase deficiency
Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children.
adamts13 endopeptidase deficiency
Thrombotic Thrombocytopenic Purpura with Severe ADAMTS-13 Deficiency in a Patient with Antiphospholipid Antibodies and Charcot-Marie-Tooth Disease.
adamts13 endopeptidase deficiency
Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome.
adamts13 endopeptidase deficiency
Thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Thrombotic thrombocytopenic purpura: a moving target.
adamts13 endopeptidase deficiency
Thrombotic thrombocytopenic purpura: A rare complication of acute pancreatitis.
adamts13 endopeptidase deficiency
Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.
adamts13 endopeptidase deficiency
Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies.
adamts13 endopeptidase deficiency
Thrombotic thrombocytopenic purpura: from diagnosis to therapy.
adamts13 endopeptidase deficiency
Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management.
adamts13 endopeptidase deficiency
Thrombotic thrombocytopenic purpura: proposal of a new pathogenic mechanism involving Helicobacter pylori infection.
adamts13 endopeptidase deficiency
Thrombotic thromboytopenic purpura: another example of immunomediated thrombosis.
adamts13 endopeptidase deficiency
Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms.
adamts13 endopeptidase deficiency
Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange.
adamts13 endopeptidase deficiency
Treatment with or without plasma exchange for patients with acquired thrombotic microangiopathy not associated with severe ADAMTS13 deficiency: a propensity score-matched study.
adamts13 endopeptidase deficiency
TTP and ADAMTS13: When Is Testing Appropriate?
adamts13 endopeptidase deficiency
TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease.
adamts13 endopeptidase deficiency
TTP/HUS and prognosis: the syndrome and the disease(s).
adamts13 endopeptidase deficiency
Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.
adamts13 endopeptidase deficiency
Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment.
adamts13 endopeptidase deficiency
Two generations with familial thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS).
adamts13 endopeptidase deficiency
Ultralarge von Willebrand factor multimers and normal ADAMTS13 activity in the umbilical cord blood.
adamts13 endopeptidase deficiency
Unbalanced expression of ADAMTS13 and von Willebrand factor in mouse endotoxinemia.
adamts13 endopeptidase deficiency
Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Unique case of autoantibody mediated inactivation of ADAMTS13 in an Indian TTP patient.
adamts13 endopeptidase deficiency
Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions.
adamts13 endopeptidase deficiency
Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy.
adamts13 endopeptidase deficiency
Validation of PLASMIC score: an academic medical center case series (2012-present).
adamts13 endopeptidase deficiency
Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, Canada.
adamts13 endopeptidase deficiency
Validation of the PLASMIC score, a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis, in Chinese patients.
adamts13 endopeptidase deficiency
Von Willebrand factor and ADAMTS13 impact on the outcome of Staphylococcus aureus sepsis.
adamts13 endopeptidase deficiency
von Willebrand factor and thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis).
adamts13 endopeptidase deficiency
von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
adamts13 endopeptidase deficiency
Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
von Willebrand factor, von Willebrand factor-cleaving protease, and shear stress.
adamts13 endopeptidase deficiency
von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience.
adamts13 endopeptidase deficiency
Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory.
adamts13 endopeptidase deficiency
von Willebrand factor-cleaving protease (ADAMTS13) in the course of stem cell transplantation.
adamts13 endopeptidase deficiency
Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.
adamts13 endopeptidase deficiency
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
adamts13 endopeptidase deficiency
VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.
adamts13 endopeptidase deficiency
What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura.
adamts13 endopeptidase deficiency
[A child with relapsing haemolytic anemia and thrombocytopenia]
adamts13 endopeptidase deficiency
[Acquired idiopathic thrombotic thrombocytopenic purpura: arguments for an autoimmune disease]
adamts13 endopeptidase deficiency
[Acute renal failure and thrombotic microangiopathy (TM)]
adamts13 endopeptidase deficiency
[Atypical hemolytic and uremic syndrome associated with von Willebrand factor-cleaving protease (ADAMTS 13) deficiency in children].
adamts13 endopeptidase deficiency
[Determination of the ADAMTS13 antigen and its activity in TTP patients and carriers]
adamts13 endopeptidase deficiency
[Diagnosis of thrombotic thrombocytopenic purpura].
adamts13 endopeptidase deficiency
[Efficacy of eculizumab in a case of pregnancy-associated aHUS].
adamts13 endopeptidase deficiency
[Frontline clinical practice for thrombotic thrombocytopenic purpura].
adamts13 endopeptidase deficiency
[Genetic polymorphism of von Willebrand factor (VWF)-cleaving protease, ADAMTS13]
adamts13 endopeptidase deficiency
[Hemolytic and uremic syndrome in the child]
adamts13 endopeptidase deficiency
[Platelet--vessel wall interactions]
adamts13 endopeptidase deficiency
[Post-transfusion acute lung injury (Trali) after plasma infusion in a patient having a constitutional thrombotic microangiopathy]
adamts13 endopeptidase deficiency
[Thrombotic thrombocytopenic purpura: Do not ignore cardiac involvement.]
adamts13 endopeptidase deficiency
[Transplantation related ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: a case report and literature review].
adamts13 endopeptidase deficiency
[Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point].
adamts13 endopeptidase deficiency
[Von Willebrand factor and ADAMTS13 balancing primary haemostasis.]
Albuminuria
Therapeutic application of recombinant human ADAMTS-13 improves shock reversal and coagulation status in a trauma hemorrhage and transfusion rat model.
Anemia
A Case of Thrombotic Thrombocytopenia Purpura Associated with Systemic Lupus Erythematosus: Diagnostic Utility of ADAMTS-13 Activity.
Anemia
A journey from sickle cell anemia to ADAMTS13.
Anemia
Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis.
Anemia
C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction.
Anemia
Clinical application of a rapid method using agarose gel electrophoresis and Western blotting to evaluate von Willebrand factor protease activity.
Anemia
Early response to caplacizumab and rituximab after anaphylaxis to Octaplas plasma in a patient with thrombotic thrombocytopenic purpura.
Anemia
Hereditary Thrombotic Thrombocytopenic Purpura in a 9-Month Old: Diagnosing and Managing an Ultra-rare Disorder.
Anemia
Microangiopathic Hemolytic Anemia Due to ADAMTS-13 Loss in Idiopathic Systemic Capillary Leak Syndrome.
Anemia
Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura.
Anemia
Prasugrel and Acquired Thrombotic Thrombocytopenic Purpura Associated with ADAMTS13 Activity Deficiency.
Anemia
Presumed complement-mediated, checkpoint inhibitor-induced, thrombotic microangiopathy in a patient with metastatic melanoma.
Anemia
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
Anemia
Schistocytic anaemia, severe thrombocytopenia, and renal dysfunction: thrombotic microangiopathy due to severe acquired ADAMTS-13 deficiency. Case 2.
Anemia
Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: Diagnosis and classification.
Anemia
[A CASE REPORT OF THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN A BREAST CANCER PATIENT].
Anemia, Hemolytic
A case of pregnancy-induced thrombotic thrombocytopenic purpura with a kidney allograft recipient.
Anemia, Hemolytic
ADAMTS-13 activity, microangiopathic haemolytic anaemia and thrombocytopenia following snake bite envenomation.
Anemia, Hemolytic
ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura.
Anemia, Hemolytic
An Imperfect Marker: SLE and TTP-Like MAHA Without Low ADAMTS13.
Anemia, Hemolytic
Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes.
Anemia, Hemolytic
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Anemia, Hemolytic
Case Report: Microangiopathic Hemolytic Anemia With Normal ADAMTS13 Activity.
Anemia, Hemolytic
Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura.
Anemia, Hemolytic
Congenital ADAMTS13 Deficiency: A Rare Mimicker of Immune Thrombocytopenic Purpura.
Anemia, Hemolytic
Congenital microangiopathic hemolytic anemia and thrombocytopenia with unusually large von Willebrand factor multimers and von Willebrand factor-cleaving protease.
Anemia, Hemolytic
Congenital Thrombotic Thrombocytopenic Purpura: Atypical Presentation and New ADAMTS 13 Mutation in a Tunisian Child.
Anemia, Hemolytic
Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
Anemia, Hemolytic
EB virus reactivation triggers thrombotic thrombocytopenic purpura in a healthy adult.
Anemia, Hemolytic
Impact of a multidisciplinary team for the management of thrombotic microangiopathy.
Anemia, Hemolytic
Infection as Trigger for Congenital Thrombotic Thrombocytopenic Purpura in an Adult Patient.
Anemia, Hemolytic
Inherited thrombotic thrombocytopenic purpura mimicking immune thrombocytopenic purpura during pregnancy: a case report.
Anemia, Hemolytic
Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?
Anemia, Hemolytic
Long-term response to rituximab in patients with relapsing thrombotic thrombocytopenic purpura.
Anemia, Hemolytic
Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease.
Anemia, Hemolytic
Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13.
Anemia, Hemolytic
Microangiopathic Hemolytic Anemia Due to ADAMTS-13 Loss in Idiopathic Systemic Capillary Leak Syndrome.
Anemia, Hemolytic
Microangiopathic hemolytic anemia due to ADAMTS-13 loss in idiopathic systemic capillary leak syndrome: comment.
Anemia, Hemolytic
Microangiopathic hemolytic anemia due to ADAMTS-13 loss in idiopathic systemic capillary leak syndrome: reply.
Anemia, Hemolytic
Nivolumab-Induced Thrombotic Thrombocytopenic Purpura in a Patient with Anal Squamous Cell Carcinoma: A Lesson on Hematologic Toxicity from Immunotherapy.
Anemia, Hemolytic
Novel therapies in thrombotic thrombocytopenic purpura.
Anemia, Hemolytic
Pathophysiology of thrombotic thrombocytopenic purpura.
Anemia, Hemolytic
Postoperative hemolytic uremic syndrome with renal cortical necrosis following laparoscopic hemicolectomy.
Anemia, Hemolytic
Predictive Value of Schistocytes in Recurrence of Acquired Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency at Discontinuation of Daily Therapeutic Plasma Exchange.
Anemia, Hemolytic
Pregnancy-associated thrombotic thrombocytopenic purpura with anti-centromere antibody-positive Raynaud's Syndrome.
Anemia, Hemolytic
Rapid ADAMTS13 availability impacts treatment for microangiopathic hemolytic anemia and thrombocytopenia.
Anemia, Hemolytic
Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura.
Anemia, Hemolytic
Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura.
Anemia, Hemolytic
Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.
Anemia, Hemolytic
Siblings with congenital thrombotic thrombocytopenic purpura.
Anemia, Hemolytic
Spontaneous recovery in a patient with acquired thrombotic thrombocytopenic purpura (TTP): observation of a 'subclinical' TTP state.
Anemia, Hemolytic
The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical andin silico study.
Anemia, Hemolytic
The features of acquired thrombotic thrombocytopenic purpura occurring at advanced age.
Anemia, Hemolytic
Therapeutic plasma exchange in thrombotic thrombocytopenic purpura.
Anemia, Hemolytic
Thrombotic microangiopathic hemolytic anemia with reduction of ADAMTS13 activity: initial manifestation of childhood-onset systemic lupus erythematosus.
Anemia, Hemolytic
Thrombotic microangiopathy as first manifestation of acute human immunodeficiency virus infection: a case report and review of the literature.
Anemia, Hemolytic
Thrombotic thrombocytopenic purpura associated to dual checkpoint inhibitor therapy for metastatic melanoma.
Anemia, Hemolytic
Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus).
Anemia, Hemolytic
Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.
Anemia, Hemolytic
Two novel mutations in ADAMTS13 in a Chinese boy with congenital thrombocytopenic purpura: a case report.
Anemia, Hemolytic
Utilizing a PLASMIC score-based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative.
Anemia, Hemolytic
Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory.
Anemia, Hemolytic
What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura.
Anemia, Hemolytic
[Activity loss of Von Willebrand factor cleaving protein (ADAMTS-13) is diagnostic for primary and pregnancy-related thrombotic thrombocytopenic purpura]
Anemia, Hemolytic
[ADAMTS13, von Willebrand factor specific cleaving protease].
Anemia, Hemolytic
[Analysis of five children with acquired thrombotic thrombocytopenic purpura].
Anemia, Hemolytic
[Clinical Analysis of 12 cases of Systemic Lupus Erythematosus Associated with Thrombotic Thrombocytopenic Purpura].
Anemia, Hemolytic
[Clopidogrel-associated thrombotic thrombocytopenic purpura].
Anemia, Hemolytic
[Diagnosis and treatment of thrombotic thrombocytopenic purpura].
Anemia, Hemolytic
[Exacerbation of cranial nerurological symptoms by platelet transfusion before the diagnosis of thrombotic thrombocytopenic purpura].
Anemia, Hemolytic
[Frontline clinical practice for thrombotic thrombocytopenic purpura].
Anemia, Hemolytic
[Thrombotic thrombocytopenic purpura after circumcision].
Anemia, Hemolytic
[Thrombotic thrombocytopenic purpura during pregnancy refractory to plasma exchange and rituximab].
Anemia, Hemolytic
[Variety of thrombotic thrombocytopenic purpura clinical course in Polish family members with ADAMTS 13 gene mutation].
Anemia, Macrocytic
ADAMTS-13 deficiency: can it cause chronic renal failure?
Anemia, Pernicious
Association of acquired thrombotic thrombocytopaenic purpura in a patient with pernicious anaemia.
Anemia, Sickle Cell
A journey from sickle cell anemia to ADAMTS13.
Anemia, Sickle Cell
Absence of exaggerated pharmacology by recombinant ADAMTS13 in the rat and monkey.
Anemia, Sickle Cell
ADAMTS13 activity in sickle cell disease.
Anemia, Sickle Cell
ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso-occlusive crisis of sickle cell disease.
Anemia, Sickle Cell
Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.
Anemia, Sickle Cell
Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease.
Anemia, Sickle Cell
Relationship of Thrombospondin 1 to von Willebrand Factor and ADAMTS-13 in Sickle Cell Disease Patients of Arab Ethnicity.
Anemia, Sickle Cell
Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease.
Aneurysm
Expression and significance of vWF, GMP-140 and ADAMTS13 in patients with aneurysmal subarachnoid hemorrhage.
Angina, Unstable
Association of the von Willebrand Factor-ADAMTS13 Ratio With Incident Cardiovascular Events in Patients With Peripheral Arterial Disease.
Angina, Unstable
Changes in plasma von Willebrand factor-cleaving protease (ADAMTS13) levels in patients with unstable angina.
Angina, Unstable
Prothrombotic response to coronary angioplasty in patients with unstable angina and raised C-reactive protein.
Anthrax
Degradation of Circulating von Willebrand Factor and Its Regulator ADAMTS13 Implicates Secreted Bacillus anthracis Metalloproteases in Anthrax Consumptive Coagulopathy.
Anti-Glomerular Basement Membrane Disease
Goodpasture's syndrome associated with thrombotic thrombocytopenic purpura secondary to an ADAMTS-13 deficit.
Antiphospholipid Syndrome
ADAMTS-13 gene expression in antiphospholipid syndrome.
Antiphospholipid Syndrome
ADAMTS-13 metalloprotease abnormalities in systemic lupus erythematosus: is there a correlation with disease status?
Antiphospholipid Syndrome
Early ADAMTS13 testing associates with pre-eclampsia occurrence in antiphospholipid syndrome.
Antiphospholipid Syndrome
Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group.
Antiphospholipid Syndrome
Plasma ADAMTS13, von Willebrand Factor (VWF), and VWF Propeptide Profiles in Patients With Connective Tissue Diseases and Antiphospholipid Syndrome.
Antiphospholipid Syndrome
The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction.
Antiphospholipid Syndrome
Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome.
Aortic Valve Stenosis
Changes in von Willebrand factor-cleaving protease (ADAMTS-13) in patients with aortic stenosis undergoing valve replacement or balloon valvuloplasty.
Aortic Valve Stenosis
Shear stress and von Willebrand factor in health and disease.
Arthritis
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.
Arthritis, Rheumatoid
Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases.
Astrocytoma
IL-1? Down-Regulates ADAMTS-13 mRNA Expression in Cells of the Central Nervous System.
Atherosclerosis
ADAMTS13 modulates atherosclerotic plaque progression in mice via a VWF-dependent mechanism.
Atherosclerosis
ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice.
Atherosclerosis
Association of a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 polymorphisms with severity of coronary stenosis in type 2 diabetes mellitus.
Atherosclerosis
Genetic ablation of Adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model.
Atherosclerosis
Inverse correlations between serum ADAMTS13 levels and systolic blood pressure, pulse pressure, and serum C-reactive protein levels observed at a general health examination in a Japanese population: A cross-sectional study.
Atherosclerosis
Inverse Regulation of Confluence-Dependent ADAMTS13 and von Willebrand Factor Expression in Human Endothelial Cells.
Atherosclerosis
Role of CD40 and ADAMTS13 in von Willebrand factor-mediated endothelial cell-platelet-monocyte interaction.
Atherosclerosis
Simvastatin Increases ADAMTS13 Expression in Podocytes.
Atrial Fibrillation
ADAMTS13--more than just TMA and TTP.
Atrial Fibrillation
Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation.
Atrial Fibrillation
Correlation analysis between ADAMTS-13 gene polymorphism and hypertension-induced atrial fibrillation.
Atrial Fibrillation
Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation.
Atrial Fibrillation
Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation.
Atrial Fibrillation
The Value of ADAMTS13 in Predicting Clinical Outcomes in Patients With Acute Ischemic Stroke Receiving Thrombolysis.
Atrial Fibrillation
Verification of the Role of ADAMTS13 in the Cardiovascular Disease Using Two-Sample Mendelian Randomization.
Atrial Fibrillation
Von Willebrand Factor and ADAMTS13 as Predictors of Adverse Outcomes in Patients With Nonvalvular Atrial Fibrillation.
Atrial Fibrillation
Von Willebrand factor and ADAMTS13 plasma in older patients with high CHA2DS2-VASc Score with and without atrial fibrillation.
Atrial Fibrillation
Von Willebrand Factor: Multimeric Structure and Functional Activity in Patients With Atrial Fibrillation With and Without Oral Anticoagulation.
Atypical Hemolytic Uremic Syndrome
A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan.
Atypical Hemolytic Uremic Syndrome
Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab.
Atypical Hemolytic Uremic Syndrome
Atypical hemolytic uremic syndrome.
Atypical Hemolytic Uremic Syndrome
Defining the genetics of thrombotic microangiopathies.
Atypical Hemolytic Uremic Syndrome
Diabetic ketoacidosis presenting with atypical hemolytic uremic syndrome associated with a variant of complement factor B in an adult: a case report.
Atypical Hemolytic Uremic Syndrome
Does severe ADAMTS13 deficiency in thrombotic microangiopathy rule out complement-mediated atypical hemolytic uremic syndrome.
Atypical Hemolytic Uremic Syndrome
Evaluation of a New, Rapid, Fully Automated Assay for the Measurement of ADAMTS13 Activity.
Atypical Hemolytic Uremic Syndrome
Indications of underdiagnosis of Atypical Hemolytic Uremic Syndrome in a cohort referred to the Coagulation Unit in Malmo, Sweden, for analysis of ADAMTS13 2007-2012.
Atypical Hemolytic Uremic Syndrome
Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group.
Atypical Hemolytic Uremic Syndrome
Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome.
Atypical Hemolytic Uremic Syndrome
Plasma ADAMTS13, von Willebrand Factor (VWF) and VWF Propeptide Profiles in Patients with DIC and Related Diseases.
Atypical Hemolytic Uremic Syndrome
Postoperative thrombotic thrombocytopenic purpura in an infant: case report and literature review.
Atypical Hemolytic Uremic Syndrome
Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura.
Atypical Hemolytic Uremic Syndrome
Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome.
Atypical Hemolytic Uremic Syndrome
Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.
Atypical Hemolytic Uremic Syndrome
Thrombocytopenia in pregnancy.
Atypical Hemolytic Uremic Syndrome
Thrombosis, Microangiopathies, and Inflammation.
Atypical Hemolytic Uremic Syndrome
Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway.
Atypical Hemolytic Uremic Syndrome
Thrombotic thrombocytopenic purpura-what is new?
Atypical Hemolytic Uremic Syndrome
Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.
Autoimmune Diseases
An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura.
Autoimmune Diseases
Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis.
Autoimmune Diseases
Concentration and Subclass Distribution of Anti-ADAMTS13 IgG Autoantibodies in Different Stages of Acquired Idiopathic Thrombotic Thrombocytopenic Purpura.
Autoimmune Diseases
Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.
Autoimmune Diseases
Quantification of von Willebrand factor and ADAMTS-13 after traumatic injury: a pilot study.
Autoimmune Diseases
Treatment of Concurrent Thrombotic Thrombocytopenic Purpura and Graves' Disease: A Report on Two Cases.
Autoimmune Diseases
TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease.
Autoimmune Diseases
Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis).
Bacteremia
Evaluation of a disintegrin-like and metalloprotease with thrombospondin type 1 repeat motifs 13 (ADAMTS13) activity enzyme-linked immunosorbent assay for measuring plasma ADAMTS13 activity in dogs.
Bacteremia
Von Willebrand factor and ADAMTS13 impact on the outcome of Staphylococcus aureus sepsis.
Bacterial Infections
Assessment of ADAMTS-13 Level in Hospitalized Children with Serious Bacterial Infections as a Possible Prognostic Marker.
Bacterial Infections
Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis.
Bacterial Infections
Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure.
Biliary Atresia
Relevance of ADAMTS13 to liver transplantation and surgery.
Border Disease
Increased expressions of ADAMTS-13, neuronal nitric oxide synthase, and neurofilament correlate with severity of neuropathology in Border disease virus-infected small ruminants.
Brain Diseases
An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical outcome.
Brain Diseases
Reversible posterior leukoencephalopathy syndrome in a patient with thrombotic thrombocytopenic purpura.
Brain Infarction
[A study on the significance of plasma thrombospondin1 in thrombotic thrombocytopenic purpura and the relationship between thrombospondin1 and von Willebrand factor cleaving protease (ADAMTS13)]
Brain Injuries
ADAMTS13 gene deletion enhances plasma high-mobility group box1 elevation and neuroinflammation in brain ischemia-reperfusion injury.
Brain Injuries
ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice.
Brain Injuries
Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication.
Brain Injuries
Effect of recombinant ADAMTS13 on microthrombosis and brain injury after experimental subarachnoid hemorrhage.
Brain Injuries
miR-525-5p inhibits ADAMTS13 and is correlated with Ischemia/reperfusion injury-induced neuronal cell death.
Brain Injuries
Recombinant ADAMTS 13 Attenuates Brain Injury After Intracerebral Hemorrhage.
Brain Injuries
Role of von Willebrand factor and ADAMTS-13 in early brain injury after experimental subarachnoid hemorrhage.
Brain Injuries
von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.
Brain Ischemia
ADAMTS13 gene deletion enhances plasma high-mobility group box1 elevation and neuroinflammation in brain ischemia-reperfusion injury.
Brain Ischemia
ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice.
Brain Ischemia
miR-525-5p inhibits ADAMTS13 and is correlated with Ischemia/reperfusion injury-induced neuronal cell death.
Brain Ischemia
Reduced ADAMTS13 activity in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
Brain Neoplasms
ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis.
Brucellosis
Microangiopathic Anemia of Acute Brucellosis - is it a True TTP?
Capillary Leak Syndrome
Microangiopathic Hemolytic Anemia Due to ADAMTS-13 Loss in Idiopathic Systemic Capillary Leak Syndrome.
Capillary Leak Syndrome
Microangiopathic hemolytic anemia due to ADAMTS-13 loss in idiopathic systemic capillary leak syndrome: comment.
Capillary Leak Syndrome
Microangiopathic hemolytic anemia due to ADAMTS-13 loss in idiopathic systemic capillary leak syndrome: reply.
Carcinogenesis
Novel protein and immune response markers of human serous tubal intraepithelial carcinoma of the ovary.
Carcinoma, Hepatocellular
A splice variant of ADAMTS13 is expressed in human hepatic stellate cells and cancerous tissues.
Carcinoma, Hepatocellular
ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Association between ADAMTS13 activity-VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic hepatitis B and C.
Carcinoma, Hepatocellular
VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
Carcinoma, Renal Cell
Biologically active ADAMTS13 is expressed in renal tubular epithelial cells.
Cardiomyopathies
Thrombocytopenic purpura and cardiomyopathy in pregnancy reversed by combined plasma exchange and infusion.
Cardiovascular Diseases
ADAMTS-13 and von Willebrand factor: a dynamic duo.
Cardiovascular Diseases
ADAMTS13 gene variants and function in women with preeclampsia: a population- based nested case- control study from the HUNT Study.
Cardiovascular Diseases
Conformational quiescence of ADAMTS13 prevents proteolytic promiscuity.
Cardiovascular Diseases
Hypercoagulability and cardiovascular disease in diabetic nephropathy.
Cardiovascular Diseases
Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure.
Cardiovascular Diseases
Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients.
Cardiovascular Diseases
Shear Stress-Induced Activation of von Willebrand Factor and Cardiovascular Pathology.
Cardiovascular Diseases
SNPs in ADAMTS13.
Cardiovascular Diseases
The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis.
Cardiovascular Diseases
Verification of the Role of ADAMTS13 in the Cardiovascular Disease Using Two-Sample Mendelian Randomization.
Cardiovascular Diseases
Von Willebrand factor and ADAMTS13 activity in relation to risk of dementia: a population-based study.
Cardiovascular Diseases
Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis.
Cardiovascular Diseases
Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study.
Carotid Stenosis
Association between fibrinogen and fibrinogen ?' and atherosclerotic plaque morphology and composition in symptomatic carotid artery stenosis: Plaque-At-RISK study.
Carotid Stenosis
von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli.
Castleman Disease
Acquired thrombotic thrombocytopenic purpura due to antibody-mediated ADAMTS13 deficiency precipitated by a localized Castleman's disease: A case report.
Cerebral Amyloid Angiopathy
ADAMTS13 maintains cerebrovascular integrity to ameliorate Alzheimer-like pathology.
Cerebral Hemorrhage
Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication.
Cerebral Hemorrhage
Recombinant ADAMTS 13 Attenuates Brain Injury After Intracerebral Hemorrhage.
Cerebral Hemorrhage
von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.
Cerebral Infarction
ADAMTS13-mediated thrombolysis of t-PA resistant occlusions in ischemic stroke in mice.
Cerebral Infarction
Assessment of the Diagnostic Value of Plasma Levels, Activities, and Their Ratios of von Willebrand Factor and ADAMTS13 in Patients with Cerebral Infarction.
Cerebral Infarction
Genetic ablation of Adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model.
Cerebral Infarction
Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease.
Cerebral Infarction
Structure-function and regulation of ADAMTS-13 protease.
Cerebral Infarction
Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis.
Cerebral Infarction
[Clinical application of a method for evaluating von Willebrand factor cleaving protease activity]
Cerebrovascular Disorders
Increased expression of ADAMTS13 mRNA correlates with ischemic cerebrovascular disease in systemic lupus erythematosus patients.
Cerebrovascular Disorders
Inverse Regulation of Confluence-Dependent ADAMTS13 and von Willebrand Factor Expression in Human Endothelial Cells.
Cerebrovascular Disorders
Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease.
Charcot-Marie-Tooth Disease
Thrombotic Thrombocytopenic Purpura with Severe ADAMTS-13 Deficiency in a Patient with Antiphospholipid Antibodies and Charcot-Marie-Tooth Disease.
Cholangitis
Platelet hyperaggregability is associated with decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute cholangitis.
Cholestasis
Increased production of ADAMTS13 in hepatic stellate cells contributes to enhanced plasma ADAMTS13 activity in rat models of cholestasis and steatohepatitis.
Coinfection
Impact of HIV infection on the haemostatic response during sepsis and malaria.
Colitis
ADAMTS13 Deficiency Worsens Colitis and Exogenous ADAMTS13 Administration Decreases Colitis Severity in Mice.
Colitis, Ulcerative
P265. Decreased plasma ADAMTS13 antigen and ADAMTS13 activity as a risk factor for hypercoagulability in patients with ulcerative colitis.
Collagen Diseases
A second national questionnaire survey of TMA.
Collagen Diseases
Quetiapine-induced thrombotic microangiopathy in a patient on maintenance dialysis.
Collagen Diseases
[Von Willebrand factor-cleaving protease activity in patients of collagen disease with antiphospholipid antibodies]
Colonic Neoplasms
Deficiency of von Willebrand factor-cleaving protease activity in the plasma of malignant patients.
Colorectal Neoplasms
Platelet Count, ADAMTS13 Activity, von Willebrand Factor Level and Survival in Patients with Colorectal Cancer: 5-Year Follow-up Study.
Coma
Systemic infections mimicking thrombotic thrombocytopenic purpura.
Communicable Diseases
Biomarkers of endothelial activation/dysfunction in infectious diseases.
Communicable Diseases
Plasma ADAMTS13, von Willebrand Factor (VWF) and VWF Propeptide Profiles in Patients with DIC and Related Diseases.
Confusion
Measurement of ADAMTS13.
Confusion
The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical andin silico study.
Congenital Abnormalities
ADAMTS proteins in human disorders.
Congenital Abnormalities
Pathogenesis of thrombotic thrombocytopenic purpura.
Connective Tissue Diseases
A 35-year-old woman with influenza A-associated thrombotic thrombocytopenic purpura.
Connective Tissue Diseases
Analyses of ADAMTS13 activity and its inhibitor in patients with thrombotic thrombocytopenic purpura secondary to connective tissue diseases: Observations in a single hospital.
Connective Tissue Diseases
Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases.
Connective Tissue Diseases
Plasma ADAMTS13, von Willebrand Factor (VWF), and VWF Propeptide Profiles in Patients With Connective Tissue Diseases and Antiphospholipid Syndrome.
Connective Tissue Diseases
Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis).
Coronary Artery Disease
ADAMTS-13 activity in the presence of elevated von Willebrand factor levels as a novel mechanism of residual platelet reactivity in high risk coronary patients on antiplatelet treatment.
Coronary Artery Disease
Association between ADAMTS13 polymorphisms and risk of cardiovascular events in chronic coronary disease.
Coronary Artery Disease
Genetic Basis of Common Human Disease: Insight into the Role of Missense SNPs from Genome-Wide Association Studies.
Coronary Artery Disease
Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease.
Coronary Artery Disease
Role of CD40 and ADAMTS13 in von Willebrand factor-mediated endothelial cell-platelet-monocyte interaction.
Coronary Artery Disease
The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis.
Coronary Disease
Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein.
Coronary Disease
Association between ADAMTS13 polymorphisms and risk of cardiovascular events in chronic coronary disease.
Coronary Disease
Decreased levels of von Willebrand factor-cleaving protease in coronary heart disease and thrombotic thrombocytopenic purpura: study of a simplified method for assaying the enzyme activity based on ristocetin-induced platelet aggregation.
Coronary Disease
Low ADAMTS-13 activity and the risk of coronary heart disease - a prospective cohort study: the Rotterdam Study.
Coronary Disease
Verification of the Role of ADAMTS13 in the Cardiovascular Disease Using Two-Sample Mendelian Randomization.
Coronary Stenosis
Acquired intracoronary ADAMTS13 deficiency and VWF retention at sites of critical coronary stenosis in patients with STEMI.
Coronary Stenosis
Association of a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 polymorphisms with severity of coronary stenosis in type 2 diabetes mellitus.
COVID-19
A Case of COVID-19 Induced Thrombotic Thrombocytopenic Purpura.
COVID-19
A mild deficiency of ADAMTS13 is associated with severity in COVID-19: comparison of the coagulation profile in critically and noncritically ill patients.
COVID-19
A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19.
COVID-19
ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19.
COVID-19
ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy.
COVID-19
ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients.
COVID-19
ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.
COVID-19
COVID 19 infection associated with thrombotic thrombocytopenic purpura.
COVID-19
Distinctive Biomarker Features in The Endotheliopathy of COVID-19 and Septic Syndromes.
COVID-19
Early response to caplacizumab and rituximab after anaphylaxis to Octaplas plasma in a patient with thrombotic thrombocytopenic purpura.
COVID-19
Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients.
COVID-19
In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation.
COVID-19
Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients.
COVID-19
Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis.
COVID-19
Insights Into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13.
COVID-19
Invited commentary to: ADAMTS13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19 by Tiffany Pascreau et al. Letter to the Editors-in-Chief, Thrombosis Research.
COVID-19
Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond.
COVID-19
Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series.
COVID-19
Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients.
COVID-19
Low ADAMTS13 Activity Correlates with Increased Mortality in COVID-19 Patients.
COVID-19
Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality.
COVID-19
Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data.
COVID-19
Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19.
COVID-19
Role of von Willebrand Factor and ADAMTS-13 in the Pathogenesis of Thrombi in SARS-CoV-2 Infection: Time to Rethink.
COVID-19
Role of von Willebrand Factor in COVID-19 Associated Coagulopathy.
COVID-19
Severe COVID-19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis.
COVID-19
The ADAMTS13-von Willebrand factor axis in COVID-19 patients.
COVID-19
Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19.
COVID-19
Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance.
COVID-19
von Willebrand Factor Multimer Formation Contributes to Immunothrombosis in Coronavirus Disease 2019.
Dementia
Von Willebrand factor and ADAMTS13 activity in relation to risk of dementia: a population-based study.
Dementia, Vascular
Localization of blood proteins thrombospondin1 and ADAMTS13 to cerebral corpora amylacea.
Demyelinating Diseases
ADAMTS13 ameliorates inflammatory responses in experimental autoimmune encephalomyelitis.
Dengue
A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infection.
Dengue
Biomarkers of endothelial activation/dysfunction in infectious diseases.
Dengue
Successful treatment of thrombotic microangiopathy associated with dengue infection: A case report and literature review.
Diabetes Complications
ADAMTS13 Predicts Renal and Cardiovascular Events in Type 2 Diabetic Patients and Response to Therapy.
Diabetes Mellitus
ADAMTS13 activity as a novel risk factor for incident type 2 diabetes mellitus: a population-based cohort study.
Diabetes Mellitus
ADAMTS13 and von Willebrand factor concentrations in patients with diabetes mellitus.
Diabetes Mellitus
Association of a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 polymorphisms with severity of coronary stenosis in type 2 diabetes mellitus.
Diabetes Mellitus
Liver up-regulation of ADAMTS13 gene expression and its correlation with renal markers in mice with type 1 diabetes mellitus and nephropathy.
Diabetes Mellitus
Plasma Peptidylarginine Deiminase IV Promotes VWF-Platelet String Formation and Accelerates Thrombosis After Vessel Injury.
Diabetes Mellitus
Von Willebrand Factor, ADAMTS13 and D-Dimer Are Correlated with Different Levels of Nephropathy in Type 1 Diabetes Mellitus.
Diabetes Mellitus, Type 1
Liver up-regulation of ADAMTS13 gene expression and its correlation with renal markers in mice with type 1 diabetes mellitus and nephropathy.
Diabetes Mellitus, Type 1
Von Willebrand Factor, ADAMTS13 and D-Dimer Are Correlated with Different Levels of Nephropathy in Type 1 Diabetes Mellitus.
Diabetes Mellitus, Type 2
ADAMTS13 activity as a novel risk factor for incident type 2 diabetes mellitus: a population-based cohort study.
Diabetic Angiopathies
ADAMTS13--more than just TMA and TTP.
Diabetic Nephropathies
ADAMTS13 Retards Progression of Diabetic Nephropathy by Inhibiting Intrarenal Thrombosis in Mice.
Diabetic Nephropathies
Association between reduced ADAMTS13 and diabetic nephropathy.
Diabetic Nephropathies
Diabetic ketoacidosis presenting with atypical hemolytic uremic syndrome associated with a variant of complement factor B in an adult: a case report.
Diabetic Nephropathies
Hypercoagulability and cardiovascular disease in diabetic nephropathy.
Diabetic Nephropathies
Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases.
Diabetic Retinopathy
Association between Von Willebrand factor, disintegrin and metalloproteinase with thrombospondin type 1 motif member 13, d-Dimer and cystatin C levels with retinopathy in type 1 diabetes mellitus.
Disseminated Intravascular Coagulation
ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin.
Disseminated Intravascular Coagulation
Correlation between plasma activity of ADAMTS-13 and coagulopathy, and prognosis in disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Decreased a disintegrin-like and metalloprotease with thrombospondin (ADAMTS)-13 is associated with a poor prognosis in sepsis-induced organ failure*
Disseminated Intravascular Coagulation
Decreased ADAMTS 13 Activity is Associated With Disease Severity and Outcome in Pediatric Severe Sepsis.
Disseminated Intravascular Coagulation
Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure.
Disseminated Intravascular Coagulation
Low ADAMTS-13 activity during hemorrhagic events with disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Measurement of ADAMTS13 activity and inhibitors.
Disseminated Intravascular Coagulation
Plasma ADAMTS13, von Willebrand Factor (VWF) and VWF Propeptide Profiles in Patients with DIC and Related Diseases.
Disseminated Intravascular Coagulation
Plasmodium falciparum Malaria Complicated by Symmetrical Peripheral Gangrene, Bowel Ischemia, Repeated Candidemia, and Bacteraemia.
Disseminated Intravascular Coagulation
Renal thrombotic microangiopathy in a patient with septic disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Sepsis-Induced Disseminated Intravascular Coagulation With Features of Thrombotic Thrombocytopenic Purpura: a Fatal Fulminant Syndrome.
Disseminated Intravascular Coagulation
Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure.
Disseminated Intravascular Coagulation
The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Von Willebrand factor and ADAMTS13 impact on the outcome of Staphylococcus aureus sepsis.
Disseminated Intravascular Coagulation
VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.
Disseminated Intravascular Coagulation
[Changes of ADAMTS13 Activity and vWF Antigen Level in Patients with Acute Myelogenous Leukemia and Their Significance].
Drug-Related Side Effects and Adverse Reactions
[Thrombotic microangiopathy after kidney transplantation]
Encephalitis
ADAMTS13 gene deletion enhances plasma high-mobility group box1 elevation and neuroinflammation in brain ischemia-reperfusion injury.
Encephalitis
Increased expressions of ADAMTS-13 and apoptosis contribute to neuropathology during Toxoplasma gondii encephalitis in mice.
Encephalitis
Role of ADAMTS-13 and nNOS expression in neuropathogenesis of listeric encephalitis of small ruminants.
Encephalomyelitis
ADAMTS13 ameliorates inflammatory responses in experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
ADAMTS13 ameliorates inflammatory responses in experimental autoimmune encephalomyelitis.
endopeptidase la deficiency
Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura.
endopeptidase la deficiency
Autosomal recessive inheritance of von Willebrand factor-cleaving protease deficiency.
endopeptidase la deficiency
Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency.
endopeptidase la deficiency
Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency.
endopeptidase la deficiency
Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation.
endopeptidase la deficiency
Thrombotic thrombocytopenic purpura--the role of ADAMTS13 assay in clinical practice.
endopeptidase la deficiency
Two generations with familial thrombotic thrombocytopenic purpura.
endopeptidase la deficiency
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
endopeptidase la deficiency
[Hemolytic and uremic syndrome in the child]
Endotoxemia
Decreased activity of plasma ADAMTS13 are related to enhanced cytokinemia and endotoxemia in patients with acute liver failure.
Endotoxemia
Platelet hyperaggregability is associated with decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute cholangitis.
Endotoxemia
Potential Role of Enhanced Cytokinemia and Plasma Inhibitor on the Decreased Activity of Plasma ADAMTS13 in Patients With Alcoholic Hepatitis: Relationship to Endotoxemia.
Endotoxemia
The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis.
Erythema
Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases.
Escherichia coli Infections
Clinical Characteristics and Outcome of Canadian Patients Diagnosed With Atypical Hemolytic Uremic Syndrome.
Exanthema
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.
Familial Primary Pulmonary Hypertension
The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension.
Fatty Liver
ADAMTS13 deficiency promotes microthrombosis in a murine model of diet-induced liver steatosis.
Fatty Liver
Increased production of ADAMTS13 in hepatic stellate cells contributes to enhanced plasma ADAMTS13 activity in rat models of cholestasis and steatohepatitis.
Fatty Liver
Role of ADAMTS13 in diet-induced liver steatosis.
Genetic Diseases, Inborn
Multiple in silico tools predict phenotypic manifestations in congenital thrombotic thrombocytopenic purpura.
Genetic Diseases, Inborn
The ADAMTS(L) family and human genetic disorders.
Glomerulonephritis
Disseminated cerebral aspergillosis complicated by thrombotic microangiopathy.
Glomerulonephritis
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.
Glomerulonephritis
Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases.
Glomerulonephritis, IGA
Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases.
Glomerulonephritis, Membranous
Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases.
Glycogen Storage Disease Type VI
Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura.
Graft vs Host Disease
[Influence of HSCT Preconditioning on ADAMTS-13 Activity and vWF level and Its Clinical Significance].
Graves Disease
Thrombotic thrombocytopenic purpura precipitated by thyrotoxicosis.
Graves Disease
Treatment of Concurrent Thrombotic Thrombocytopenic Purpura and Graves' Disease: A Report on Two Cases.
Hantavirus Infections
Platelet ligands and ADAMTS13 during Puumala hantavirus infection and associated thrombocytopenia.
Heart Defects, Congenital
Compounding variants rescue the effect of a deleterious ADAMTS13 mutation in a child with severe congenital heart disease.
Heart Defects, Congenital
Decreased plasma ADAMTS-13 activity as a predictor of postoperative bleeding in cyanotic congenital heart disease.
Heart Defects, Congenital
In silico features of ADAMTS13 contributing to plasmatic ADAMTS13 levels in neonates with congenital heart disease.
Heart Defects, Congenital
Plasmatic ADAMTS-13 metalloprotease and von Willebrand factor in children with cyanotic congenital heart disease.
Heart Diseases
Diagnosis and Management of Acquired von Willebrand Disease in Heart Disease: A Review of the Literature.
Heart Diseases
Successful Perioperative Management of Orthotopic Cardiac Transplantation in a Pediatric Patient With Concurrent Congenital von Willebrand Disease and Acquired von Willebrand Syndrome Using Recombinant von Willebrand Factor.
Heart Failure
Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure.
Heart Failure
Plasma Proteomics of COVID-19 Associated Cardiovascular Complications: Implications for Pathophysiology and Therapeutics.
Heart Failure
Update on ADAMTS13 and VWF in cardiovascular and hematological disorders.
Heart Failure
Verification of the Role of ADAMTS13 in the Cardiovascular Disease Using Two-Sample Mendelian Randomization.
HELLP Syndrome
Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome.
HELLP Syndrome
ADAMTS13 deficiency in severe postpartum HELLP syndrome.
HELLP Syndrome
Hemolysis, Elevated Liver Enzymes, and Low Platelet Count Syndrome With Severe Thrombocytopenia and Severe ADAMTS13 Activity Deficiency.
HELLP Syndrome
Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia.
HELLP Syndrome
Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome.
HELLP Syndrome
Severe reduction of free-form ADAMTS13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome.
Hematologic Diseases
ADAMTS13 turns 3.
Hematologic Neoplasms
ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin.
Hematologic Neoplasms
Decreased ADAMTS-13 level is related to inflammation factors and risk stratification of acute lymphoblastic leukemia patients.
Hematologic Neoplasms
Recipient ADAMTS13 Single-Nucleotide Polymorphism Predicts Relapse after Unrelated Bone Marrow Transplantation for Hematologic Malignancy.
Hematologic Neoplasms
Reduced ADAMTS-13 level negatively correlates with inflammation factors in plasma of acute myeloid leukemia patients.
Hematologic Neoplasms
[Changes of ADAMTS13 Activity and TSP1 Level in Patients with Hematologic Malignancies].
Hemoglobinopathies
Refractory acquired thrombotic thrombocytopenic purpura in a patient with sickle cell trait successfully treated with caplacizumab.
Hemoglobinuria
Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway.
Hemoglobinuria, Paroxysmal
Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway.
Hemolytic-Uremic Syndrome
ADAMTS-13 level in children with severe diarrhea-associated hemolytic uremic syndrome: Unmasking new association.
Hemolytic-Uremic Syndrome
ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
Hemolytic-Uremic Syndrome
ADAMTS13 Gene mutations in children with hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
ADAMTS13, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura.
Hemolytic-Uremic Syndrome
Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura.
Hemolytic-Uremic Syndrome
Atypical reduction of plasma ADAMTS13 activity by a non-IgG-type inhibitor in a patient with hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli.
Hemolytic-Uremic Syndrome
Clinical experience in treatment of thrombotic thrombocytopenic purpura--hemolytic uremic syndrome with 28 patients.
Hemolytic-Uremic Syndrome
Deficiency of complement factor H-related proteins and autoantibody-positive hemolytic uremic syndrome in an infant with combined partial deficiencies and autoantibodies to complement factor H and ADAMTS13.
Hemolytic-Uremic Syndrome
Diagnostic relevance of ADAMTS13 activity: evaluation of 28 patients with thrombotic thrombocytopenic purpura - hemolytic uremic syndrome clinical diagnosis.
Hemolytic-Uremic Syndrome
Erratum: Deficiency of complement factor H-related proteins and autoantibody-positive hemolytic uremic syndrome in an infant with combined partial deficiencies and autoantibodies to complement factor H and ADAMTS13.
Hemolytic-Uremic Syndrome
Hemolytic uremic syndrome associated with Escherichia coli O157:H7 infection in older adults: a case report and review of the literature.
Hemolytic-Uremic Syndrome
Immature platelet fraction can help adjust therapy in refractory thrombotic microangiopathic hemolytic anemia cases.
Hemolytic-Uremic Syndrome
Intravenous gamma globulin for thrombotic microangiopathy of unknown etiology.
Hemolytic-Uremic Syndrome
Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency?
Hemolytic-Uremic Syndrome
Natural history of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.
Hemolytic-Uremic Syndrome
Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Severe transient ADAMTS13 deficiency in pneumococcal-associated hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Shear stress and von Willebrand factor in health and disease.
Hemolytic-Uremic Syndrome
Shiga Toxin as a Potential Trigger of CFHR1 Deletion-Associated Thrombotic Microangiopathy.
Hemolytic-Uremic Syndrome
Successful treatment of thrombotic microangiopathy associated with dengue infection: A case report and literature review.
Hemolytic-Uremic Syndrome
Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: A pediatric report and literature review.
Hemolytic-Uremic Syndrome
Thrombotic microangiopathy (TTP and HUS): advances in differentiation and diagnosis.
Hemolytic-Uremic Syndrome
Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Thrombotic thrombocytopenic purpura--a syndrome caused by multiple pathogenetic mechanisms.
Hemolytic-Uremic Syndrome
Thrombotic thrombocytopenic purpura: from platelet aggregates to plasma.
Hemolytic-Uremic Syndrome
Total deficiency of specific von Willebrand factor-cleaving protease and recovery following plasma therapy in one patient with hemolytic-uremic syndrome.
Hemolytic-Uremic Syndrome
von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.
Hemolytic-Uremic Syndrome
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome.
Hemolytic-Uremic Syndrome
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Hemolytic-Uremic Syndrome
[Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Current perspectives on EHEC, complement mutations and ADAMTS13]
Hemophilia A
Factor VIII concentrate infusion in patients with haemophilia results in decreased von Willebrand factor and ADAMTS-13 activity.
Hemophilia B
Development of novel treatment options for patients with haemophilia.
Hemorrhagic Stroke
von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.
Hepatic Encephalopathy
Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis.
Hepatic Veno-Occlusive Disease
Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation.
Hepatitis
Decreased activity of plasma ADAMTS13 are related to enhanced cytokinemia and endotoxemia in patients with acute liver failure.
Hepatitis B, Chronic
Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment.
Hepatitis B, Chronic
Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment.
Hepatitis B, Chronic
Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic hepatitis B and C.
Hepatitis C
Active Hepatitis C Leading to Refractory Thrombotic Thrombocytopenic Purpura - A Dubious Association and The Challenges Faced in Management.
Hepatitis C
ADAMTS13 Levels in Young Patients With ?-Thalassemia Major: Relation to Hepatitis C Virus Infection, Liver Cirrhosis, and Iron Overload.
Hepatitis C
Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura.
Hepatitis C
Opana ER (Oxymorphone)-Induced Thrombotic Microangiopathy: An Atypical Presentation in a Patient With Hepatitis C.
Hepatitis C, Chronic
Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review.
Hepatitis C, Chronic
Thrombotic thrombocytopenic purpura associated with pegylated-interferon alpha-2a by an ADAMTS13 inhibitor in a patient with chronic hepatitis C.
Hepatitis, Alcoholic
Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis.
Hepatitis, Alcoholic
Increased von Willebrand Factor Over Decreased ADAMTS13 Activity May Contribute to the Development of Liver Disturbance and Multiorgan Failure in Patients With Alcoholic Hepatitis.
Hepatitis, Alcoholic
Potential role of ADAMTS13 in the progression of alcoholic hepatitis.
Hepatitis, Alcoholic
Potential Role of Enhanced Cytokinemia and Plasma Inhibitor on the Decreased Activity of Plasma ADAMTS13 in Patients With Alcoholic Hepatitis: Relationship to Endotoxemia.
Hepatitis, Autoimmune
Altered von Willebrand Factor and ADAMTS13 Levels in Children With Cirrhosis and Extrahepatic Portal Hypertension.
Hepatitis, Autoimmune
The significance of ADAMTS13 in a patient with thrombotic thrombocytopenic purpura complicated autoimmune hepatitis.
Hepatorenal Syndrome
Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis.
HIV Infections
Von Willebrand Factor Adhesive Activity and ADAMTS13 Protease Activity in HIV-1-Infected Men.
Hyperbilirubinemia, Neonatal
Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome.
Hypercholesterolemia
Gender-dependent up-regulation of ADAMTS-13 in mice with obesity and hypercholesterolemia.
Hyperferritinemia
Secretion of von Willebrand Factor and Suppression of ADAMTS-13 Activity by Markedly High Concentration of Ferritin.
Hyperlipidemias
Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.
Hypersensitivity
Idiopathic Relapsing Thrombotic Thrombocytopenic Purpura with Persistent ADAMTS13 Inhibitor Activity Treated Sequentially with Plasmapheresis, Rituximab, Cyclophosphamide and Splenectomy.
Hypertension
Absolute immature platelet count helps differentiate thrombotic thrombocytopenic purpura from hypertension-induced thrombotic microangiopathy.
Hypertension
Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension.
Hypertension
Circulating miR-3656 induces human umbilical vein endothelial cell injury by targeting eNOS and ADAMTS13: a novel biomarker for hypertension.
Hypertension
Correlation analysis between ADAMTS-13 gene polymorphism and hypertension-induced atrial fibrillation.
Hypertension
Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura.
Hypertension
Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?
Hypertension
Porto-pulmonary hypertension exacerbated by platelet transfusion in a patient with ADAMTS13 deficiency.
Hypertension
The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension.
Hypertension
The kidney in thrombotic thrombocytopenic purpura.
Hypertension
Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/ thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other?
Hypertension
Update on ADAMTS13 and VWF in cardiovascular and hematological disorders.
Hypertension, Malignant
Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension.
Hypertension, Malignant
Catastrophic APS in the context of other thrombotic microangiopathies.
Hypertension, Malignant
Thrombotic microangiopathy due to malignant hypertension complicated with late-onset bleeding after renal biopsy.
Hypertension, Portal
ADAMTS13 deficiency, despite well-compensated liver functions in patients with noncirrhotic portal hypertension.
Hypertension, Portal
ADAMTS13 missense variants associated with defective activity and secretion of ADAMTS13 in a patient with non-cirrhotic portal hypertension.
Hypertension, Portal
Altered von Willebrand Factor and ADAMTS13 Levels in Children With Cirrhosis and Extrahepatic Portal Hypertension.
Hypertension, Portal
Idiopathic Noncirrhotic Intrahepatic Portal Hypertension is Associated with Sustained ADAMTS13 Deficiency.
Hypertension, Portal
Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis.
Hypertension, Portal
Orthotopic liver transplantation (OLTx) in non-cirrhotic portal hypertension secondary to ADAMTS13 deficiency.
Hypertension, Portal
Plasma ADAMTS-13 protein is not associated with portal hypertension or hemodynamic changes in patients with cirrhosis.
Hypertension, Pregnancy-Induced
Changes of plasma Von Willebrand factor and Von Willebrand factor-cleaving protease levels in pregnancy-induced hypertension.
Hypertension, Pulmonary
Porto-pulmonary hypertension exacerbated by platelet transfusion in a patient with ADAMTS13 deficiency.
Hypertension, Pulmonary
The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension.
Hypertensive Retinopathy
[Clinical reasoning and decision making in practice. A 39-year-old woman with somnolence, hypertension and haemolysis]
Immune System Diseases
Treatment of refractory thrombotic thrombocytopenic purpura using multimodality therapy including splenectomy and cyclosporine.
Immunoglobulin G4-Related Disease
Thrombotic thrombocytopenic purpura in IgG4-related disease with severe deficiency of ADAMTS-13 activity and IgG4 autoantibody against ADAMTS-13.
Immunoglobulin Light-chain Amyloidosis
Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis.
Infarction, Middle Cerebral Artery
ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion.
Infarction, Middle Cerebral Artery
ADAMTS13 gene deletion enhances plasma high-mobility group box1 elevation and neuroinflammation in brain ischemia-reperfusion injury.
Infarction, Middle Cerebral Artery
Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication.
Infections
A 35-year-old woman with influenza A-associated thrombotic thrombocytopenic purpura.
Infections
A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infection.
Infections
A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan.
Infections
A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria.
Infections
Acquired thrombotic thrombocytopenic purpura due to antibody-mediated ADAMTS13 deficiency precipitated by a localized Castleman's disease: A case report.
Infections
ADAMTS-13 activity reduction in plasma of acute myeloid leukemia predicts poor prognosis after bone marrow transplantation.
Infections
ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
Infections
ADAMTS13 Levels in Young Patients With ?-Thalassemia Major: Relation to Hepatitis C Virus Infection, Liver Cirrhosis, and Iron Overload.
Infections
ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.
Infections
Atypical hemolytic uremic syndrome: from diagnosis to treatment.
Infections
Biomarkers of endothelial activation/dysfunction in infectious diseases.
Infections
Catastrophic APS in the context of other thrombotic microangiopathies.
Infections
Clinical Characteristics and Outcome of Canadian Patients Diagnosed With Atypical Hemolytic Uremic Syndrome.
Infections
Coagulopathy in malaria.
Infections
COVID 19 infection associated with thrombotic thrombocytopenic purpura.
Infections
Decreased ADAMTS-13 level is related to inflammation factors and risk stratification of acute lymphoblastic leukemia patients.
Infections
Degradation of Circulating von Willebrand Factor and Its Regulator ADAMTS13 Implicates Secreted Bacillus anthracis Metalloproteases in Anthrax Consumptive Coagulopathy.
Infections
Idiopathic TTP in the Middle East: Epidemiology and clinical outcomes in infection associated episodes.
Infections
Low Plasma ADAMTS13 Activity Is Associated with Coagulopathy, Endothelial Cell Damage and Mortality after Severe Paediatric Trauma.
Infections
Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era.
Infections
Platelet ligands and ADAMTS13 during Puumala hantavirus infection and associated thrombocytopenia.
Infections
Reduced ADAMTS-13 level negatively correlates with inflammation factors in plasma of acute myeloid leukemia patients.
Infections
Renal thrombotic microangiopathy in a patient with septic disseminated intravascular coagulation.
Infections
Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura.
Infections
Role of von Willebrand Factor in COVID-19 Associated Coagulopathy.
Infections
Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition.
Infections
Shiga Toxin as a Potential Trigger of CFHR1 Deletion-Associated Thrombotic Microangiopathy.
Infections
Short Course of Eculizumab May Be Effective in Dialysis-Dependent Transplantation-Associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: A Case Report.
Infections
Successful treatment of thrombotic microangiopathy associated with dengue infection: A case report and literature review.
Infections
Systemic infections mimicking thrombotic thrombocytopenic purpura.
Infections
Ten patient stories illustrating the extraordinarily diverse clinical features of patients with thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency.
Infections
Von Willebrand Factor Adhesive Activity and ADAMTS13 Protease Activity in HIV-1-Infected Men.
Infections
Von Willebrand factor and ADAMTS13 impact on the outcome of Staphylococcus aureus sepsis.
Infections
von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome.
Infections
von Willebrand factor increases in experimental cerebral malaria but is not essential for late-stage pathogenesis in mice.
Infections
von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome.
Infections
VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.
Infections
[Changes of ADAMTS13 Activity and TSP1 Level in Patients with Hematologic Malignancies].
Infections
[Changes of ADAMTS13 Activity and vWF Antigen Level in Patients with Acute Myelogenous Leukemia and Their Significance].
Inflammatory Bowel Diseases
ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis.
Inflammatory Bowel Diseases
ADAMTS13 in health and disease.
Inflammatory Bowel Diseases
Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease.
Influenza, Human
A 35-year-old woman with influenza A-associated thrombotic thrombocytopenic purpura.
Influenza, Human
Acquired Thrombotic Thrombocytopenic Purpura Without Anti-ADAMTS13 Antibody Caused by Influenza A (H1N1) Virus Successfully Treated by Plasma Exchange: A Case Report.
Influenza, Human
H1N1 Influenza (Swine Flu)-Associated Thrombotic Microangiopathy with a Markedly High Plasma Ratio of von Willebrand Factor to ADAMTS13.
Invasive Pulmonary Aspergillosis
ADAMTS-13 regulates neutrophil recruitment in a mouse model of invasive pulmonary aspergillosis.
Invasive Pulmonary Aspergillosis
Author Correction: ADAMTS-13 regulates neutrophil recruitment in a mouse model of invasive pulmonary aspergillosis.
Iron Overload
ADAMTS13 Levels in Young Patients With ?-Thalassemia Major: Relation to Hepatitis C Virus Infection, Liver Cirrhosis, and Iron Overload.
Ischemic Attack, Transient
Association between fibrinogen and fibrinogen ?' and atherosclerotic plaque morphology and composition in symptomatic carotid artery stenosis: Plaque-At-RISK study.
Ischemic Attack, Transient
Increased expression of ADAMTS13 mRNA correlates with ischemic cerebrovascular disease in systemic lupus erythematosus patients.
Ischemic Attack, Transient
von Willebrand factor/ADAMTS13 ratio at presentation of acute ischemic brain injury is predictive of outcome.
Ischemic Stroke
ADAMTS-13 Activity Predicts Outcome in Acute Ischaemic Stroke Patients Undergoing Endovascular Treatment.
Ischemic Stroke
ADAMTS13 activity is associated with early neurological improvement in acute ischemic stroke patients treated with intravenous thrombolysis.
Ischemic Stroke
ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice.
Ischemic Stroke
ADAMTS13-mediated thrombolysis of t-PA resistant occlusions in ischemic stroke in mice.
Ischemic Stroke
ADAMTS13: An Emerging Target in Stroke Therapy.
Ischemic Stroke
Association between fibrinogen and fibrinogen ?' and atherosclerotic plaque morphology and composition in symptomatic carotid artery stenosis: Plaque-At-RISK study.
Ischemic Stroke
Association between genetic variation at the ADAMTS13 locus and ischemic stroke.
Ischemic Stroke
Author response: Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke.
Ischemic Stroke
Characterization and treatment of congenital thrombotic thrombocytopenic purpura.
Ischemic Stroke
Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication.
Ischemic Stroke
Editors' note: Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke.
Ischemic Stroke
Enhanced activity of an ADAMTS-13 variant (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic stroke.
Ischemic Stroke
High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability.
Ischemic Stroke
High VWF, low ADAMTS13 puts women at risk.
Ischemic Stroke
High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women.
Ischemic Stroke
Immune-Thrombotic Thrombocytopenic Purpura is a Rare Cause of Ischemic Stroke in Young Adults: Case Reports and Literature Review.
Ischemic Stroke
Insights Into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13.
Ischemic Stroke
Low ADAMTS-13 activity and the risk of coronary heart disease - a prospective cohort study: the Rotterdam Study.
Ischemic Stroke
Low ADAMTS13 activity is associated with an increased risk of ischemic stroke.
Ischemic Stroke
Plasma ADAMTS-13 levels and the risk of myocardial infarction: an individual patient data meta-analysis.
Ischemic Stroke
Reader response: Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke.
Ischemic Stroke
Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease.
Ischemic Stroke
Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke.
Ischemic Stroke
Role of reduced ADAMTS13 in arterial ischemic stroke: a pediatric cohort study.
Ischemic Stroke
The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis.
Ischemic Stroke
The Role of von Willebrand Factor, ADAMTS13, and Cerebral Artery Thrombus Composition in Patient Outcome Following Mechanical Thrombectomy for Acute Ischemic Stroke.
Ischemic Stroke
The Value of ADAMTS13 in Predicting Clinical Outcomes in Patients With Acute Ischemic Stroke Receiving Thrombolysis.
Ischemic Stroke
Update on ADAMTS13 and VWF in cardiovascular and hematological disorders.
Ischemic Stroke
Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke.
Ischemic Stroke
Von Willebrand factor and ADAMTS13 activity in relation to risk of dementia: a population-based study.
Ischemic Stroke
von Willebrand factor/ADAMTS13 ratio at presentation of acute ischemic brain injury is predictive of outcome.
Ischemic Stroke
[Determination of ADAMTS13 antigen and activity levels in patients with acute myocardial infarction and acute ischemic stroke]
Ischemic Stroke
[Genetic polymorphism of von Willebrand factor (VWF)-cleaving protease, ADAMTS13]
Ischemic Stroke
[Study of C1423T polymorphism of the von Willebrand factor-cleaving protease gene in Chinese Han population]
Kidney Diseases
ADAMTS13 and Von Willebrand factor in patients undergoing hemodialysis.
Kidney Failure, Chronic
Predictive value of ADAMTS-13 on concealed chronic renal failure in COPD patients.
Kidney Failure, Chronic
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.
Larva Migrans, Visceral
Atypical presentation of hepatic visceral larva migrans mimicking cancer and associated with ADAMTS13 deficiency-mediated thrombotic microangiopathy: A first report from Reunion Island.
Leukemia
Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders.
Leukemia
Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review.
Leukemia
Thrombogenesis and thrombotic disorders based on 'two-path unifying theory of hemostasis': philosophical, physiological, and phenotypical interpretation.
Leukemia
[ADAMTS13 Level in Prothrombotic Status and Its Related Factor Analysis].
Leukemia, Hairy Cell
Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review.
Leukemia, Myeloid, Acute
ADAMTS-13 activity reduction in plasma of acute myeloid leukemia predicts poor prognosis after bone marrow transplantation.
Leukemia, Myeloid, Acute
Reduced ADAMTS-13 level negatively correlates with inflammation factors in plasma of acute myeloid leukemia patients.
Leukemia, Myeloid, Acute
[Changes of ADAMTS13 Activity and vWF Antigen Level in Patients with Acute Myelogenous Leukemia and Their Significance].
Leukemia, Promyelocytic, Acute
Thrombogenesis and thrombotic disorders based on 'two-path unifying theory of hemostasis': philosophical, physiological, and phenotypical interpretation.
Leukemia, Promyelocytic, Acute
[ADAMTS13 Level in Prothrombotic Status and Its Related Factor Analysis].
Liver Cirrhosis
ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score.
Liver Cirrhosis
ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis.
Liver Cirrhosis
ADAMTS13 in health and disease.
Liver Cirrhosis
ADAMTS13 Levels in Young Patients With ?-Thalassemia Major: Relation to Hepatitis C Virus Infection, Liver Cirrhosis, and Iron Overload.
Liver Cirrhosis
Clinical insights from observations on ADAMTS13 deficiency in liver cirrhosis.
Liver Cirrhosis
Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis.
Liver Cirrhosis
Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis.
Liver Cirrhosis
Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura.
Liver Cirrhosis
Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo.
Liver Cirrhosis
Increased production of ADAMTS13 in hepatic stellate cells contributes to enhanced plasma ADAMTS13 activity in rat models of cholestasis and steatohepatitis.
Liver Cirrhosis
Plasma ADAMTS-13 protein is not associated with portal hypertension or hemodynamic changes in patients with cirrhosis.
Liver Cirrhosis
Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study.
Liver Cirrhosis
Serum ADAMTS-13 Levels as an Indicator of Portal Vein Thrombosis.
Liver Cirrhosis, Alcoholic
Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis.
Liver Cirrhosis, Alcoholic
Increased von Willebrand Factor Over Decreased ADAMTS13 Activity May Contribute to the Development of Liver Disturbance and Multiorgan Failure in Patients With Alcoholic Hepatitis.
Liver Cirrhosis, Biliary
Relevance of ADAMTS13 to liver transplantation and surgery.
Liver Diseases
ADAMTS13 activity decreases after hepatectomy, reflecting a postoperative liver dysfunction.
Liver Diseases
ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score.
Liver Diseases
ADAMTS13 deficiency promotes microthrombosis in a murine model of diet-induced liver steatosis.
Liver Diseases
Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.
Liver Diseases
Localization of ADAMTS13 to the stellate cells of human liver.
Liver Diseases
Pivotal role of ADAMTS13 function in liver diseases.
Liver Diseases
Role of ADAMTS13 in diet-induced liver steatosis.
Liver Failure
ADAMTS13 activity decreases after hepatectomy, reflecting a postoperative liver dysfunction.
Liver Failure
An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical outcome.
Liver Failure
Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure.
Liver Failure, Acute
An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical outcome.
Liver Failure, Acute
Decreased activity of plasma ADAMTS13 are related to enhanced cytokinemia and endotoxemia in patients with acute liver failure.
Lung Neoplasms
Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer.
Lung Neoplasms
Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer.
Lupus Erythematosus, Systemic
A Case of Thrombotic Thrombocytopenia Purpura Associated with Systemic Lupus Erythematosus: Diagnostic Utility of ADAMTS-13 Activity.
Lupus Erythematosus, Systemic
A patient with SLE-associated thrombotic microangiopathy and non-neutralizing antibodies against ADAMTS13.
Lupus Erythematosus, Systemic
Acquired deficiency of von Willebrand factor-cleaving protease in a patient suffering from acute systemic lupus erythematosus.
Lupus Erythematosus, Systemic
ADAMTS-13 metalloprotease abnormalities in systemic lupus erythematosus: is there a correlation with disease status?
Lupus Erythematosus, Systemic
Alteration of ADAMTS13 antigen levels in patients with idiopathic thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura and systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Characteristics and Outcomes of Patients with Systemic Lupus Erythematosus-associated Thrombotic Microangiopathy, and Their Acquired ADAMTS13 Inhibitor Profiles.
Lupus Erythematosus, Systemic
Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders.
Lupus Erythematosus, Systemic
Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases.
Lupus Erythematosus, Systemic
Increased expression of ADAMTS13 mRNA correlates with ischemic cerebrovascular disease in systemic lupus erythematosus patients.
Lupus Erythematosus, Systemic
Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13.
Lupus Erythematosus, Systemic
Occurrence of thrombotic thrombocytopenic purpura in a systemic lupus erythematosus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand factor-cleaving protease.
Lupus Erythematosus, Systemic
Reduced ADAMTS13 activity is associated with thrombotic risk in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura.
Lupus Erythematosus, Systemic
Successful treatment of refractory thrombotic thrombocytopenic purpura with cyclosporine and corticosteroids in a patient with systemic lupus erythematosus and antibodies to ADAMTS13.
Lupus Erythematosus, Systemic
Systemic lupus erythematosus with ADAMTS13 inhibitor-negative thrombotic microangiopathy treated with combination of mycophenolate mofetil, plasma exchange and steroid.
Lupus Erythematosus, Systemic
Thrombotic microangiopathic hemolytic anemia with reduction of ADAMTS13 activity: initial manifestation of childhood-onset systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Thrombotic thrombocytopenic purpura as an initial presentation of systemic lupus erythematosus with acquired ADAMTS 13 antibody.
Lupus Erythematosus, Systemic
Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis).
Lupus Erythematosus, Systemic
[The association of von Willebrand factor and von Willebrand factor-cleaving protease in systemic lupus erythematosus]
Lupus Nephritis
Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome.
Lupus Nephritis
Microangiopathic haemolytic anaemia secondary to lupus nephritis: an important differential diagnosis of thrombotic thrombocytopenic purpura.
Lupus Nephritis
Plasma ADAMTS-13 activity in proliferative lupus nephritis: a large cohort study from China.
Lupus Nephritis
Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases.
Lymphoma
Chemotherapy-resistant intravascular lymphoma accompanied by ADAMTS13 inhibitor successfully treated with rituximab.
Lymphoma
[Thrombotic microangiopathy]
Lymphopenia
Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series.
Lymphopenia
Thrombotic microangiopathy as first manifestation of acute human immunodeficiency virus infection: a case report and review of the literature.
Malaria
ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria.
Malaria
Biomarkers of endothelial activation/dysfunction in infectious diseases.
Malaria
Impact of HIV infection on the haemostatic response during sepsis and malaria.
Malaria
Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13.
Malaria
Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition.
Malaria
Structure-function and regulation of ADAMTS-13 protease.
Malaria
von Willebrand factor in experimental malaria-associated acute respiratory distress syndrome.
Malaria
VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.
Malaria, Cerebral
ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
Malaria, Cerebral
Association of ADAMTS13 polymorphism with cerebral malaria.
Malaria, Falciparum
Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition.
Malaria, Vivax
ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria.
Melanoma
High Frequency of Mutations in Genes Encoding Factor VIII, von Willebrand Factor, and ADAMTS13 in Skin Cutaneous Melanoma.
Melanoma
Thrombotic thrombocytopenic purpura associated to dual checkpoint inhibitor therapy for metastatic melanoma.
Melioidosis
Correction: Increased Von Willebrand factor, decreased ADAMTS13 and thrombocytopenia in melioidosis.
Melioidosis
Increased Von Willebrand factor, decreased ADAMTS13 and thrombocytopenia in melioidosis.
Mesenteric Ischemia
De Novo Mutation of the ADAMTS13 Gene with Mesenteric Ischemia in an Infant with Congenital Thrombotic Thrombocytopenic Purpura.
Monoclonal Gammopathy of Undetermined Significance
Antibodies against the CUB1-2 domains of ADAMTS13 in a patient with benign monoclonal gammopathy: no causal relationship.
Mucocutaneous Lymph Node Syndrome
Involvement of the ADAMTS13-VWF axis in acute Kawasaki disease and effects of intravenous immunoglobulin.
Multiple Sclerosis
ADAMTS13 ameliorates inflammatory responses in experimental autoimmune encephalomyelitis.
Multiple Sclerosis
Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review.
Multiple Sclerosis
Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis.
Myelodysplastic Syndromes
Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study.
Myocardial Infarction
Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation.
Myocardial Infarction
ADAMTS-13 attenuates thrombus formation on type I collagen surface and disrupted plaques under flow conditions.
Myocardial Infarction
ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men.
Myocardial Infarction
ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
Myocardial Infarction
ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice.
Myocardial Infarction
ADAMTS13 safeguards the myocardium in a mouse model of acute myocardial infarction.
Myocardial Infarction
ADAMTS13--more than just TMA and TTP.
Myocardial Infarction
Association of the von Willebrand Factor-ADAMTS13 Ratio With Incident Cardiovascular Events in Patients With Peripheral Arterial Disease.
Myocardial Infarction
Effect of Acute Myocardial Infarction on a Disintegrin and Metalloprotease with Thrombospondin Motif 13 and Von Willebrand Factor and Their Relationship with Markers of Inflammation.
Myocardial Infarction
Evaluation and clinical application of a new method for detecting ADAMTS13 activity.
Myocardial Infarction
Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack.
Myocardial Infarction
High VWF, low ADAMTS13 puts women at risk.
Myocardial Infarction
High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women.
Myocardial Infarction
Inverse Regulation of Confluence-Dependent ADAMTS13 and von Willebrand Factor Expression in Human Endothelial Cells.
Myocardial Infarction
Link between von Willebrand factor multimers, relapses and coronary microcirculation in patients with thrombotic thrombocytopenic purpura in remission.
Myocardial Infarction
Measurement of ADAMTS13 activity and inhibitors.
Myocardial Infarction
Molecular Imaging of VWF (von Willebrand Factor) and Platelet Adhesion in Postischemic Impaired Microvascular Reflow.
Myocardial Infarction
Plasma ADAMTS-13 levels and the risk of myocardial infarction: an individual patient data meta-analysis.
Myocardial Infarction
Plasma levels of active Von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: A multicenter and multiethnic study.
Myocardial Infarction
Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice.
Myocardial Infarction
Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction.
Myocardial Infarction
Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction.
Myocardial Infarction
The role of ADAMTS13 in acute myocardial infarction: cause or consequence?
Myocardial Infarction
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy.
Myocardial Infarction
Update on ADAMTS13 and VWF in cardiovascular and hematological disorders.
Myocardial Infarction
Verification of the Role of ADAMTS13 in the Cardiovascular Disease Using Two-Sample Mendelian Randomization.
Myocardial Infarction
Von Willebrand factor antigen predicts response to double dose of aspirin and clopidogrel by PFA-100 in patients undergoing primary angioplasty for ST elevation myocardial infarction.
Myocardial Infarction
[A study on the significance of plasma thrombospondin1 in thrombotic thrombocytopenic purpura and the relationship between thrombospondin1 and von Willebrand factor cleaving protease (ADAMTS13)]
Myocardial Infarction
[Determination of ADAMTS13 antigen and activity levels in patients with acute myocardial infarction and acute ischemic stroke]
Myocardial Infarction
[Genetic polymorphism of von Willebrand factor (VWF)-cleaving protease, ADAMTS13]
Myocardial Infarction
[Relationship between post-stenting coronary thrombolysis in myocardial infarction flow and plasma von Willebrand factor and ADAMTS-13 levels in patients with ST segment elevation myocardial infarction].
Myocardial Infarction
[Study of C1423T polymorphism of the von Willebrand factor-cleaving protease gene in Chinese Han population]
Myocardial Ischemia
ADAMTS-13 activity and ischemic heart disease: a Mendelian randomization study.
Myocardial Ischemia
Mutations and Common Polymorphisms in ADAMTS13 and vWF Genes Responsible for Increasing Risk of Thrombosis.
Neoplasm Metastasis
ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis.
Neoplasm Metastasis
Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer.
Neoplasms
Acquired thrombotic thrombocytopenic purpura due to antibody-mediated ADAMTS13 deficiency precipitated by a localized Castleman's disease: A case report.
Neoplasms
ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis.
Neoplasms
ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.
Neoplasms
ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma.
Neoplasms
ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
Neoplasms
All-trans retinoic acid modulates the balance of ADAMTS13 and VWF in human microvascular endothelial cells.
Neoplasms
Association between ADAMTS13 activity-VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma.
Neoplasms
Atypical presentation of hepatic visceral larva migrans mimicking cancer and associated with ADAMTS13 deficiency-mediated thrombotic microangiopathy: A first report from Reunion Island.
Neoplasms
Blood biomarkers associated with neurological deterioration in patients with acute penetrating artery territory infarction: A multicenter prospective observational study.
Neoplasms
Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency.
Neoplasms
Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.
Neoplasms
Circular RNA profiling identifies circADAMTS13 as a miR-484 sponge which suppresses cell proliferation in hepatocellular carcinoma.
Neoplasms
Decreased ADAMTS-13 level is related to inflammation factors and risk stratification of acute lymphoblastic leukemia patients.
Neoplasms
Deficiency of von Willebrand factor-cleaving protease activity in the plasma of malignant patients.
Neoplasms
Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies.
Neoplasms
Detection of a secreted metalloprotease within the nuclei of liver cells.
Neoplasms
Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study.
Neoplasms
Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.
Neoplasms
Evaluation of von Willebrand factor-cleaving protease activity in patients with thrombotic thrombocytopenic purpura.
Neoplasms
Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative.
Neoplasms
Inverse Regulation of Confluence-Dependent ADAMTS13 and von Willebrand Factor Expression in Human Endothelial Cells.
Neoplasms
Long-lasting prothrombotic state implied by changes of plasma von Willebrand factor parameters after radical prostatectomy for prostate malignancy.
Neoplasms
Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease.
Neoplasms
Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer.
Neoplasms
Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease).
Neoplasms
Potential Role of Enhanced Cytokinemia and Plasma Inhibitor on the Decreased Activity of Plasma ADAMTS13 in Patients With Alcoholic Hepatitis: Relationship to Endotoxemia.
Neoplasms
Presence of ADAMTS13 activity in a patient with metastatic cancer and thrombotic microangiopathy.
Neoplasms
Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity.
Neoplasms
Proteasome inhibitor associated thrombotic microangiopathy.
Neoplasms
Quetiapine-induced thrombotic microangiopathy in a patient on maintenance dialysis.
Neoplasms
Reduced ADAMTS-13 level negatively correlates with inflammation factors in plasma of acute myeloid leukemia patients.
Neoplasms
The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study.
Neoplasms
Validation of PLASMIC score: an academic medical center case series (2012-present).
Neoplasms
von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans.
Neoplasms
Von Willebrand factor, ADAMTS13 activity, TNF-? and their relationships in patients with chronic kidney disease.
Neoplasms
Von Willebrand factor:antigen and ADAMTS-13 level, but not soluble P-selectin, are risk factors for the first asymptomatic deep vein thrombosis in cancer patients undergoing chemotherapy.
Neoplasms
[ADAMTS13 Level in Prothrombotic Status and Its Related Factor Analysis].
Neoplasms
[Changes of ADAMTS13 Activity and TSP1 Level in Patients with Hematologic Malignancies].
Neoplasms
[Residual collagen binding assay for von Willebrand factor-cleaving protease activity and its clinical application]
Nephrosclerosis
ADAMTS13--more than just TMA and TTP.
Nephrosis, Lipoid
Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases.
Neuroblastoma
IL-1? Down-Regulates ADAMTS-13 mRNA Expression in Cells of the Central Nervous System.
Neurodegenerative Diseases
Increased expressions of ADAMTS-13, neuronal nitric oxide synthase, and neurofilament correlate with severity of neuropathology in Border disease virus-infected small ruminants.
Neuroinflammatory Diseases
ADAMTS13 gene deletion enhances plasma high-mobility group box1 elevation and neuroinflammation in brain ischemia-reperfusion injury.
Neurologic Manifestations
A case of pregnancy-induced thrombotic thrombocytopenic purpura with a kidney allograft recipient.
Neurologic Manifestations
Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan.
Neurologic Manifestations
Atypical presentations of thrombotic thrombocytopenic purpura: a diagnostic role for ADAMTS13.
Neurologic Manifestations
Long-term response to rituximab in patients with relapsing thrombotic thrombocytopenic purpura.
Neurologic Manifestations
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.
Neurologic Manifestations
Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes.
Neurologic Manifestations
[Allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy: 16 cases report and literature review].
Non-alcoholic Fatty Liver Disease
Preserved hemostatic status in patients with non-alcoholic fatty liver disease.
Obesity
ADAMTS13 deficiency in mice does not affect adipose tissue development.
Obesity
ADAMTS13 deficiency promotes microthrombosis in a murine model of diet-induced liver steatosis.
Obesity
Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers.
Obesity
Gender-dependent up-regulation of ADAMTS-13 in mice with obesity and hypercholesterolemia.
Obesity
Identification of Novel Candidate Markers of Type 2 Diabetes and Obesity in Russia by Exome Sequencing with a Limited Sample Size.
Obesity
Non-O blood group thrombotic thrombocytopenic purpura patients take longer to recover as measured by number of therapeutic plasma exchanges needed for platelet recovery.
Obesity
Platelet rescue by macrophage depletion in obese ADAMTS-13-deficient mice at risk of thrombotic thrombocytopenic purpura.
Obesity
Presence of anti-ADAMTS13 antibodies in obesity.
Obesity
Weight loss reduces anti-ADAMTS13 autoantibodies and improves inflammatory and coagulative parameters in obese patients.
Oliguria
The kidney in thrombotic thrombocytopenic purpura.
Pancreatitis
A case of acute pancreatitis-induced microangiopathic hemolytic anemia with thrombocytopenia.
Pancreatitis
A Rare Case of Acquired Thrombotic Thrombocytopenic Purpura Triggered by Acute Pancreatitis.
Pancreatitis
A rare case of thrombotic microangiopathy triggered by acute pancreatitis.
Pancreatitis
Acute pancreatitis-induced thrombotic thrombocytopenic purpura with recurrent acute pancreatitis.
Pancreatitis
Lessons from acute pancreatitis-induced thrombotic thrombocytopenic purpura.
Pancreatitis
Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports.
Pancreatitis
Plasma ADAMTS13 activity parallels the APACHE II score, reflecting an early prognostic indicator for patients with severe acute pancreatitis.
Pancreatitis
Thrombotic thrombocytopenic purpura associated with severe acute pancreatitis in a context of decreased ADAMTS13 activity: a case report.
Persistent Infection
Increased expressions of ADAMTS-13 and apoptosis contribute to neuropathology during Toxoplasma gondii encephalitis in mice.
Placenta Diseases
Early ADAMTS13 testing associates with pre-eclampsia occurrence in antiphospholipid syndrome.
Pneumococcal Infections
Severe transient ADAMTS13 deficiency in pneumococcal-associated hemolytic uremic syndrome.
Pneumococcal Infections
The thrombotic microangiopathies.
Pneumonia
ADAMTS-13 regulates neutrophil recruitment in a mouse model of invasive pulmonary aspergillosis.
Pneumonia
Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a case-control study.
Polycythemia Vera
Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review.
Post-Cardiac Arrest Syndrome
Decreased a disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 activity and neurologic outcome in patients with successful resuscitation of out-of-hospital cardiac arrest: A prospective observational study.
Pre-Eclampsia
Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome.
Pre-Eclampsia
ADAMTS 1, 4, 12, and 13 levels in maternal blood, cord blood, and placenta in preeclampsia.
Pre-Eclampsia
ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
Pre-Eclampsia
ADAMTS13 gene variants and function in women with preeclampsia: a population- based nested case- control study from the HUNT Study.
Pre-Eclampsia
ADAMTS13, FVIII, von Willebrand factor, ABO blood group assessment in preeclampsia.
Pre-Eclampsia
Early ADAMTS13 testing associates with pre-eclampsia occurrence in antiphospholipid syndrome.
Pre-Eclampsia
Expression of ADAMTS13 in Normal and Abnormal Placentae and Its Potential Role in Angiogenesis and Placenta Development.
Pre-Eclampsia
Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia.
Pre-Eclampsia
Increased VWF antigen levels and decreased ADAMTS13 activity in preeclampsia.
Pre-Eclampsia
Management of Thrombotic Thrombocytopenic Purpura with Autoantibodies to ADAMTS-13 and Concurrent Preeclampsia in Pregnancy: Multidisciplinary Team Approach.
Pre-Eclampsia
Structure-function and regulation of ADAMTS-13 protease.
Pre-Eclampsia
The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
Pre-Eclampsia
Thrombocytopenia in pregnancy.
Pre-Eclampsia
Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology.
Pre-Eclampsia
Von Willebrand factor antigen and ADAMTS13 activity assay in pregnant women and severe preeclamptic patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Decreased ADAMTS-13 level is related to inflammation factors and risk stratification of acute lymphoblastic leukemia patients.
Prediabetic State
ADAMTS13 activity as a novel risk factor for incident type 2 diabetes mellitus: a population-based cohort study.
Pregnancy Complications
ADAMTS-13 gene expression in antiphospholipid syndrome.
Proteinuria
ADAMTS13 inhibits oxidative stress and ameliorates progressive chronic kidney disease following ischaemia/reperfusion injury.
Proteinuria
Characteristics and Outcomes of Patients with Systemic Lupus Erythematosus-associated Thrombotic Microangiopathy, and Their Acquired ADAMTS13 Inhibitor Profiles.
Proteinuria
Microangiopathic haemolytic anaemia secondary to lupus nephritis: an important differential diagnosis of thrombotic thrombocytopenic purpura.
Proteinuria
Plasma ADAMTS-13 activity in proliferative lupus nephritis: a large cohort study from China.
Proteinuria
Successful treatment of refractory thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with combination of plasma exchange and low-dose rituximab.
Pulmonary Disease, Chronic Obstructive
Predictive value of ADAMTS-13 on concealed chronic renal failure in COPD patients.
Pulmonary Embolism
Changes in von Willebrand factor and ADAMTS-13 in patients following arthroplasty.
Pulmonary Embolism
Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial.
Purpura
A Case of Thrombotic Thrombocytopenia Purpura Associated with Systemic Lupus Erythematosus: Diagnostic Utility of ADAMTS-13 Activity.
Purpura
A patient with SLE-associated thrombotic microangiopathy and non-neutralizing antibodies against ADAMTS13.
Purpura
A perspective on the measurement of ADAMTS13 in thrombotic thrombocytopaenic purpura.
Purpura
A Severe Case of Congenital Thrombotic Thrombocytopenia Purpura Resulting From Compound Heterozygosity Involving a Novel ADAMTS13 Pathogenic Variant.
Purpura
Acquired thrombotic thrombocytopenia purpura associated with severe ADAMTS13 deficiency in a 3-year-old boy: a case report and review of the literature.
Purpura
ADAMTS 13 in non-thrombotic thrombocytopaenic purpura conditions.
Purpura
ADAMTS-13 regulates platelet adhesion under flow. A new method for differentiation between inherited and acquired thrombotic thrombocytopenic purpura.
Purpura
ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro.
Purpura
Effects of naturally occurring mutations in CUB-1 domain on synthesis, stability, and activity of ADAMTS-13.
Purpura
Emerging roles of adjunct therapies in acquired thrombotic thrombocytopenia purpura.
Purpura
Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH.
Purpura
Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand Factor A2 domain polypeptide as substrate.
Purpura
External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment.
Purpura
Fatal relapse of thrombotic thrombocytopaenic purpura after cardiac surgery in patient with congenital absence of vWF-cleaving protease activity.
Purpura
Malignant hypertension as a rare cause of thrombotic microangiopathy.
Purpura
Myocardial infarction is a complication of factor H-associated atypical HUS.
Purpura
Prospective evaluation of ADAMTS-13 and von Willebrand factor multimers in cardiac surgery.
Purpura
Refractory thrombotic thrombocytopenic purpura associated with oral contraceptives and factor V Leiden: a case report.
Purpura
The role of ADAMTS-13 in the coagulopathy of sepsis.
Purpura
Thrombotic thrombocytopaenic purpura in HIV-infected patients.
Purpura
Thrombotic thrombocytopenic purpura relapse induced by acute hepatitis E transmitted by cryosupernatant plasma and successfully controlled with ribavirin.
Purpura
[Hemolytic and uremic syndrome and related thrombotic microangiopathies: Epidemiology, pathophysiology and clinics].
Purpura, Thrombocytopenic
A successfully treated case of an acute presentation of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) with decreased ADAMTS13 during late stage of pregnancy.
Purpura, Thrombocytopenic
Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent.
Purpura, Thrombocytopenic
ADAMTS-13 regulates platelet adhesion under flow. A new method for differentiation between inherited and acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombocytopenic
ADAMTS13 turns 3.
Purpura, Thrombocytopenic
ADAMTS13--more than just TMA and TTP.
Purpura, Thrombocytopenic
Deficiency of ADAMTS-13 in thrombotic and thrombocytopenic purpura.
Purpura, Thrombocytopenic
Diarrhea-associated Hemolytic Uremic Syndrome in Adults: Two Case Reports and Review of the Literature.
Purpura, Thrombocytopenic
How do we reduce plasma transfusion in Rhode Island?
Purpura, Thrombocytopenic
Interrelationship between ADAMTS13 activity, von Willebrand factor, and complement activation in remission from immune-mediated trhrombotic thrombocytopenic purpura.
Purpura, Thrombocytopenic
Shiga Toxin as a Potential Trigger of CFHR1 Deletion-Associated Thrombotic Microangiopathy.
Purpura, Thrombocytopenic
Two novel mutations in ADAMTS13 in a Chinese boy with congenital thrombocytopenic purpura: a case report.
Purpura, Thrombocytopenic
[Identification of two novel mutations in ADAMTS13 gene in a patient with hereditary thrombotic thrombocytopenic purpura]
Purpura, Thrombocytopenic
[Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
Purpura, Thrombocytopenic, Idiopathic
A successfully treated case of an acute presentation of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) with decreased ADAMTS13 during late stage of pregnancy.
Purpura, Thrombocytopenic, Idiopathic
Alteration of ADAMTS13 antigen levels in patients with idiopathic thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura and systemic lupus erythematosus.
Purpura, Thrombocytopenic, Idiopathic
An Imperfect Marker: SLE and TTP-Like MAHA Without Low ADAMTS13.
Purpura, Thrombocytopenic, Idiopathic
Congenital ADAMTS13 Deficiency: A Rare Mimicker of Immune Thrombocytopenic Purpura.
Purpura, Thrombocytopenic, Idiopathic
Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders.
Purpura, Thrombocytopenic, Idiopathic
Evaluation and clinical application of a new method for detecting ADAMTS13 activity.
Purpura, Thrombotic Thrombocytopenic
Purpura, Thrombotic Thrombocytopenic
A 9-month-old infant with acquired idiopathic thrombotic thrombocytopenic purpura caused by inhibitory IgG-autoantibody to ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
A case for consideration by apheresis practitioners: Melanoma and PD-1 inhibitor treatment in a patient with multiple relapses of immune thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
A case of congenital TTP presenting with microganiopathy in adulthood.
Purpura, Thrombotic Thrombocytopenic
A case of severe ADAMTS13 deficiency presenting as thrombotic thrombocytopenic purpura in pregnancy.
Purpura, Thrombotic Thrombocytopenic
A case of thrombotic thrombocytopenic purpura induced by acute pancreatitis.
Purpura, Thrombotic Thrombocytopenic
A common origin of the 4143insA ADAMTS13 mutation.
Purpura, Thrombotic Thrombocytopenic
A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
A Difficult Diagnosis Case of Prolonged Thrombocytopenia With Sepsis and Disseminated Intravascular Coagulation.
Purpura, Thrombotic Thrombocytopenic
A human monoclonal antibody against the distal carboxyl terminus of ADAMTS-13 modulates its susceptibility to an inhibitor in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
A life-threatening case of pregnancy-related atypical Haemolytic uremic syndrome and successful treatment with Eculizumab.
Purpura, Thrombotic Thrombocytopenic
A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity.
Purpura, Thrombotic Thrombocytopenic
A new ADAMTS13 missense mutation (D1362V) in thrombotic thrombocytopenic purpura diagnosed during pregnancy.
Purpura, Thrombotic Thrombocytopenic
A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
A Novel Case of Leflunomide-Induced Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
A novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity.
Purpura, Thrombotic Thrombocytopenic
A novel homozygous frameshift mutation in Exon 7 of the ADAMTS13 gene in a patient with congenital thrombotic thrombocytopenic purpura from India: a case report.
Purpura, Thrombotic Thrombocytopenic
A novel homozygous missense ADAMTS13 mutation Y658C in a patient with recurrent thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
A novel mutation in ADAMTS13 of a child with Upshaw-Schulman Syndrome.
Purpura, Thrombotic Thrombocytopenic
A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan.
Purpura, Thrombotic Thrombocytopenic
A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom.
Purpura, Thrombotic Thrombocytopenic
A rapid enzyme-linked assay for ADAMTS-13.
Purpura, Thrombotic Thrombocytopenic
A Severe Case of Congenital Thrombotic Thrombocytopenia Purpura Resulting From Compound Heterozygosity Involving a Novel ADAMTS13 Pathogenic Variant.
Purpura, Thrombotic Thrombocytopenic
A shear-based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
A successfully treated case of an acute presentation of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) with decreased ADAMTS13 during late stage of pregnancy.
Purpura, Thrombotic Thrombocytopenic
A Unique Case Involving a Female Patient with Upshaw-Schulman Syndrome: Low Titers of Antibodies against ADAMTS13 prior to Pregnancy Disappeared after Successful Delivery.
Purpura, Thrombotic Thrombocytopenic
AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Absence of exaggerated pharmacology by recombinant ADAMTS13 in the rat and monkey.
Purpura, Thrombotic Thrombocytopenic
Absolute immature platelet count dynamics of thrombotic thrombocytopenic purpura patients with high ADAMTS13 inhibitor.
Purpura, Thrombotic Thrombocytopenic
Absolute immature platelet count helps differentiate thrombotic thrombocytopenic purpura from hypertension-induced thrombotic microangiopathy.
Purpura, Thrombotic Thrombocytopenic
Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan.
Purpura, Thrombotic Thrombocytopenic
Acquired thrombotic thrombocytopenic purpura due to antibody-mediated ADAMTS13 deficiency precipitated by a localized Castleman's disease: A case report.
Purpura, Thrombotic Thrombocytopenic
Acquired thrombotic thrombocytopenic purpura with a smoldering clinical course.
Purpura, Thrombotic Thrombocytopenic
Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade.
Purpura, Thrombotic Thrombocytopenic
Acquired Thrombotic Thrombocytopenic Purpura Without Anti-ADAMTS13 Antibody Caused by Influenza A (H1N1) Virus Successfully Treated by Plasma Exchange: A Case Report.
Purpura, Thrombotic Thrombocytopenic
Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease.
Purpura, Thrombotic Thrombocytopenic
Acquired TTP: ADAMTS13 meets the immune system.
Purpura, Thrombotic Thrombocytopenic
Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS 13 assays.
Purpura, Thrombotic Thrombocytopenic
Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity.
Purpura, Thrombotic Thrombocytopenic
Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity: comment.
Purpura, Thrombotic Thrombocytopenic
Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity: reply.
Purpura, Thrombotic Thrombocytopenic
Acute thrombotic thrombocytopenic purpura in Louisiana: Seasonal distribution and evaluation of an ADAMTS13 order screening protocol.
Purpura, Thrombotic Thrombocytopenic
ADAMTS proteases in cardiovascular physiology and disease.
Purpura, Thrombotic Thrombocytopenic
ADAMTS proteins in human disorders.
Purpura, Thrombotic Thrombocytopenic
ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
ADAMTS-13 activity and ischemic heart disease: a Mendelian randomization study.
Purpura, Thrombotic Thrombocytopenic
ADAMTS-13 activity and von Willebrand factor levels in methylene-blue photo-inactivated plasma processed by either the Springe method or an 'in house' system.
Purpura, Thrombotic Thrombocytopenic
ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate.
Purpura, Thrombotic Thrombocytopenic
ADAMTS-13 and Von Willebrand factor in relation to platelet response during plasma exchange in thrombotic thrombocytopenic purpura: a clue for disease mechanism?
Purpura, Thrombotic Thrombocytopenic
ADAMTS-13 antigen and activity levels in thrombocytopenic disorders including thrombotic thrombocytopenic purpura in Kuwait.
Purpura, Thrombotic Thrombocytopenic
ADAMTS-13 assays in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage.
Purpura, Thrombotic Thrombocytopenic
ADAMTS-13 gene expression in antiphospholipid syndrome.
Purpura, Thrombotic Thrombocytopenic
ADAMTS-13 level in children with severe diarrhea-associated hemolytic uremic syndrome: Unmasking new association.
Purpura, Thrombotic Thrombocytopenic
ADAMTS-13 levels in fresh, stored, and solvent detergent treated plasma.
Purpura, Thrombotic Thrombocytopenic
ADAMTS-13 may not predict disease or outcome in patients with Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor.
Purpura, Thrombotic Thrombocytopenic
ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences.
Purpura, Thrombotic Thrombocytopenic
ADAMTS-13 regulates platelet adhesion under flow. A new method for differentiation between inherited and acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 activity and genetic mutations in Japan.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 activity and inhibitor.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus-related thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 and microvascular thrombosis.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 and thrombotic thrombocytopenic purpura: where we are and where we need to go.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 and von Willebrand factor interactions.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 assays and ADAMTS13-deficient mice.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 Deficiency and Thrombotic Thrombocytopenic Purpura Associated with Trimethoprim-Sulfamethoxazole.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 deficiency in mice does not affect adipose tissue development.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 deficiency, an important cause of thrombocytopenia during pregnancy.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 Gene Mutations Influence ADAMTS13 Conformation and Disease Age-Onset in the French Cohort of Upshaw-Schulman Syndrome.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 is expressed in hepatic stellate cells.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 kinetics after therapeutic plasma exchange and plasma infusion in patients with Upshaw-Schulman syndrome.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 promotes angiogenesis and modulates VEGF-induced angiogenesis.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 related markers and von Willebrand factor in plasma from patients with thrombotic microangiopathy (TMA).
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 test and/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 Testing Methodologies and Thrombotic Thrombocytopenic Purpura (TTP): Conflicting Results Can Pose a Clinical Dilemma.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 testing update: Focus on laboratory aspects of difficult thrombotic thrombocytopenic purpura diagnoses and effects of new therapies.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13 unbound to larger von Willebrand factor multimers in cryosupernatant: implications for selection of plasma preparations for thrombotic thrombocytopenic purpura treatment.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice.
Purpura, Thrombotic Thrombocytopenic
Adult-onset congenital thrombotic thrombocytopenic purpura caused by a novel compound heterozygous mutation of the ADAMTS13 gene.
Purpura, Thrombotic Thrombocytopenic
Advantages and limits of ADAMTS13 testing in the prognostic assessment of thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
Purpura, Thrombotic Thrombocytopenic
AFM Imaging Reveals Multiple Conformational States of ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Alteration of ADAMTS13 antigen levels in patients with idiopathic thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura and systemic lupus erythematosus.
Purpura, Thrombotic Thrombocytopenic
Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP.
Purpura, Thrombotic Thrombocytopenic
Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor.
Purpura, Thrombotic Thrombocytopenic
Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.
Purpura, Thrombotic Thrombocytopenic
An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF.
Purpura, Thrombotic Thrombocytopenic
An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations.
Purpura, Thrombotic Thrombocytopenic
An IAP retrotransposon in the mouse ADAMTS13 gene creates ADAMTS13 variant proteins that are less effective in cleaving von Willebrand factor multimers.
Purpura, Thrombotic Thrombocytopenic
An inquiry into the relationship between ABO blood group and thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
An unusual case of rapidly progressive hyperbilirubinemia.
Purpura, Thrombotic Thrombocytopenic
An unusual presentation of primary pulmonary extranodal marginal zone lymphoma of mucosal associated lymphoid tissue: An autopsy case report.
Purpura, Thrombotic Thrombocytopenic
An update on the pathogenesis and management of acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Analyses of ADAMTS13 activity and its inhibitor in patients with thrombotic thrombocytopenic purpura secondary to connective tissue diseases: Observations in a single hospital.
Purpura, Thrombotic Thrombocytopenic
Analysis on the Molecular Species and Concentration of Circulating ADAMTS13 in Blood.
Purpura, Thrombotic Thrombocytopenic
Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigen.
Purpura, Thrombotic Thrombocytopenic
Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts.
Purpura, Thrombotic Thrombocytopenic
Application of PLASMIC score in prediction of ADAMTS13 deficiency in a pediatric case of acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Assays of ADAMTS-13 activity.
Purpura, Thrombotic Thrombocytopenic
Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension.
Purpura, Thrombotic Thrombocytopenic
Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab.
Purpura, Thrombotic Thrombocytopenic
Atypical hemolytic uremic syndrome.
Purpura, Thrombotic Thrombocytopenic
Atypical presentations of thrombotic thrombocytopenic purpura: a diagnostic role for ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis.
Purpura, Thrombotic Thrombocytopenic
Autopsy case of sudden maternal death from thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Bilateral serous retinal detachment as a complication of acquired peripartum thrombotic thrombocytopenic purpura bout.
Purpura, Thrombotic Thrombocytopenic
Biological variations of ADAMTS13 and von Willebrand factor in human adults.
Purpura, Thrombotic Thrombocytopenic
Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency.
Purpura, Thrombotic Thrombocytopenic
Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report.
Purpura, Thrombotic Thrombocytopenic
Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Cancer-associated Microangiopathic Hemolytic Anemia with Thrombocytopenia: an important diagnostic consideration.
Purpura, Thrombotic Thrombocytopenic
Candidate gene analysis using genomic quantitative PCR: identification of ADAMTS13 large deletions in two patients with Upshaw-Schulman syndrome.
Purpura, Thrombotic Thrombocytopenic
Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.
Purpura, Thrombotic Thrombocytopenic
Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13.
Purpura, Thrombotic Thrombocytopenic
Case of maternal and fetal deaths due to severe congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) during pregnancy.
Purpura, Thrombotic Thrombocytopenic
Case Report: Microangiopathic Hemolytic Anemia With Normal ADAMTS13 Activity.
Purpura, Thrombotic Thrombocytopenic
CD4+ T cells from patients with acquired thrombotic thrombocytopenic purpura recognize CUB2 domain-derived peptides.
Purpura, Thrombotic Thrombocytopenic
Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.
Purpura, Thrombotic Thrombocytopenic
Changes in plasma von Willebrand factor and von Willebrand factor cleaving protease in thrombotic thrombocytopenic purpura: A case report.
Purpura, Thrombotic Thrombocytopenic
Characterization and treatment of congenital thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Characterization of conformation-sensitive antibodies to ADAMTS13, the von Willebrand cleavage protease.
Purpura, Thrombotic Thrombocytopenic
Chikungunya Fever Presenting as Life Threatening Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
Purpura, Thrombotic Thrombocytopenic
Child-onset thrombotic thrombocytopenic purpura caused by p.R498C and p.G259PfsX133 mutations in ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features.
Purpura, Thrombotic Thrombocytopenic
Chronic relapsing thrombotic thrombocytopenic purpura due to a deficiency of von Willebrand factor-cleaving protease activity.
Purpura, Thrombotic Thrombocytopenic
Ciclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity.
Purpura, Thrombotic Thrombocytopenic
Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies.
Purpura, Thrombotic Thrombocytopenic
Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions.
Purpura, Thrombotic Thrombocytopenic
Cleavage of von Willebrand factor by ADAMTS-13 on endothelial cells.
Purpura, Thrombotic Thrombocytopenic
Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity.
Purpura, Thrombotic Thrombocytopenic
Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry.
Purpura, Thrombotic Thrombocytopenic
Clinical application of a rapid method using agarose gel electrophoresis and Western blotting to evaluate von Willebrand factor protease activity.
Purpura, Thrombotic Thrombocytopenic
Clinical Characteristics and Outcome of Canadian Patients Diagnosed With Atypical Hemolytic Uremic Syndrome.
Purpura, Thrombotic Thrombocytopenic
Clinical experience in treatment of thrombotic thrombocytopenic purpura--hemolytic uremic syndrome with 28 patients.
Purpura, Thrombotic Thrombocytopenic
Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience.
Purpura, Thrombotic Thrombocytopenic
Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Clinical study on five cases of thrombotic thrombocytopenic purpura complicating pregnancy.
Purpura, Thrombotic Thrombocytopenic
Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Cloning, expression and functional characterization of the full-length murine ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Cocaine-induced microangiopathic hemolytic anemia mimicking idiopathic thrombotic thrombocytopenic purpura: A case report and review of the literature.
Purpura, Thrombotic Thrombocytopenic
Comparison and stability of ADAMTS13 activity in therapeutic plasma products.
Purpura, Thrombotic Thrombocytopenic
Comparison of ADAMTS13 and Von Willebrand factor levels and activities, and plasminogen levels, in plasma products currently available for the treatment of thrombotic thrombocytopenic purpura in South Africa.
Purpura, Thrombotic Thrombocytopenic
Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Complement Activation Associated with ADAMTS13 Deficiency in Human and Murine Thrombotic Microangiopathy.
Purpura, Thrombotic Thrombocytopenic
Complement activation associated with ADAMTS13 deficiency may contribute to the characteristic glomerular manifestations in Upshaw-Schulman syndrome.
Purpura, Thrombotic Thrombocytopenic
Complement activation in diseases presenting with thrombotic microangiopathy.
Purpura, Thrombotic Thrombocytopenic
Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement.
Purpura, Thrombotic Thrombocytopenic
Complete ADAMTS13 remission in a patient with refractory autoimmune-mediated thrombotic thrombocytopenic purpura after infliximab.
Purpura, Thrombotic Thrombocytopenic
Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Concentration and Subclass Distribution of Anti-ADAMTS13 IgG Autoantibodies in Different Stages of Acquired Idiopathic Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Conformational plasticity of ADAMTS13 in hemostasis and autoimmunity.
Purpura, Thrombotic Thrombocytopenic
Congenital ADAMTS13 Deficiency: A Rare Mimicker of Immune Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Congenital microangiopathic hemolytic anemia and thrombocytopenia with unusually large von Willebrand factor multimers and von Willebrand factor-cleaving protease.
Purpura, Thrombotic Thrombocytopenic
Congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) caused by novel ADAMTS13 mutations.
Purpura, Thrombotic Thrombocytopenic
Congenital Thrombotic Thrombocytopenic Purpura Associated With Moyamoya Syndrome in a 3-Year-Old Girl: A Case Report.
Purpura, Thrombotic Thrombocytopenic
Congenital thrombotic thrombocytopenic purpura associated with unilateral moyamoya disease.
Purpura, Thrombotic Thrombocytopenic
Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the ADAMTS13 gene.
Purpura, Thrombotic Thrombocytopenic
Congenital thrombotic thrombocytopenic purpura in a large cohort of patients carrying a novel mutation in ADAMTS13 gene.
Purpura, Thrombotic Thrombocytopenic
Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Congenital Thrombotic Thrombocytopenic Purpura related to a Novel Mutation in ADAMTS13 Gene and Management during Pregnancy.
Purpura, Thrombotic Thrombocytopenic
Congenital Thrombotic Thrombocytopenic Purpura With a Novel ADAMTS13 Gene Mutation.
Purpura, Thrombotic Thrombocytopenic
Congenital thrombotic thrombocytopenic purpura with novel mutations in three unrelated Turkish children.
Purpura, Thrombotic Thrombocytopenic
Congenital Thrombotic Thrombocytopenic Purpura: Atypical Presentation and New ADAMTS 13 Mutation in a Tunisian Child.
Purpura, Thrombotic Thrombocytopenic
Coombs Positive Thrombotic Thrombocytopenic Purpura in a Male Pediatric Patient: An Urgent Diagnostic Challenge.
Purpura, Thrombotic Thrombocytopenic
Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.
Purpura, Thrombotic Thrombocytopenic
Correction to: Long-Term Prevention of Congenital Thrombotic Thrombocytopenic Purpura in ADAMTS13 Knockout Mice by Sleeping Beauty Transposon-Mediated Gene Therapy.
Purpura, Thrombotic Thrombocytopenic
Correction to: Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Cost-effectiveness of thrombotic thrombocytopenic purpura diagnosis: a retrospective analysis in the University Hospital Center of Lyon (France).
Purpura, Thrombotic Thrombocytopenic
COVID 19 infection associated with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report.
Purpura, Thrombotic Thrombocytopenic
Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor.
Purpura, Thrombotic Thrombocytopenic
Current and Future Perspectives on ADAMTS13 and Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Current concepts in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Current management of thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Current prophylactic plasma infusion protocols do not adequately prevent long-term cumulative organ damage in the Japanese congenital thrombotic thrombocytopenic purpura cohort.
Purpura, Thrombotic Thrombocytopenic
Cyclosporin A impairs the secretion and activity of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat).
Purpura, Thrombotic Thrombocytopenic
Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
De Novo Mutation of the ADAMTS13 Gene with Mesenteric Ischemia in an Infant with Congenital Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Decreased levels of von Willebrand factor-cleaving protease in coronary heart disease and thrombotic thrombocytopenic purpura: study of a simplified method for assaying the enzyme activity based on ristocetin-induced platelet aggregation.
Purpura, Thrombotic Thrombocytopenic
Defective ADAMTS13 synthesis as a possible consequence of NASH in an obese patient with recurrent thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Deficiency of ADAMTS-13 in pediatric patients with severe sepsis and impact on in-hospital mortality.
Purpura, Thrombotic Thrombocytopenic
Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Deficient activity of von Willebrand factor-cleaving protease in patients with Upshaw-Schulman syndrome.
Purpura, Thrombotic Thrombocytopenic
Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease.
Purpura, Thrombotic Thrombocytopenic
Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Defining the genetics of thrombotic microangiopathies.
Purpura, Thrombotic Thrombocytopenic
Degradation of two novel congenital TTP ADAMTS13 mutants by the cell proteasome prevents ADAMTS13 secretion.
Purpura, Thrombotic Thrombocytopenic
Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study.
Purpura, Thrombotic Thrombocytopenic
Detection of intracellular ADAMTS13, a secreted zinc-metalloprotease, via flow cytometry.
Purpura, Thrombotic Thrombocytopenic
Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report.
Purpura, Thrombotic Thrombocytopenic
Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis.
Purpura, Thrombotic Thrombocytopenic
Development and validation of a multivariable prediction rule for detecting a severe acquired ADAMTS13 activity deficiency in patients with thrombotic microangiopathies.
Purpura, Thrombotic Thrombocytopenic
Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.
Purpura, Thrombotic Thrombocytopenic
Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Developments in the use of plasma exchange and adjunctive therapies to treat immune-mediated thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Diagnosis and follow-up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay.
Purpura, Thrombotic Thrombocytopenic
Diagnosis of complement alternative pathway disorders.
Purpura, Thrombotic Thrombocytopenic
Diagnosis of Hereditary TTP Caused by Homozygosity for a Rare Complex ADAMTS13 Allele After Salmonella Infection in a 43-Year-Old Asylum Seeker.
Purpura, Thrombotic Thrombocytopenic
Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20.
Purpura, Thrombotic Thrombocytopenic
Diagnosis of thrombotic thrombocytopenic purpura with normal ADAMTS13 activity and absence of its inhibitor (anti-ADAMTS13 antibodies).
Purpura, Thrombotic Thrombocytopenic
Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Diagnostic relevance of ADAMTS13 activity: evaluation of 28 patients with thrombotic thrombocytopenic purpura - hemolytic uremic syndrome clinical diagnosis.
Purpura, Thrombotic Thrombocytopenic
Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators.
Purpura, Thrombotic Thrombocytopenic
Difficulties in diagnosing congenital thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Discrepant activity levels of von Willebrand factor-cleaving protease (ADAMTS-13) in congenital thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Disseminated intravascular coagulation: is it fact or fancy?
Purpura, Thrombotic Thrombocytopenic
Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Drop of residual plasmatic activity of ADAMTS13 to undetectable levels during acute disease in a patient with adult-onset congenital thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
EB virus reactivation triggers thrombotic thrombocytopenic purpura in a healthy adult.
Purpura, Thrombotic Thrombocytopenic
Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Effect of blood group on idiopathic thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Effects of naturally occurring mutations in CUB-1 domain on synthesis, stability, and activity of ADAMTS-13.
Purpura, Thrombotic Thrombocytopenic
Efficacy and Safety of Rituximab for Refractory and Relapsing Thrombotic Thrombocytopenic Purpura: A Cohort of 10 Cases.
Purpura, Thrombotic Thrombocytopenic
Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis.
Purpura, Thrombotic Thrombocytopenic
Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy?
Purpura, Thrombotic Thrombocytopenic
Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.
Purpura, Thrombotic Thrombocytopenic
Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Evaluating the impact of the ABO blood group on the clinical outcome of thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency.
Purpura, Thrombotic Thrombocytopenic
Evaluation and clinical application of a new method for detecting ADAMTS13 activity.
Purpura, Thrombotic Thrombocytopenic
Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13).
Purpura, Thrombotic Thrombocytopenic
Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement.
Purpura, Thrombotic Thrombocytopenic
Evaluation of a rapid turn-over, fully-automated ADAMTS13 activity assay: a method comparison study.
Purpura, Thrombotic Thrombocytopenic
Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome.
Purpura, Thrombotic Thrombocytopenic
Evaluation of von Willebrand factor-cleaving protease activity in patients with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Evidence based therapeutic apheresis in autoimmune and other hemolytic anemias.
Purpura, Thrombotic Thrombocytopenic
Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Evolution of ADAMTS13 antibodies in a fatal case of thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Exome Sequencing Identifies Abnormalities in Glycosylation and ANKRD36C in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Expression and characterization of recombinant human ADAMTS-13.
Purpura, Thrombotic Thrombocytopenic
External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment.
Purpura, Thrombotic Thrombocytopenic
Factor XI/ADAMTS13 complexes are quantitatively insignificant in human plasma.
Purpura, Thrombotic Thrombocytopenic
Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins.
Purpura, Thrombotic Thrombocytopenic
Fatal case of chikungunya and concomitant thrombotic thrombocytopenic purpura in French Guiana during air flight medical evacuation.
Purpura, Thrombotic Thrombocytopenic
Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin.
Purpura, Thrombotic Thrombocytopenic
First reported case of congenital thrombotic thrombocytopenic purpura in Taiwan with novel mutation of ADAMTS13 gene.
Purpura, Thrombotic Thrombocytopenic
FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients.
Purpura, Thrombotic Thrombocytopenic
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.
Purpura, Thrombotic Thrombocytopenic
Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Generation and validation of small ADAMTS13 fragments for epitope mapping of anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Genetic and Functional Characterization of ADAMTS13 Variants in a Patient Cohort with Upshaw-Schulman Syndrome Investigated in Germany.
Purpura, Thrombotic Thrombocytopenic
Genetic screening in haemolytic uraemic syndrome.
Purpura, Thrombotic Thrombocytopenic
Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency.
Purpura, Thrombotic Thrombocytopenic
Gold nanoparticle enhanced multiplexed biosensing on a fiber optic surface plasmon resonance probe.
Purpura, Thrombotic Thrombocytopenic
Goodpasture's syndrome associated with thrombotic thrombocytopenic purpura secondary to an ADAMTS-13 deficit.
Purpura, Thrombotic Thrombocytopenic
Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment.
Purpura, Thrombotic Thrombocytopenic
Heparin cofactor II as a predictor of thrombotic microangiopathy after bone marrow transplantation.
Purpura, Thrombotic Thrombocytopenic
Heparin-induced thrombocytopenia antibody and the pathogenesis of thrombotic microangiopathy after stem cell transplantation.
Purpura, Thrombotic Thrombocytopenic
Heparin-induced thrombocytopenia as a cause of prolonged low platelet count in a patient with thrombotic thrombocytopenic purpura treated with plasmapheresis.
Purpura, Thrombotic Thrombocytopenic
Hepatic stellate cell damage may lead to decreased plasma ADAMTS13 activity in rats.
Purpura, Thrombotic Thrombocytopenic
Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry.
Purpura, Thrombotic Thrombocytopenic
Hereditary Thrombotic Thrombocytopenic Purpura in a 9-Month Old: Diagnosing and Managing an Ultra-rare Disorder.
Purpura, Thrombotic Thrombocytopenic
Hereditary Thrombotic Thrombocytopenic Purpura in a Chinese Boy With a Novel Compound Heterozygous Mutation of the ADAMTS13 Gene.
Purpura, Thrombotic Thrombocytopenic
Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases.
Purpura, Thrombotic Thrombocytopenic
High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence.
Purpura, Thrombotic Thrombocytopenic
High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome.
Purpura, Thrombotic Thrombocytopenic
Highly elevated plasma level of von Willebrand factor accelerates the formation of platelet thrombus under high shear stress in plasma with deficient ADAMTS13 activity.
Purpura, Thrombotic Thrombocytopenic
Histone-induced thrombotic thrombocytopenic purpura in adamts13-/- zebrafish depends on von Willebrand factor.
Purpura, Thrombotic Thrombocytopenic
HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians.
Purpura, Thrombotic Thrombocytopenic
How I treat thrombotic thrombocytopenic purpura in pregnancy.
Purpura, Thrombotic Thrombocytopenic
Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link.
Purpura, Thrombotic Thrombocytopenic
Human Neutrophil Peptides (HNPs) Inhibit Proteolytic Cleavage of von Willebrand Factor by ADAMTS13: A Potential Link between Inflammation and Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Hypersensitivity to plasma exchange in a patient with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Identification of glycans on plasma-derived ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Identification of N-linked glycosylation and putative O-fucosylation, C-mannosylation sites in plasma derived ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Idiopathic Noncirrhotic Intrahepatic Portal Hypertension is Associated with Sustained ADAMTS13 Deficiency.
Purpura, Thrombotic Thrombocytopenic
Idiopathic Relapsing Thrombotic Thrombocytopenic Purpura with Persistent ADAMTS13 Inhibitor Activity Treated Sequentially with Plasmapheresis, Rituximab, Cyclophosphamide and Splenectomy.
Purpura, Thrombotic Thrombocytopenic
Immature platelet dynamics correlate with ADAMTS13 deficiency and predict therapy response in immune-mediated thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Immature platelet fraction can help adjust therapy in refractory thrombotic microangiopathic hemolytic anemia cases.
Purpura, Thrombotic Thrombocytopenic
Immune-Mediated Thrombotic Thrombocytopenic Purpura: A Narrative Review of Diagnosis and Treatment in Adults.
Purpura, Thrombotic Thrombocytopenic
Immune-Thrombotic Thrombocytopenic Purpura is a Rare Cause of Ischemic Stroke in Young Adults: Case Reports and Literature Review.
Purpura, Thrombotic Thrombocytopenic
Immunoadsorption for the treatment of a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange: kinetics of an inhibitor of ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Immunotherapy for thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Implementation of a rapid assay of ADAMTS13 activity was associated with improved 30-day survival rate in patients with acquired primary thrombotic thrombocytopenic purpura who received platelet transfusions.
Purpura, Thrombotic Thrombocytopenic
In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Incidence of obstetrical thrombotic thrombocytopenic purpura in a retrospective study within thrombocytopenic pregnant women. A difficult diagnosis and a treatable disease.
Purpura, Thrombotic Thrombocytopenic
Increased urinary albumin excretion following recovery from thrombotic thrombocytopenic purpura due to acquired ADAMTS13 deficiency.
Purpura, Thrombotic Thrombocytopenic
Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis.
Purpura, Thrombotic Thrombocytopenic
Indicators Differentiating Thrombotic Thrombocytopenic Purpura From Other Thrombotic Microangiopathies in a Canadian Apheresis Referral Center.
Purpura, Thrombotic Thrombocytopenic
Infection as Trigger for Congenital Thrombotic Thrombocytopenic Purpura in an Adult Patient.
Purpura, Thrombotic Thrombocytopenic
Influence of Personality, Resilience and Life Conditions on Depression and Anxiety in 104 Patients Having Survived Acute Autoimmune Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Inherited ADAMTS13 deficiency (Upshaw-Schulman syndrome): a short review.
Purpura, Thrombotic Thrombocytopenic
Inherited ADMATS13 deficiency: When to evoke the in the newborn?
Purpura, Thrombotic Thrombocytopenic
Inherited and de novo mutations of ADAMTS13 in a patient with Upshaw-Schulman syndrome.
Purpura, Thrombotic Thrombocytopenic
Inherited Thrombotic Thrombocytopenic Purpura (Upshaw Schulman Syndrome) as Differential Diagnosis to Neonatal Septicaemia with Disseminated Intravascular Coagulation - a Case Series.
Purpura, Thrombotic Thrombocytopenic
Inherited thrombotic thrombocytopenic purpura in children.
Purpura, Thrombotic Thrombocytopenic
Inherited thrombotic thrombocytopenic purpura in pregnancy.
Purpura, Thrombotic Thrombocytopenic
Inherited thrombotic thrombocytopenic purpura mimicking immune thrombocytopenic purpura during pregnancy: a case report.
Purpura, Thrombotic Thrombocytopenic
Inherited Thrombotic Thrombocytopenic Purpura Revealed by Recurrent Strokes in a Male Adult: Case Report and Literature Review.
Purpura, Thrombotic Thrombocytopenic
Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons.
Purpura, Thrombotic Thrombocytopenic
Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient.
Purpura, Thrombotic Thrombocytopenic
Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Inhibitory anti ADAMTS13 antibodies with a new rapid fully automated CLiA assay.
Purpura, Thrombotic Thrombocytopenic
Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.
Purpura, Thrombotic Thrombocytopenic
Insights into 3D Structure of ADAMTS13: A Stepping Stone towards Novel Therapeutic Treatment of Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Insights into ADAMTS13 structure: impact on thrombotic thrombocytopenic purpura diagnosis and management.
Purpura, Thrombotic Thrombocytopenic
Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis.
Purpura, Thrombotic Thrombocytopenic
Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Interferon-? is not elevated in idiopathic thrombotic thrombocytopenic purpura patients.
Purpura, Thrombotic Thrombocytopenic
International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Intravenous gamma globulin for thrombotic microangiopathy of unknown etiology.
Purpura, Thrombotic Thrombocytopenic
Inverse correlations between serum ADAMTS13 levels and systolic blood pressure, pulse pressure, and serum C-reactive protein levels observed at a general health examination in a Japanese population: A cross-sectional study.
Purpura, Thrombotic Thrombocytopenic
Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency?
Purpura, Thrombotic Thrombocytopenic
Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site.
Purpura, Thrombotic Thrombocytopenic
Limitations of ADAMTS-13 Activity Level in Diagnosing Thrombotic Thrombocytopenic Purpura in Pregnancy.
Purpura, Thrombotic Thrombocytopenic
Linear relationship between ADAMTS13 activity and platelet dynamics even before severe thrombocytopenia.
Purpura, Thrombotic Thrombocytopenic
Link between von Willebrand factor multimers, relapses and coronary microcirculation in patients with thrombotic thrombocytopenic purpura in remission.
Purpura, Thrombotic Thrombocytopenic
Long Term Management of Acquired Thrombotic Thrombocytopenic Purpura Using Serial Plasma ADAMTS13 Measurements.
Purpura, Thrombotic Thrombocytopenic
Long-Term Prevention of Congenital Thrombotic Thrombocytopenic Purpura in ADAMTS13 Knockout Mice by Sleeping Beauty Transposon-Mediated Gene Therapy.
Purpura, Thrombotic Thrombocytopenic
Long-term response to rituximab in patients with relapsing thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Low ADAMTS-13 in plavix induced thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Low Incidence of ADAMTS13 Missense Mutation R1060W in Adult Egyptian Patients with Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study.
Purpura, Thrombotic Thrombocytopenic
Making the Correct Diagnosis in Thrombotic Microangiopathy: A Narrative Review.
Purpura, Thrombotic Thrombocytopenic
Management of cancer-associated thrombotic microangiopathy: what is the right approach?
Purpura, Thrombotic Thrombocytopenic
Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group.
Purpura, Thrombotic Thrombocytopenic
Management of Thrombotic Thrombocytopenic Purpura with Autoantibodies to ADAMTS-13 and Concurrent Preeclampsia in Pregnancy: Multidisciplinary Team Approach.
Purpura, Thrombotic Thrombocytopenic
Mass spectrometry-assisted identification of ADAMTS13-derived peptides presented on HLA-DR and HLA-DQ.
Purpura, Thrombotic Thrombocytopenic
Measurement of ADAMTS13 activity and inhibitors.
Purpura, Thrombotic Thrombocytopenic
Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods.
Purpura, Thrombotic Thrombocytopenic
Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why?
Purpura, Thrombotic Thrombocytopenic
Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity.
Purpura, Thrombotic Thrombocytopenic
Methodologies and clinical utility of ADAMTS-13 activity testing.
Purpura, Thrombotic Thrombocytopenic
Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease.
Purpura, Thrombotic Thrombocytopenic
Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Microangiopathic haemolytic anaemia with thrombocytopenia induced by vitamin B12 deficiency long term after gastrectomy.
Purpura, Thrombotic Thrombocytopenic
Minor stroke as singular manifestation of hereditary thrombotic thrombocytopenic purpura in a young man.
Purpura, Thrombotic Thrombocytopenic
Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation.
Purpura, Thrombotic Thrombocytopenic
Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.
Purpura, Thrombotic Thrombocytopenic
Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome.
Purpura, Thrombotic Thrombocytopenic
Molecular characterization of four ADAMTS13 mutations responsible for congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).
Purpura, Thrombotic Thrombocytopenic
Molecular cloning, in vitro expression and functional characterization of canine ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice.
Purpura, Thrombotic Thrombocytopenic
Multicentric evaluation of the new HemosIL Acustar® chemiluminescence ADAMTS13 activity assay.
Purpura, Thrombotic Thrombocytopenic
Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Multiple in silico tools predict phenotypic manifestations in congenital thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
N-glycan-mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP.
Purpura, Thrombotic Thrombocytopenic
N-Glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity.
Purpura, Thrombotic Thrombocytopenic
Natural history of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Purpura, Thrombotic Thrombocytopenic
Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan.
Purpura, Thrombotic Thrombocytopenic
Neonate with Congenital Thrombotic Thrombocytopenic Purpura: a Case Report of a de novo Compound Heterozygote Mutation in ADAMTS13 Gene and Review of Literature.
Purpura, Thrombotic Thrombocytopenic
Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13.
Purpura, Thrombotic Thrombocytopenic
New strategies in diagnosis and treatment of thrombotic thrombocytopenic purpura: case report and review.
Purpura, Thrombotic Thrombocytopenic
Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Nonsteroidal Anti-inflammatory Drug Induced Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development.
Purpura, Thrombotic Thrombocytopenic
Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Novel ADAMTS13 mutations in an obstetric patient with upshaw-schulman syndrome.
Purpura, Thrombotic Thrombocytopenic
Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure.
Purpura, Thrombotic Thrombocytopenic
Novel frameshift mutations in ADAMTS13 in two families with hereditary thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Novel Heterozygous Mutations of Congenital Thrombotic Thrombocytopenic Purpura: A Rare Case Report.
Purpura, Thrombotic Thrombocytopenic
Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity.
Purpura, Thrombotic Thrombocytopenic
Novel mutations in ADAMTS13 CUB domains cause abnormal pre-mRNA splicing and defective secretion of ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Novel therapeutic approaches for thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Novel therapies in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
O-fucosylation is required for ADAMTS13 secretion.
Purpura, Thrombotic Thrombocytopenic
Occurrence of thrombotic thrombocytopenic purpura in a systemic lupus erythematosus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand factor-cleaving protease.
Purpura, Thrombotic Thrombocytopenic
Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Optimization of the detection of inhibitory autoantibodies against the VWF-cleaving protease ADAMTS13 with an automated chemiluminescent ADAMTS13 activity immunoassay.
Purpura, Thrombotic Thrombocytopenic
Overweight individuals are at increased risk for thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Paradigm shift of childhood thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency.
Purpura, Thrombotic Thrombocytopenic
Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome.
Purpura, Thrombotic Thrombocytopenic
Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.
Purpura, Thrombotic Thrombocytopenic
Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Plasma ADAMTS13, von Willebrand Factor (VWF) and VWF Propeptide Profiles in Patients with DIC and Related Diseases.
Purpura, Thrombotic Thrombocytopenic
Plasma levels of ADAMTS13 antigen determined with an enzyme immunoassay using a neutralizing monoclonal antibody parallel ADAMTS13 activity LevEls.
Purpura, Thrombotic Thrombocytopenic
Plasma Levels of Big Endothelin-1 Are Associated with Renal Insufficiency and In-Hospital Mortality of Immune Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Plasma of patients with Upshaw-Schulman syndrome, a congenital deficiency of von Willebrand factor-cleaving protease activity, enhances the aggregation of normal platelets under high shear stress.
Purpura, Thrombotic Thrombocytopenic
Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency.
Purpura, Thrombotic Thrombocytopenic
Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy.
Purpura, Thrombotic Thrombocytopenic
Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1-A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro.
Purpura, Thrombotic Thrombocytopenic
Platelet activation and the formation of the platelet plug: deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Platelet activation in hemolytic uremic syndrome.
Purpura, Thrombotic Thrombocytopenic
Platelet rescue by macrophage depletion in obese ADAMTS-13-deficient mice at risk of thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models.
Purpura, Thrombotic Thrombocytopenic
Platelet-free shear flow assay facilitates analysis of shear-dependent functions of VWF and ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Polymorphisms and mutations of ADAMTS13 in the Japanese population and estimation of the number of patients with Upshaw-Schulman syndrome.
Purpura, Thrombotic Thrombocytopenic
Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma.
Purpura, Thrombotic Thrombocytopenic
Positive Response and Increase in ADAMTS13 with Scheduled Rituximab in a Patient with Relapsing Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Postoperative thrombotic thrombocytopenic purpura in an infant: case report and literature review.
Purpura, Thrombotic Thrombocytopenic
Postpartum plasma exchange in a woman with suspected thrombotic thrombocytopenic purpura (TTP) vs. hemolysis, elevated liver enzymes, and low platelet syndrome (HELLP): a case study.
Purpura, Thrombotic Thrombocytopenic
Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review.
Purpura, Thrombotic Thrombocytopenic
Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Potential impact of a delayed ADAMTS13 result in the treatment of thrombotic microangiopathy: an economic analysis.
Purpura, Thrombotic Thrombocytopenic
Potential role of ADAMTS13 in the progression of alcoholic hepatitis.
Purpura, Thrombotic Thrombocytopenic
Practical issues in ADAMTS13 testing and emerging therapies in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Prasugrel and Acquired Thrombotic Thrombocytopenic Purpura Associated with ADAMTS13 Activity Deficiency.
Purpura, Thrombotic Thrombocytopenic
Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity.
Purpura, Thrombotic Thrombocytopenic
Prediction of spacer-?6 complex: a novel insight into binding of ADAMTS13 with A2 domain of von Willebrand factor under forces.
Purpura, Thrombotic Thrombocytopenic
Predictive Value of Schistocytes in Recurrence of Acquired Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency at Discontinuation of Daily Therapeutic Plasma Exchange.
Purpura, Thrombotic Thrombocytopenic
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Preferential HLA-DRB1*11 dependent presentation of CUB2 derived peptides by ADAMTS13 pulsed dendritic cells.
Purpura, Thrombotic Thrombocytopenic
Pregnancy in Upshaw-Schulman syndrome.
Purpura, Thrombotic Thrombocytopenic
Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients.
Purpura, Thrombotic Thrombocytopenic
Presence of anti-ADAMTS13 antibodies in obesity.
Purpura, Thrombotic Thrombocytopenic
Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Prevention of relapse in patients with acquired thrombotic thrombocytopenic purpura undergoing elective surgery: a case series.
Purpura, Thrombotic Thrombocytopenic
Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Prolonged inhibition of von Willebrand factor-cleaving protease after splenectomy in a 22-year-old patient with acute and plasma refractory thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Proteolytic fragmentation and sugar chains of plasma ADAMTS13 purified by a conformation-dependent monoclonal antibody.
Purpura, Thrombotic Thrombocytopenic
Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.
Purpura, Thrombotic Thrombocytopenic
Quantitative Western blot analysis of plasma ADAMTS13 antigen in patients with Upshaw-Schulman syndrome.
Purpura, Thrombotic Thrombocytopenic
Rapid quantitative assay of ADAMTS13 activity on an automated coagulation analyzer: clinical applications and comparison with immunoblot method.
Purpura, Thrombotic Thrombocytopenic
Real-world experience with caplacizumab in the management of acute TTP.
Purpura, Thrombotic Thrombocytopenic
Recombinant ADAMTS 13 in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies.
Purpura, Thrombotic Thrombocytopenic
Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Redefining outcomes in immune TTP: an international working group consensus report.
Purpura, Thrombotic Thrombocytopenic
Reduced ADAMTS-13 level negatively correlates with inflammation factors in plasma of acute myeloid leukemia patients.
Purpura, Thrombotic Thrombocytopenic
Reduced ADAMTS13 activity in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
Purpura, Thrombotic Thrombocytopenic
Reduced ADAMTS13 activity is associated with thrombotic risk in systemic lupus erythematosus.
Purpura, Thrombotic Thrombocytopenic
Relapsing thrombotic thrombocytopenic purpura with low ADAMTS13 antigen levels: An indication for splenectomy?
Purpura, Thrombotic Thrombocytopenic
Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke.
Purpura, Thrombotic Thrombocytopenic
Relevance of ADAMTS13 to liver transplantation and surgery.
Purpura, Thrombotic Thrombocytopenic
Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.
Purpura, Thrombotic Thrombocytopenic
Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.
Purpura, Thrombotic Thrombocytopenic
Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma.
Purpura, Thrombotic Thrombocytopenic
Renal thrombotic microangiopathy and pulmonary arterial hypertension in a patient with late-onset cobalamin C deficiency.
Purpura, Thrombotic Thrombocytopenic
Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain.
Purpura, Thrombotic Thrombocytopenic
Retinal involvement in acute thrombotic thrombocytopenic purpura: a case report.
Purpura, Thrombotic Thrombocytopenic
Retrospective analysis of bleeding events after central venous catheter placement in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.
Purpura, Thrombotic Thrombocytopenic
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
Purpura, Thrombotic Thrombocytopenic
Rituximab as prophylaxis in chronic relapsing thrombotic thrombocytopenic purpura: a case report and review of the literature.
Purpura, Thrombotic Thrombocytopenic
Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP.
Purpura, Thrombotic Thrombocytopenic
Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.
Purpura, Thrombotic Thrombocytopenic
Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature.
Purpura, Thrombotic Thrombocytopenic
Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report.
Purpura, Thrombotic Thrombocytopenic
Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan.
Purpura, Thrombotic Thrombocytopenic
Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders.
Purpura, Thrombotic Thrombocytopenic
Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
Purpura, Thrombotic Thrombocytopenic
Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Safety and efficacy of cryoprecipitate-poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: A single center retrospective evaluation.
Purpura, Thrombotic Thrombocytopenic
Schistocytic anaemia, severe thrombocytopenia, and renal dysfunction: thrombotic microangiopathy due to severe acquired ADAMTS-13 deficiency. Case 2.
Purpura, Thrombotic Thrombocytopenic
Seasonal distribution of severe ADAMTS13 deficient idiopathic thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Sepsis-Induced Disseminated Intravascular Coagulation With Features of Thrombotic Thrombocytopenic Purpura: a Fatal Fulminant Syndrome.
Purpura, Thrombotic Thrombocytopenic
Serial ADAMTS13 measurements during initial plasma exchange therapy guide decisions for management of unresponsive thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.
Purpura, Thrombotic Thrombocytopenic
Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome.
Purpura, Thrombotic Thrombocytopenic
Severe HELLP syndrome masquerading as thrombocytopenic thrombotic purpura: a case report.
Purpura, Thrombotic Thrombocytopenic
Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure.
Purpura, Thrombotic Thrombocytopenic
Severe vitamin B-12 deficiency in a child mimicking thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Shear stress and von Willebrand factor in health and disease.
Purpura, Thrombotic Thrombocytopenic
Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice.
Purpura, Thrombotic Thrombocytopenic
Siblings with congenital thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Simple plasma exchange reduced autoantibody to von Willebrand factor-cleaving protease in a Japanese man with ticlopidine-associated thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Simvastatin Increases ADAMTS13 Expression in Podocytes.
Purpura, Thrombotic Thrombocytopenic
Single-nucleotide variations defining previously unreported ADAMTS13 haplotypes are associated with differential expression and activity of the VWF-cleaving protease in a Salvadoran congenital thrombotic thrombocytopenic purpura family.
Purpura, Thrombotic Thrombocytopenic
SNPs in ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Structural and functional correlation of ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Structure-function and regulation of ADAMTS-13 protease.
Purpura, Thrombotic Thrombocytopenic
Successful management of pregnancy-associated thrombotic thrombocytopenic purpura by monitoring ADAMTS13 activity.
Purpura, Thrombotic Thrombocytopenic
Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI).
Purpura, Thrombotic Thrombocytopenic
Successful treatment of a young infant who developed high-titer inhibitors against VWF-cleaving protease (ADAMTS-13): important discrimination from Upshaw-Schulman syndrome.
Purpura, Thrombotic Thrombocytopenic
Successful treatment of an elderly frail patient with acquired idiopathic thrombotic thrombocytopenic purpura under close monitoring of ADAMTS13 activity and anti-ADAMTS13 antibody titers.
Purpura, Thrombotic Thrombocytopenic
Successful treatment of congenital thrombotic thrombocytopenic purpura using the intermediate purity factor VIII concentrate BPL 8Y.
Purpura, Thrombotic Thrombocytopenic
Successful treatment of refractory thrombotic thrombocytopenic purpura with cyclosporine and corticosteroids in a patient with systemic lupus erythematosus and antibodies to ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Successful treatment of thrombotic microangiopathy associated with dengue infection: A case report and literature review.
Purpura, Thrombotic Thrombocytopenic
Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: A pediatric report and literature review.
Purpura, Thrombotic Thrombocytopenic
Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature.
Purpura, Thrombotic Thrombocytopenic
Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.
Purpura, Thrombotic Thrombocytopenic
Synergistic interactions between interferon-gamma and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis.
Purpura, Thrombotic Thrombocytopenic
Systemic antithrombotic effects of ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Systemic Lupus Erythematosus Presenting as Refractory Thrombotic Thrombocytopenic Purpura: A Diagnostic and Management Challenge. A Case Report and Concise Review of the Literature.
Purpura, Thrombotic Thrombocytopenic
Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).
Purpura, Thrombotic Thrombocytopenic
Ten patient stories illustrating the extraordinarily diverse clinical features of patients with thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency.
Purpura, Thrombotic Thrombocytopenic
Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease.
Purpura, Thrombotic Thrombocytopenic
The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission.
Purpura, Thrombotic Thrombocytopenic
The ADAMTS(L) family and human genetic disorders.
Purpura, Thrombotic Thrombocytopenic
The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome.
Purpura, Thrombotic Thrombocytopenic
The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure?
Purpura, Thrombotic Thrombocytopenic
The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine.
Purpura, Thrombotic Thrombocytopenic
The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical andin silico study.
Purpura, Thrombotic Thrombocytopenic
The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
The function of ADAMTS13 in thrombogenesis in vivo: insights from mutant mice.
Purpura, Thrombotic Thrombocytopenic
The HLA Variant rs6903608 Is Associated with Disease Onset and Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Caucasians.
Purpura, Thrombotic Thrombocytopenic
The homozygous p.C1024R- ADAMTS13 gene mutation links to a late-onset phenotype of Upshaw-Schulman syndrome in Japan.
Purpura, Thrombotic Thrombocytopenic
The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: Key findings at enrolment until 2017.
Purpura, Thrombotic Thrombocytopenic
The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells.
Purpura, Thrombotic Thrombocytopenic
The novel ADAMTS13-p.D187H mutation impairs ADAMTS13 activity and secretion and contributes to thrombotic thrombocytopenic purpura in mice.
Purpura, Thrombotic Thrombocytopenic
The potential therapeutic benefit of targeting ADAMTS13 activity.
Purpura, Thrombotic Thrombocytopenic
The role of ADAMT-13 in platelet adhesion in flow: methods for diagnosis of thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.
Purpura, Thrombotic Thrombocytopenic
The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
Purpura, Thrombotic Thrombocytopenic
The role of von Willebrand factor in hemorrhagic and thrombotic disorders.
Purpura, Thrombotic Thrombocytopenic
The significance of ADAMTS13 in a patient with thrombotic thrombocytopenic purpura complicated autoimmune hepatitis.
Purpura, Thrombotic Thrombocytopenic
The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs.
Purpura, Thrombotic Thrombocytopenic
The use of 50% albumin/plasma replacement fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies.
Purpura, Thrombotic Thrombocytopenic
The utility of a fast turnaround ADAMTS13 activity in the diagnosis and exclusion of thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry.
Purpura, Thrombotic Thrombocytopenic
The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange.
Purpura, Thrombotic Thrombocytopenic
The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP).
Purpura, Thrombotic Thrombocytopenic
The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction.
Purpura, Thrombotic Thrombocytopenic
Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Thrombocytopenia and severe hyperbilirubinemia in the neonatal period secondary to congenital thrombotic thrombocytopenic purpura and ADAMTS13 deficiency.
Purpura, Thrombotic Thrombocytopenic
Thrombocytopenia in pregnancy.
Purpura, Thrombotic Thrombocytopenic
Thrombocytopenia-Associated Multiple Organ Failure.
Purpura, Thrombotic Thrombocytopenic
Thrombogenesis and thrombotic disorders based on 'two-path unifying theory of hemostasis': philosophical, physiological, and phenotypical interpretation.
Purpura, Thrombotic Thrombocytopenic
Thrombosis, Microangiopathies, and Inflammation.
Purpura, Thrombotic Thrombocytopenic
Thrombospondin-1 and ADAMTS13 competitively bind to VWF A2 and A3 domains in vitro.
Purpura, Thrombotic Thrombocytopenic
Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway.
Purpura, Thrombotic Thrombocytopenic
Thrombotic microangiopathies assessment: mind the complement.
Purpura, Thrombotic Thrombocytopenic
Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13.
Purpura, Thrombotic Thrombocytopenic
Thrombotic microangiopathies: towards a pathophysiology-based classification.
Purpura, Thrombotic Thrombocytopenic
Thrombotic microangiopathy (TTP and HUS): advances in differentiation and diagnosis.
Purpura, Thrombotic Thrombocytopenic
Thrombotic microangiopathy associated with Valproic acid toxicity.
Purpura, Thrombotic Thrombocytopenic
Thrombotic microangiopathy caused by interferon ?-1b for multiple sclerosis: a case report.
Purpura, Thrombotic Thrombocytopenic
Thrombotic Microangiopathy in the Setting of HIV Infection: A Case Report and Review of the Differential Diagnosis and Therapy.
Purpura, Thrombotic Thrombocytopenic
Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura as an initial presentation of systemic lupus erythematosus with acquired ADAMTS 13 antibody.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura associated with pegylated-interferon alpha-2a by an ADAMTS13 inhibitor in a patient with chronic hepatitis C.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura associated with severe acute pancreatitis in a context of decreased ADAMTS13 activity: a case report.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura attributable to von Willebrand factor-cleaving protease inhibitor in an 8-year-old boy.
Purpura, Thrombotic Thrombocytopenic
Thrombotic Thrombocytopenic Purpura Cases and Consumption of Large Quantities of Energy Drink: Related or Coincidence?
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus).
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura during pregnancy versus imitator of preeclampsia.
Purpura, Thrombotic Thrombocytopenic
Thrombotic Thrombocytopenic Purpura in a Child Treated for Acute Lymphoblastic Leukemia: Case Report and Review of Literature.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura in a patient with rapidly progressive glomerulonephritis with both anti-glomerular basement membrane antibodies and myeloperoxidase anti-neutrophil cytoplasmic antibodies.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura in children.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura in IgG4-related disease with severe deficiency of ADAMTS-13 activity and IgG4 autoantibody against ADAMTS-13.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura presenting with pathologic fracture: a case report.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura related to ADAMTS13 deficiency, and successful treatment in a chimpanzee (Pan troglodytes verus).
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children.
Purpura, Thrombotic Thrombocytopenic
Thrombotic Thrombocytopenic Purpura Treated with Rituximab Associated with Primary Sjögren's Syndrome and Primary Hypothyroidism.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura with an autoantibody to ADAMTS13 complicating Sjögren's syndrome: two cases and a literature review.
Purpura, Thrombotic Thrombocytopenic
Thrombotic Thrombocytopenic Purpura with Severe ADAMTS-13 Deficiency in a Patient with Antiphospholipid Antibodies and Charcot-Marie-Tooth Disease.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura with unusual 33 recurrences: a case report.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura-what is new?
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura: a diagnostic and therapeutic challenge.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura: a moving target.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies.
Purpura, Thrombotic Thrombocytopenic
Thrombotic Thrombocytopenic Purpura: Beyond Empiricism and Plasma Exchange.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura: The role of ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine.
Purpura, Thrombotic Thrombocytopenic
Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR).
Purpura, Thrombotic Thrombocytopenic
Ticlopidine-Associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity.
Purpura, Thrombotic Thrombocytopenic
Transcriptional regulation of ADAMTS13.
Purpura, Thrombotic Thrombocytopenic
Transfer of ADAMTS13 antibody-mediated thrombotic thrombocytopenic purpura via kidney transplantation.
Purpura, Thrombotic Thrombocytopenic
Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Treatment of Concurrent Thrombotic Thrombocytopenic Purpura and Graves' Disease: A Report on Two Cases.
Purpura, Thrombotic Thrombocytopenic
Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab.
Purpura, Thrombotic Thrombocytopenic
Treatment of refractory thrombotic thrombocytopenic purpura using multimodality therapy including splenectomy and cyclosporine.
Purpura, Thrombotic Thrombocytopenic
Treatment with or without plasma exchange for patients with acquired thrombotic microangiopathy not associated with severe ADAMTS13 deficiency: a propensity score-matched study.
Purpura, Thrombotic Thrombocytopenic
Two approaches to the clinical dilemma of treating TTP with therapeutic plasma exchange in patients with a history of anaphylactic reactions to plasma.
Purpura, Thrombotic Thrombocytopenic
Two newborn-onset patients of Upshaw-Schulman syndrome with distinct subsequent clinical courses.
Purpura, Thrombotic Thrombocytopenic
Two novel heterozygote missense mutations of the ADAMTS13 gene in a child with recurrent thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Two novel mutations in ADAMTS13 in a Chinese boy with congenital thrombocytopenic purpura: a case report.
Purpura, Thrombotic Thrombocytopenic
Ultralarge von Willebrand factor multimers and normal ADAMTS13 activity in the umbilical cord blood.
Purpura, Thrombotic Thrombocytopenic
Unwinding the von Willebrand factor strings puzzle.
Purpura, Thrombotic Thrombocytopenic
Update on ADAMTS13 and VWF in cardiovascular and hematological disorders.
Purpura, Thrombotic Thrombocytopenic
Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Upshaw-Schulman Syndrome With c.2728C>T Mutation in ADAMTS13 Gene.
Purpura, Thrombotic Thrombocytopenic
Upshaw-Schulman syndrome-associated ADAMTS13 variants possess proteolytic activity at the surface of endothelial cells and in simulated circulation.
Purpura, Thrombotic Thrombocytopenic
Use of the ADAMTS13 Activity Assay Improved the Accuracy and Efficiency of the Diagnosis and Treatment of Suspected Acquired Thrombotic Thrombocytopenic Purpura.
Purpura, Thrombotic Thrombocytopenic
Utility of ADAMTS13 assays in diagnosing thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Utility of ADAMTS13 assays in diagnosing thrombotic thrombocytopenic purpura. In reply.
Purpura, Thrombotic Thrombocytopenic
Validation of a panel of ADAMTS13 assays for diagnosis of thrombotic thrombocytopenic purpura: activity, functional inhibitor, and autoantibody test.
Purpura, Thrombotic Thrombocytopenic
Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy.
Purpura, Thrombotic Thrombocytopenic
Validation of PLASMIC score: an academic medical center case series (2012-present).
Purpura, Thrombotic Thrombocytopenic
Validation of the PLASMIC score at a University Medical Center.
Purpura, Thrombotic Thrombocytopenic
Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, Canada.
Purpura, Thrombotic Thrombocytopenic
Value of ADAMTS13 activity and inhibitor in the postmortem diagnosis of thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
von Willebrand factor and its cleaving protease ADAMTS13 balance in coronary artery vessels: Lessons learned from thrombotic thrombocytopenic purpura. A narrative review.
Purpura, Thrombotic Thrombocytopenic
Von Willebrand factor and thrombosis.
Purpura, Thrombotic Thrombocytopenic
von Willebrand factor and thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis).
Purpura, Thrombotic Thrombocytopenic
von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Purpura, Thrombotic Thrombocytopenic
von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP.
Purpura, Thrombotic Thrombocytopenic
von Willebrand Factor Multimer Formation Contributes to Immunothrombosis in Coronavirus Disease 2019.
Purpura, Thrombotic Thrombocytopenic
von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
von Willebrand factor, von Willebrand factor-cleaving protease, and shear stress.
Purpura, Thrombotic Thrombocytopenic
Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory.
Purpura, Thrombotic Thrombocytopenic
von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women.
Purpura, Thrombotic Thrombocytopenic
Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Von Willebrand factor-cleaving protease activity remains at the intermediate level in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome.
Purpura, Thrombotic Thrombocytopenic
von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome.
Purpura, Thrombotic Thrombocytopenic
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome.
Purpura, Thrombotic Thrombocytopenic
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Purpura, Thrombotic Thrombocytopenic
Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
von Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
von Willebrand factor/ADAMTS-13 interactions at birth: implications for thrombosis in the neonatal period.
Purpura, Thrombotic Thrombocytopenic
Von Willebrand factor: another janus-faced hemostasis protein.
Purpura, Thrombotic Thrombocytopenic
von Willebrand factor: two sides of a coin.
Purpura, Thrombotic Thrombocytopenic
VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.
Purpura, Thrombotic Thrombocytopenic
VWF-cleaving protease (ADAMTS13) in premature infants.
Purpura, Thrombotic Thrombocytopenic
What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
[A child with relapsing haemolytic anemia and thrombocytopenia]
Purpura, Thrombotic Thrombocytopenic
[A clinical study of congenital thrombotic thrombocytopenic purpura]
Purpura, Thrombotic Thrombocytopenic
[A study on the significance of plasma thrombospondin1 in thrombotic thrombocytopenic purpura and the relationship between thrombospondin1 and von Willebrand factor cleaving protease (ADAMTS13)]
Purpura, Thrombotic Thrombocytopenic
[Acquired thrombotic thrombocytopenic purpura after vascular prosthesis implantation for impending rupture of an abdominal aortic aneurysm].
Purpura, Thrombotic Thrombocytopenic
[Activity loss of Von Willebrand factor cleaving protein (ADAMTS-13) is diagnostic for primary and pregnancy-related thrombotic thrombocytopenic purpura]
Purpura, Thrombotic Thrombocytopenic
[ADAMTS13, von Willebrand factor specific cleaving protease].
Purpura, Thrombotic Thrombocytopenic
[Biology of von Willebrand factor]
Purpura, Thrombotic Thrombocytopenic
[Changes of ADAMTS13 activity and endothelial cell markers in TMA cases]
Purpura, Thrombotic Thrombocytopenic
[Clinical application of a method for evaluating von Willebrand factor cleaving protease activity]
Purpura, Thrombotic Thrombocytopenic
[Clinical observation of a patient with thrombotic thrombocytopenic purpura with renal and intestinal lesions].
Purpura, Thrombotic Thrombocytopenic
[Determination of the ADAMTS13 antigen and its activity in TTP patients and carriers]
Purpura, Thrombotic Thrombocytopenic
[Development and application of a new ADAMTS13 assay for TTP diagnosis]
Purpura, Thrombotic Thrombocytopenic
[Diagnosis and treatment of thrombotic thrombocytopenic purpura].
Purpura, Thrombotic Thrombocytopenic
[Diagnosis of thrombosis by hemostatic markers].
Purpura, Thrombotic Thrombocytopenic
[Effect of Recombinant Protein in the Spacer Domain on ADAMTS13 Activity].
Purpura, Thrombotic Thrombocytopenic
[Exacerbation of cranial nerurological symptoms by platelet transfusion before the diagnosis of thrombotic thrombocytopenic purpura].
Purpura, Thrombotic Thrombocytopenic
[From gene to disease; congenital thrombotic thrombocytopenic purpura due to mutations in the ADAMTS13 gene]
Purpura, Thrombotic Thrombocytopenic
[Frontline clinical practice for thrombotic thrombocytopenic purpura].
Purpura, Thrombotic Thrombocytopenic
[Genetic polymorphism of von Willebrand factor (VWF)-cleaving protease, ADAMTS13]
Purpura, Thrombotic Thrombocytopenic
[Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Current perspectives on EHEC, complement mutations and ADAMTS13]
Purpura, Thrombotic Thrombocytopenic
[Hemolytic-uremic syndrome]
Purpura, Thrombotic Thrombocytopenic
[Hereditary form of thrombotic thrombocytopenic purpura]
Purpura, Thrombotic Thrombocytopenic
[Human immunodeficiency virus-associated thrombotic microangiopathies.]
Purpura, Thrombotic Thrombocytopenic
[Identification of two novel mutations in ADAMTS13 gene in a patient with hereditary thrombotic thrombocytopenic purpura]
Purpura, Thrombotic Thrombocytopenic
[Latent malignant lymphoma diagnosed at autopsy in a patient with cold agglutinin disease coexisting thrombotic thrombocytopenic purpura].
Purpura, Thrombotic Thrombocytopenic
[New marker in thrombotic thrombocytopenic purpura]
Purpura, Thrombotic Thrombocytopenic
[Platelet--vessel wall interactions]
Purpura, Thrombotic Thrombocytopenic
[Role of plasmapheresis and immunoadsorption in salvage therapy of rheumatological diseases].
Purpura, Thrombotic Thrombocytopenic
[Structure and function of ADAMTS13 protease and its relation with diagnosis and treatment of TTP].
Purpura, Thrombotic Thrombocytopenic
[Successful treatment with rituximab of a patient with coincident acquired hemophilia A and thrombotic thrombocytopenic purpura].
Purpura, Thrombotic Thrombocytopenic
[The value of von Willebrand factor pro-peptide and ADAMTS13 in diagnosis of thrombotic thrombocytopenic purpura].
Purpura, Thrombotic Thrombocytopenic
[Thrombotic microangiopathies].
Purpura, Thrombotic Thrombocytopenic
[Thrombotic microangiopathy under an effective treatment with gemcitabine]
Purpura, Thrombotic Thrombocytopenic
[Thrombotic thrombocytopenic purpura during pregnancy refractory to plasma exchange and rituximab].
Purpura, Thrombotic Thrombocytopenic
[Thrombotic thrombocytopenic purpura in a child with low ADAMTS13 enzyme level.]
Purpura, Thrombotic Thrombocytopenic
[Thrombotic thrombocytopenic purpura in childhood]
Purpura, Thrombotic Thrombocytopenic
[Thrombotic thrombocytopenic purpura induced by antibody to von Willebrand factor-cleaving protease]
Purpura, Thrombotic Thrombocytopenic
[Thrombotic thrombocytopenic purpura. Reduced activity of von Willebrand factor cleaving protease]
Purpura, Thrombotic Thrombocytopenic
[Thrombotic thrombocytopenic purpura: Do not ignore cardiac involvement.]
Purpura, Thrombotic Thrombocytopenic
[Transplantation related ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: a case report and literature review].
Purpura, Thrombotic Thrombocytopenic
[Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point].
Purpura, Thrombotic Thrombocytopenic
[Treatment strategy for patients with thrombotic thrombocytopenic purpura].
Purpura, Thrombotic Thrombocytopenic
[Variety of thrombotic thrombocytopenic purpura clinical course in Polish family members with ADAMTS 13 gene mutation].
Purpura, Thrombotic Thrombocytopenic
[Von Willebrand factor and ADAMTS13 balancing primary haemostasis.]
Raynaud Disease
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.
Renal Insufficiency
Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.
Renal Insufficiency
Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?
Renal Insufficiency
Neutrophil Protease Cleavage of Von Willebrand Factor in Glomeruli - An Anti-thrombotic Mechanism in the Kidney.
Renal Insufficiency
Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure.
Renal Insufficiency
Prasugrel and Acquired Thrombotic Thrombocytopenic Purpura Associated with ADAMTS13 Activity Deficiency.
Renal Insufficiency
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.
Renal Insufficiency
Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure.
Renal Insufficiency
Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison.
Renal Insufficiency
Systemic infections mimicking thrombotic thrombocytopenic purpura.
Renal Insufficiency
Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis.
Renal Insufficiency
Thrombotic Thrombocytopenic Purpura in a Child with Diabetic Ketoacidosis.
Renal Insufficiency
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).
Renal Insufficiency
Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory.
Renal Insufficiency
What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura.
Renal Insufficiency, Chronic
ADAMTS-13 deficiency: can it cause chronic renal failure?
Renal Insufficiency, Chronic
ADAMTS13 inhibits oxidative stress and ameliorates progressive chronic kidney disease following ischaemia/reperfusion injury.
Renal Insufficiency, Chronic
Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review.
Renal Insufficiency, Chronic
Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases.
Renal Insufficiency, Chronic
Von Willebrand factor, ADAMTS13 activity, TNF-? and their relationships in patients with chronic kidney disease.
Reperfusion Injury
ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion.
Reperfusion Injury
ADAMTS13 gene deletion enhances plasma high-mobility group box1 elevation and neuroinflammation in brain ischemia-reperfusion injury.
Reperfusion Injury
ADAMTS13 protects mice against renal ischemia-reperfusion injury by reducing inflammation and improving endothelial function.
Reperfusion Injury
Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases.
Reperfusion Injury
Relevance of ADAMTS13 to liver transplantation and surgery.
Reperfusion Injury
Von Willebrand Factor Aggravates Hepatic Ischemia-Reperfusion Injury by Promoting Neutrophil Recruitment in Mice.
Respiratory Distress Syndrome
Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13.
Retinal Detachment
Bilateral serous retinal detachment as a complication of acquired peripartum thrombotic thrombocytopenic purpura bout.
Rocky Mountain Spotted Fever
Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006.
Salmonella Infections
Diagnosis of Hereditary TTP Caused by Homozygosity for a Rare Complex ADAMTS13 Allele After Salmonella Infection in a 43-Year-Old Asylum Seeker.
Scleroderma, Systemic
ADAMTS13 deficiency and immunological abnormalities in patients with systemic sclerosis.
Scleroderma, Systemic
Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases.
Scleroderma, Systemic
Pregnancy-associated thrombotic thrombocytopenic purpura with anti-centromere antibody-positive Raynaud's Syndrome.
Scleroderma, Systemic
The Plasma Levels of ADAMTS-13, von Willebrand Factor, VWFpp, and Fibrin-Related Markers in Patients With Systemic Sclerosis Having Thrombosis.
Scleroderma, Systemic
Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis).
Sepsis
Acid sphingomyelinase promotes endothelial stress response in systemic inflammation and sepsis.
Sepsis
Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis.
Sepsis
ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin) and endothelial dysfunction in sepsis: marker or culprit?
Sepsis
ADAMTS-13 in Critically Ill Patients With Septic Syndromes and Non-Infectious Systemic Inflammatory Response Syndrome.
Sepsis
ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock.
Sepsis
ADAMTS13 activity is decreased in a septic porcine model. Significance for glomerular thrombus deposition.
Sepsis
An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura.
Sepsis
Assessment of ADAMTS-13 Level in Hospitalized Children with Serious Bacterial Infections as a Possible Prognostic Marker.
Sepsis
Biomarkers of endothelial activation/dysfunction in infectious diseases.
Sepsis
Characterization of ADAMTS13 and von Willebrand factor levels in septic and non-septic ICU patients.
Sepsis
Clinical features and outcomes in patients with thrombotic microangiopathy not associated with severe ADAMTS13 deficiency.
Sepsis
Decreased a disintegrin-like and metalloprotease with thrombospondin (ADAMTS)-13 is associated with a poor prognosis in sepsis-induced organ failure*
Sepsis
Decreased ADAMTS 13 Activity is Associated With Disease Severity and Outcome in Pediatric Severe Sepsis.
Sepsis
Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure.
Sepsis
Deficiency of ADAMTS-13 in pediatric patients with severe sepsis and impact on in-hospital mortality.
Sepsis
Impact of HIV infection on the haemostatic response during sepsis and malaria.
Sepsis
Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor.
Sepsis
Inverse correlations between serum ADAMTS13 levels and systolic blood pressure, pulse pressure, and serum C-reactive protein levels observed at a general health examination in a Japanese population: A cross-sectional study.
Sepsis
Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure.
Sepsis
Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13.
Sepsis
Plasma Peptidylarginine Deiminase IV Promotes VWF-Platelet String Formation and Accelerates Thrombosis After Vessel Injury.
Sepsis
Preserved Expression of mRNA Coding von Willebrand Factor-Cleaving Protease ADAMTS13 by Selenite and Activated Protein C.
Sepsis
Prognostic value of ADAMTS13 in patients with severe sepsis and septic shock.
Sepsis
Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity.
Sepsis
Ratio of von Willebrand Factor Propeptide to ADAMTS13 is Associated with Severity of Sepsis.
Sepsis
Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome.
Sepsis
Risk stratification and prognostic evaluation of endothelial cell-specific molecule1, von Willebrand factor, and a disintegrin-like and metalloprotease with thrombospondin type 1 motif for sepsis in the emergency department: An observational study.
Sepsis
Secondary thrombotic microangiopathy with severely reduced ADAMTS13 activity in a patient with Capnocytophaga canimorsus sepsis: a case report.
Sepsis
Severe transient ADAMTS13 deficiency in pneumococcal-associated hemolytic uremic syndrome.
Sepsis
The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation.
Sepsis
The role of ADAMTS-13 in the coagulopathy of sepsis.
Sepsis
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy.
Sepsis
Variation of endothelium-related hemostatic factors during sepsis.
Sepsis
Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure.
Sepsis
Von Willebrand factor and ADAMTS13 impact on the outcome of Staphylococcus aureus sepsis.
Sepsis
von Willebrand factor is a major determinant of ADAMTS-13 decrease during mouse sepsis induced by cecum ligation and puncture.
Sepsis
VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.
Sepsis
[ADAMTS13 Level in Prothrombotic Status and Its Related Factor Analysis].
Severe Dengue
Severe dengue is associated with consumption of von Willebrand factor and its cleaving enzyme ADAMTS-13.
Shock, Septic
ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock.
Shock, Septic
Decreased ADAMTS 13 Activity is Associated With Disease Severity and Outcome in Pediatric Severe Sepsis.
Shock, Septic
Prognostic value of ADAMTS13 in patients with severe sepsis and septic shock.
Shock, Septic
Ratio of von Willebrand Factor Propeptide to ADAMTS13 is Associated with Severity of Sepsis.
Shock, Septic
The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation.
Spinal Cord Injuries
ADAMTS-13 is produced by glial cells and upregulated after spinal cord injury.
Spotted Fever Group Rickettsiosis
Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006.
ST Elevation Myocardial Infarction
Acquired intracoronary ADAMTS13 deficiency and VWF retention at sites of critical coronary stenosis in patients with STEMI.
ST Elevation Myocardial Infarction
Clinical significance of dynamic changes in hs-CRP and ADAMTS13 levels in the blood serum of patients with no-reflow after PCI operation.
ST Elevation Myocardial Infarction
The role of ADAMTS13 in acute myocardial infarction: cause or consequence?
Still's Disease, Adult-Onset
Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease.
Stroke
ADAMTS proteases in cardiovascular physiology and disease.
Stroke
ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
Stroke
ADAMTS13 controls vascular remodeling by modifying VWF reactivity during stroke recovery.
Stroke
ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion.
Stroke
ADAMTS13-mediated thrombolysis of t-PA resistant occlusions in ischemic stroke in mice.
Stroke
ADAMTS13: An Emerging Target in Stroke Therapy.
Stroke
Association of the von Willebrand Factor-ADAMTS13 Ratio With Incident Cardiovascular Events in Patients With Peripheral Arterial Disease.
Stroke
Biomarkers of Unfavorable Outcome in Acute Ischemic Stroke Patients with Successful Recanalization by Endovascular Thrombectomy.
Stroke
Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation.
Stroke
Enhanced activity of an ADAMTS-13 variant (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic stroke.
Stroke
High levels of von Willebrand factor and low levels of its cleaving protease, ADAMTS13, are associated with stroke in young HIV-infected patients.
Stroke
High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability.
Stroke
In silico features of ADAMTS13 contributing to plasmatic ADAMTS13 levels in neonates with congenital heart disease.
Stroke
Increased expression of ADAMTS13 mRNA correlates with ischemic cerebrovascular disease in systemic lupus erythematosus patients.
Stroke
Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series.
Stroke
Measurement of ADAMTS13 activity and inhibitors.
Stroke
Minor stroke as singular manifestation of hereditary thrombotic thrombocytopenic purpura in a young man.
Stroke
Rare Variants in the ADAMTS13 Von Willebrand Factor-Binding Domain Contribute to Pediatric Stroke.
Stroke
Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice.
Stroke
Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors.
Stroke
Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease.
Stroke
Role of reduced ADAMTS13 in arterial ischemic stroke: a pediatric cohort study.
Stroke
Serum and cerebrospinal fluid host proteins indicate stroke in children with tuberculous meningitis.
Stroke
Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence.
Stroke
The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis.
Stroke
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy.
Stroke
The Role of von Willebrand Factor, ADAMTS13, and Cerebral Artery Thrombus Composition in Patient Outcome Following Mechanical Thrombectomy for Acute Ischemic Stroke.
Stroke
Tissue Plasminogen Activator Neurotoxicity is Neutralized by Recombinant ADAMTS 13.
Stroke
von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli.
Stroke
von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.
Stroke
[Exacerbation of cranial nerurological symptoms by platelet transfusion before the diagnosis of thrombotic thrombocytopenic purpura].
Subarachnoid Hemorrhage
Association between variation in ADAMTS13 and aneurysmal subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Effect of ADAMTS-13 on cerebrovascular microthrombosis and neuronal injury after experimental subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Effect of recombinant ADAMTS13 on microthrombosis and brain injury after experimental subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Expression and significance of vWF, GMP-140 and ADAMTS13 in patients with aneurysmal subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Reduced ADAMTS13 activity in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Role of von Willebrand factor and ADAMTS-13 in early brain injury after experimental subarachnoid hemorrhage.
Subarachnoid Hemorrhage
The changes of von willebrand factor/a disintegrin-like and metalloprotease with thrombospondin type I repeats-13 balance in aneurysmal subarachnoid hemorrhage.
Thalassemia
ADAMTS13 Levels in Young Patients With ?-Thalassemia Major: Relation to Hepatitis C Virus Infection, Liver Cirrhosis, and Iron Overload.
Thrombocytopenia
A 9-month-old infant with acquired idiopathic thrombotic thrombocytopenic purpura caused by inhibitory IgG-autoantibody to ADAMTS13.
Thrombocytopenia
A case of pregnancy-induced thrombotic thrombocytopenic purpura with a kidney allograft recipient.
Thrombocytopenia
A Case of Thrombotic Thrombocytopenia Purpura Associated with Systemic Lupus Erythematosus: Diagnostic Utility of ADAMTS-13 Activity.
Thrombocytopenia
A Difficult Diagnosis Case of Prolonged Thrombocytopenia With Sepsis and Disseminated Intravascular Coagulation.
Thrombocytopenia
A rare combination of thrombotic thrombocytopenic purpura and antiphospholipid syndrome.
Thrombocytopenia
A role for tissue plasminogen activator in thrombotic thrombocytopenic purpura.
Thrombocytopenia
A Severe Case of Congenital Thrombotic Thrombocytopenia Purpura Resulting From Compound Heterozygosity Involving a Novel ADAMTS13 Pathogenic Variant.
Thrombocytopenia
Absolute immature platelet count helps differentiate thrombotic thrombocytopenic purpura from hypertension-induced thrombotic microangiopathy.
Thrombocytopenia
Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.
Thrombocytopenia
Acquired thrombotic thrombocytopenia purpura associated with severe ADAMTS13 deficiency in a 3-year-old boy: a case report and review of the literature.
Thrombocytopenia
Acquired thrombotic thrombocytopenic purpura with a smoldering clinical course.
Thrombocytopenia
ADAMTS-13 activity, microangiopathic haemolytic anaemia and thrombocytopenia following snake bite envenomation.
Thrombocytopenia
ADAMTS-13 gene expression in antiphospholipid syndrome.
Thrombocytopenia
ADAMTS13 activity decreases after hepatectomy, reflecting a postoperative liver dysfunction.
Thrombocytopenia
ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro.
Thrombocytopenia
ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria.
Thrombocytopenia
ADAMTS13 deficiency, an important cause of thrombocytopenia during pregnancy.
Thrombocytopenia
ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura.
Thrombocytopenia
Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes.
Thrombocytopenia
Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis.
Thrombocytopenia
C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction.
Thrombocytopenia
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Thrombocytopenia
Characteristics and Outcomes of Patients with Systemic Lupus Erythematosus-associated Thrombotic Microangiopathy, and Their Acquired ADAMTS13 Inhibitor Profiles.
Thrombocytopenia
Clinical application of a rapid method using agarose gel electrophoresis and Western blotting to evaluate von Willebrand factor protease activity.
Thrombocytopenia
Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura.
Thrombocytopenia
Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura.
Thrombocytopenia
Congenital microangiopathic hemolytic anemia and thrombocytopenia with unusually large von Willebrand factor multimers and von Willebrand factor-cleaving protease.
Thrombocytopenia
Congenital Thrombotic Thrombocytopenic Purpura With a Novel ADAMTS13 Gene Mutation.
Thrombocytopenia
Correction: Increased Von Willebrand factor, decreased ADAMTS13 and thrombocytopenia in melioidosis.
Thrombocytopenia
Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
Thrombocytopenia
Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders.
Thrombocytopenia
Deficiency of ADAMTS-13 in pediatric patients with severe sepsis and impact on in-hospital mortality.
Thrombocytopenia
Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura.
Thrombocytopenia
Early response to caplacizumab and rituximab after anaphylaxis to Octaplas plasma in a patient with thrombotic thrombocytopenic purpura.
Thrombocytopenia
EB virus reactivation triggers thrombotic thrombocytopenic purpura in a healthy adult.
Thrombocytopenia
Effects of naturally occurring mutations in CUB-1 domain on synthesis, stability, and activity of ADAMTS-13.
Thrombocytopenia
Emerging roles of adjunct therapies in acquired thrombotic thrombocytopenia purpura.
Thrombocytopenia
Erratum to: Prolonged thrombocytopenia after living donor liver transplantation is a strong prognostic predictor irrespective of history of splenectomy: the significance of ADAMTS13 and graft function.
Thrombocytopenia
Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand Factor A2 domain polypeptide as substrate.
Thrombocytopenia
External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment.
Thrombocytopenia
Hemolysis, Elevated Liver Enzymes, and Low Platelet Count Syndrome With Severe Thrombocytopenia and Severe ADAMTS13 Activity Deficiency.
Thrombocytopenia
Hereditary Thrombotic Thrombocytopenic Purpura in a 9-Month Old: Diagnosing and Managing an Ultra-rare Disorder.
Thrombocytopenia
Hereditary Thrombotic Thrombocytopenic Purpura in a Chinese Boy With a Novel Compound Heterozygous Mutation of the ADAMTS13 Gene.
Thrombocytopenia
Immature platelet fraction can help adjust therapy in refractory thrombotic microangiopathic hemolytic anemia cases.
Thrombocytopenia
Immune-Mediated Thrombotic Thrombocytopenic Purpura: A Narrative Review of Diagnosis and Treatment in Adults.
Thrombocytopenia
Impact of a multidisciplinary team for the management of thrombotic microangiopathy.
Thrombocytopenia
Incidence of obstetrical thrombotic thrombocytopenic purpura in a retrospective study within thrombocytopenic pregnant women. A difficult diagnosis and a treatable disease.
Thrombocytopenia
Increased Von Willebrand factor, decreased ADAMTS13 and thrombocytopenia in melioidosis.
Thrombocytopenia
Infection as Trigger for Congenital Thrombotic Thrombocytopenic Purpura in an Adult Patient.
Thrombocytopenia
Inherited thrombotic thrombocytopenic purpura mimicking immune thrombocytopenic purpura during pregnancy: a case report.
Thrombocytopenia
Inherited Thrombotic Thrombocytopenic Purpura Revealed by Recurrent Strokes in a Male Adult: Case Report and Literature Review.
Thrombocytopenia
Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure.
Thrombocytopenia
Intensive plasma exchange increases ADAMTS-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure.
Thrombocytopenia
Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review.
Thrombocytopenia
Is it quinine TTP/HUS or quinine TMA? ADAMTS13 levels and implications for therapy.
Thrombocytopenia
Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?
Thrombocytopenia
Linear relationship between ADAMTS13 activity and platelet dynamics even before severe thrombocytopenia.
Thrombocytopenia
Long-term response to rituximab in patients with relapsing thrombotic thrombocytopenic purpura.
Thrombocytopenia
Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.
Thrombocytopenia
Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura.
Thrombocytopenia
Nivolumab-Induced Thrombotic Thrombocytopenic Purpura in a Patient with Anal Squamous Cell Carcinoma: A Lesson on Hematologic Toxicity from Immunotherapy.
Thrombocytopenia
Nonsteroidal Anti-inflammatory Drug Induced Thrombotic Thrombocytopenic Purpura.
Thrombocytopenia
Novel therapies in thrombotic thrombocytopenic purpura.
Thrombocytopenia
Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria.
Thrombocytopenia
Pathophysiology of thrombotic thrombocytopenic purpura.
Thrombocytopenia
Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases.
Thrombocytopenia
Platelet ligands and ADAMTS13 during Puumala hantavirus infection and associated thrombocytopenia.
Thrombocytopenia
Platelet rescue by macrophage depletion in obese ADAMTS-13-deficient mice at risk of thrombotic thrombocytopenic purpura.
Thrombocytopenia
Platelets: thrombotic thrombocytopenic purpura.
Thrombocytopenia
Postoperative hemolytic uremic syndrome with renal cortical necrosis following laparoscopic hemicolectomy.
Thrombocytopenia
Prasugrel and Acquired Thrombotic Thrombocytopenic Purpura Associated with ADAMTS13 Activity Deficiency.
Thrombocytopenia
Predictive Value of Schistocytes in Recurrence of Acquired Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency at Discontinuation of Daily Therapeutic Plasma Exchange.
Thrombocytopenia
Pregnancy-associated thrombotic thrombocytopenic purpura with anti-centromere antibody-positive Raynaud's Syndrome.
Thrombocytopenia
Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients.
Thrombocytopenia
Presumed complement-mediated, checkpoint inhibitor-induced, thrombotic microangiopathy in a patient with metastatic melanoma.
Thrombocytopenia
Prolonged thrombocytopenia after living donor liver transplantation is a strong prognostic predictor irrespective of history of splenectomy: the significance of ADAMTS13 and graft function.
Thrombocytopenia
Rapid ADAMTS13 availability impacts treatment for microangiopathic hemolytic anemia and thrombocytopenia.
Thrombocytopenia
Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura.
Thrombocytopenia
Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura.
Thrombocytopenia
Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab.
Thrombocytopenia
Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma.
Thrombocytopenia
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
Thrombocytopenia
Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura.
Thrombocytopenia
Schistocytic anaemia, severe thrombocytopenia, and renal dysfunction: thrombotic microangiopathy due to severe acquired ADAMTS-13 deficiency. Case 2.
Thrombocytopenia
Serial ADAMTS13 measurements during initial plasma exchange therapy guide decisions for management of unresponsive thrombotic thrombocytopenic purpura.
Thrombocytopenia
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.
Thrombocytopenia
Severe vitamin B-12 deficiency in a child mimicking thrombotic thrombocytopenic purpura.
Thrombocytopenia
Siblings with congenital thrombotic thrombocytopenic purpura.
Thrombocytopenia
Silent Thrombotic Thrombocytopenic Purpura: PLASMIC, Lessons Learned, and Current Management Overview.
Thrombocytopenia
Spontaneous recovery in a patient with acquired thrombotic thrombocytopenic purpura (TTP): observation of a 'subclinical' TTP state.
Thrombocytopenia
The Association Between Human Leukocyte Antigens and ITP, TTP, and HIT.
Thrombocytopenia
The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis.
Thrombocytopenia
The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical andin silico study.
Thrombocytopenia
The features of acquired thrombotic thrombocytopenic purpura occurring at advanced age.
Thrombocytopenia
The Importance of the Full Blood Count in Cerebral Ischemia: A Review of 609 Consecutive Young Patients with Stroke and Transient Ischemic Attacks.
Thrombocytopenia
The role of ADAMTS-13 in the coagulopathy of sepsis.
Thrombocytopenia
Therapeutic plasma exchange in thrombotic thrombocytopenic purpura.
Thrombocytopenia
Thrombocytopenia and severe hyperbilirubinemia in the neonatal period secondary to congenital thrombotic thrombocytopenic purpura and ADAMTS13 deficiency.
Thrombocytopenia
Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/ thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other?
Thrombocytopenia
Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: Diagnosis and classification.
Thrombocytopenia
Thrombotic thrombocytopenic purpura associated to dual checkpoint inhibitor therapy for metastatic melanoma.
Thrombocytopenia
Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus).
Thrombocytopenia
Thrombotic thrombocytopenic purpura in a newborn.
Thrombocytopenia
Thrombotic thrombocytopenic purpura relapse induced by acute hepatitis E transmitted by cryosupernatant plasma and successfully controlled with ribavirin.
Thrombocytopenia
Thrombotic Thrombocytopenic Purpura with Severe ADAMTS-13 Deficiency in a Patient with Antiphospholipid Antibodies and Charcot-Marie-Tooth Disease.
Thrombocytopenia
Thrombotic thrombocytopenic purpura: a moving target.
Thrombocytopenia
Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.
Thrombocytopenia
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).
Thrombocytopenia
Two novel mutations in ADAMTS13 in a Chinese boy with congenital thrombocytopenic purpura: a case report.
Thrombocytopenia
Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
Thrombocytopenia
Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory.
Thrombocytopenia
Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.
Thrombocytopenia
What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura.
Thrombocytopenia
[A CASE REPORT OF THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN A BREAST CANCER PATIENT].
Thrombocytopenia
[Activity loss of Von Willebrand factor cleaving protein (ADAMTS-13) is diagnostic for primary and pregnancy-related thrombotic thrombocytopenic purpura]
Thrombocytopenia
[ADAMTS13, von Willebrand factor specific cleaving protease].
Thrombocytopenia
[Analysis of five children with acquired thrombotic thrombocytopenic purpura].
Thrombocytopenia
[Clinical Analysis of 12 cases of Systemic Lupus Erythematosus Associated with Thrombotic Thrombocytopenic Purpura].
Thrombocytopenia
[Clopidogrel-associated thrombotic thrombocytopenic purpura].
Thrombocytopenia
[Diagnosis and treatment of thrombotic thrombocytopenic purpura].
Thrombocytopenia
[Exacerbation of cranial nerurological symptoms by platelet transfusion before the diagnosis of thrombotic thrombocytopenic purpura].
Thrombocytopenia
[Frontline clinical practice for thrombotic thrombocytopenic purpura].
Thrombocytopenia
[Measurement of plasma von Willebrand factor cleaving protease in patients with varied thrombotic microangiopathy]
Thrombocytopenia
[Thrombotic thrombocytopenic purpura during pregnancy refractory to plasma exchange and rituximab].
Thromboinflammation
Insights Into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13.
Thromboinflammation
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy.
Thrombophilia
ADAMTS13 and Von Willebrand factor in patients undergoing hemodialysis.
Thrombophilia
Association between ADAMTS13 activity-VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma.
Thrombophilia
Association between Von Willebrand factor, disintegrin and metalloproteinase with thrombospondin type 1 motif member 13, d-Dimer and cystatin C levels with retinopathy in type 1 diabetes mellitus.
Thrombophilia
Hypercoagulability and cardiovascular disease in diabetic nephropathy.
Thrombophilia
Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer.
Thrombophilia
P265. Decreased plasma ADAMTS13 antigen and ADAMTS13 activity as a risk factor for hypercoagulability in patients with ulcerative colitis.
Thrombophilia
Thrombotic microangiopathy in patients with phosphatidylserine dependent antiprothrombin antibodies and antiphospholipid syndrome.
Thrombophilia
von Willebrand factor increases in experimental cerebral malaria but is not essential for late-stage pathogenesis in mice.
Thrombophilia
Von Willebrand Factor, ADAMTS13 and D-Dimer Are Correlated with Different Levels of Nephropathy in Type 1 Diabetes Mellitus.
Thrombophilia
[THE EFFECT OF VITAMIN D ON THE EXPRESSION OF ADAMTS13 IN CULTURED ENDOTHELIAL CELLS EXPOSED TO A DIABETIC-LIKE ENVIRONMENT].
Thrombosis
A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome.
Thrombosis
A model for single-substrate trimolecular enzymatic kinetics.
Thrombosis
A new name in thrombosis, ADAMTS13.
Thrombosis
A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry.
Thrombosis
ADAMTS-13 and von Willebrand factor: a dynamic duo.
Thrombosis
ADAMTS-13 attenuates thrombus formation on type I collagen surface and disrupted plaques under flow conditions.
Thrombosis
ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies.
Thrombosis
ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock.
Thrombosis
ADAMTS13 activity is decreased in a septic porcine model. Significance for glomerular thrombus deposition.
Thrombosis
ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis.
Thrombosis
ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis.
Thrombosis
ADAMTS13 ameliorates inflammatory responses in experimental autoimmune encephalomyelitis.
Thrombosis
ADAMTS13 and microvascular thrombosis.
Thrombosis
ADAMTS13 exerts a thrombolytic effect in microcirculation.
Thrombosis
ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion.
Thrombosis
ADAMTS13 gene variants and function in women with preeclampsia: a population- based nested case- control study from the HUNT Study.
Thrombosis
ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice.
Thrombosis
ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.
Thrombosis
ADAMTS13 Retards Progression of Diabetic Nephropathy by Inhibiting Intrarenal Thrombosis in Mice.
Thrombosis
ADAMTS13: a new link between thrombosis and inflammation.
Thrombosis
ADAMTS13: An Emerging Target in Stroke Therapy.
Thrombosis
ADAMTS13: more than a regulator of thrombosis.
Thrombosis
AFM Imaging Reveals Multiple Conformational States of ADAMTS13.
Thrombosis
Allosteric activation of ADAMTS13 by von Willebrand factor.
Thrombosis
Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor.
Thrombosis
anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura.
Thrombosis
Association of a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 polymorphisms with severity of coronary stenosis in type 2 diabetes mellitus.
Thrombosis
Association of the von Willebrand Factor-ADAMTS13 Ratio With Incident Cardiovascular Events in Patients With Peripheral Arterial Disease.
Thrombosis
Bench-to-bedside review: thrombocytopenia-associated multiple organ failure--a newly appreciated syndrome in the critically ill.
Thrombosis
Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13.
Thrombosis
Binding of von Willebrand factor cleaving protease ADAMTS13 to Lys-plasmin(ogen).
Thrombosis
Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner.
Thrombosis
Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation.
Thrombosis
Changes in von Willebrand factor and ADAMTS-13 in patients following arthroplasty.
Thrombosis
Characterization of the interactions of ADAMTS13 CUB1 domain to WT- and GOF-Spacer domain by molecular dynamics simulation.
Thrombosis
Cilostazol down-regulates the height of mural platelet thrombi formed under a high-shear rate flow in the absence of ADAMTS13 activity.
Thrombosis
Clinical application of a rapid method using agarose gel electrophoresis and Western blotting to evaluate von Willebrand factor protease activity.
Thrombosis
Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies.
Thrombosis
Conformational plasticity of ADAMTS13 in hemostasis and autoimmunity.
Thrombosis
Conformational quiescence of ADAMTS13 prevents proteolytic promiscuity.
Thrombosis
Congenital ADAMTS-13 deficiency presenting as life-threatening thrombosis during pregnancy.
Thrombosis
Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.
Thrombosis
Correction to: Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.
Thrombosis
Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura.
Thrombosis
Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor.
Thrombosis
Current concepts in thrombotic thrombocytopenic purpura.
Thrombosis
Degradation of Circulating von Willebrand Factor and Its Regulator ADAMTS13 Implicates Secreted Bacillus anthracis Metalloproteases in Anthrax Consumptive Coagulopathy.
Thrombosis
Destabilization of the von Willebrand factor A2 domain under oxidizing conditions investigated by molecular dynamics simulations.
Thrombosis
Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets.
Thrombosis
Development of a Hyperactive Primary Hemostatic System During Off-Pump Lung Transplantation Resulting From an Unbalance Between von Willebrand Factor and Its Cleaving Protease ADAMTS13.
Thrombosis
Effect of ADAMTS-13 on cerebrovascular microthrombosis and neuronal injury after experimental subarachnoid hemorrhage.
Thrombosis
Effect of recombinant ADAMTS13 on microthrombosis and brain injury after experimental subarachnoid hemorrhage.
Thrombosis
Effects of naturally occurring mutations in CUB-1 domain on synthesis, stability, and activity of ADAMTS-13.
Thrombosis
Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis.
Thrombosis
Elevated preoperative von Willebrand factor is associated with perioperative thrombosis in infants and neonates with congenital heart disease.
Thrombosis
Endothelial CD40 Mediates Microvascular von Willebrand Factor-Dependent Platelet Adhesion Inducing Inflammatory Venothrombosis in ADAMTS13 Knockout Mice.
Thrombosis
Enhanced activity of an ADAMTS-13 variant (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic stroke.
Thrombosis
Escherichia coli-derived von Willebrand factor-A2 domain fluorescence/Förster resonance energy transfer proteins that quantify ADAMTS13 activity.
Thrombosis
Essential Domains of ADAMTS13 Metalloprotease Required for Modulation of Arterial Thrombosis.
Thrombosis
Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH.
Thrombosis
Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease.
Thrombosis
Formation and Resolution of Pial Microvascular Thrombosis in a Mouse Model of Thrombotic Thrombocytopenic Purpura.
Thrombosis
Functional imaging of shear-dependent activity of ADAMTS13 in regulating mural thrombus growth under whole blood flow conditions.
Thrombosis
Genetic ablation of Adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model.
Thrombosis
High levels of von Willebrand factor and low levels of its cleaving protease, ADAMTS13, are associated with stroke in young HIV-infected patients.
Thrombosis
High titer of ADAMTS13 inhibitor associated with thrombotic microangiopathy of the gut and skeletal muscle after allogeneic hematopoietic stem cell transplantation.
Thrombosis
Highly elevated plasma level of von Willebrand factor accelerates the formation of platelet thrombus under high shear stress in plasma with deficient ADAMTS13 activity.
Thrombosis
Identification of ADAMTS13 peptide sequences binding to von Willebrand factor.
Thrombosis
In silico features of ADAMTS13 contributing to plasmatic ADAMTS13 levels in neonates with congenital heart disease.
Thrombosis
In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura.
Thrombosis
Increased ADAMTS13 activity in patients with venous thromboembolism.
Thrombosis
Increased dipeptidyl peptidase-4 accelerates chronic stress-related thrombosis in a mouse carotid artery model.
Thrombosis
Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis.
Thrombosis
Inflammation, von Willebrand factor, and ADAMTS13.
Thrombosis
Influence of Personality, Resilience and Life Conditions on Depression and Anxiety in 104 Patients Having Survived Acute Autoimmune Thrombotic Thrombocytopenic Purpura.
Thrombosis
Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure.
Thrombosis
Intensive plasma exchange increases ADAMTS-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure.
Thrombosis
Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis.
Thrombosis
Interplay between ADAMTS13 and von Willebrand factor in inherited and acquired thrombotic microangiopathies.
Thrombosis
Inverse correlations between serum ADAMTS13 levels and systolic blood pressure, pulse pressure, and serum C-reactive protein levels observed at a general health examination in a Japanese population: A cross-sectional study.
Thrombosis
Inverse Regulation of Confluence-Dependent ADAMTS13 and von Willebrand Factor Expression in Human Endothelial Cells.
Thrombosis
Invited commentary to: ADAMTS13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19 by Tiffany Pascreau et al. Letter to the Editors-in-Chief, Thrombosis Research.
Thrombosis
Involvement of the ADAMTS13-VWF axis in acute Kawasaki disease and effects of intravenous immunoglobulin.
Thrombosis
Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond.
Thrombosis
Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
Thrombosis
Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients.
Thrombosis
Macrovascular thrombosis in critically ill patients with thrombotic micro-angiopathies.
Thrombosis
Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.
Thrombosis
Modifier genes for disorders of thrombosis and hemostasis.
Thrombosis
Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.
Thrombosis
Molecular mechanisms in thrombotic thrombocytopenic purpura.
Thrombosis
Multi-step binding of ADAMTS13 to VWF.
Thrombosis
Mutations and Common Polymorphisms in ADAMTS13 and vWF Genes Responsible for Increasing Risk of Thrombosis.
Thrombosis
Neutrophil Protease Cleavage of Von Willebrand Factor in Glomeruli - An Anti-thrombotic Mechanism in the Kidney.
Thrombosis
Next-Generation Sequencing and In Vitro Expression Study of ADAMTS13 Single Nucleotide Variants in Deep Vein Thrombosis.
Thrombosis
Next-generation sequencing study finds an excess of rare, coding single-nucleotide variants of ADAMTS13 in patients with deep vein thrombosis.
Thrombosis
Novel mutations in ADAMTS13 CUB domains cause abnormal pre-mRNA splicing and defective secretion of ADAMTS13.
Thrombosis
Pathogenesis of thrombotic thrombocytopenic purpura.
Thrombosis
Pathophysiology of thrombotic thrombocytopenic purpura.
Thrombosis
Phylogenetic and functional analysis of ADAMTS13 identifies highly conserved domains essential for allosteric regulation.
Thrombosis
Plasma ADAMTS13 activity and von Willebrand factor antigen and activity in patients with subarachnoid haemorrhage.
Thrombosis
Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases.
Thrombosis
Plasma ADAMTS13, von Willebrand Factor (VWF), and VWF Propeptide Profiles in Patients With Connective Tissue Diseases and Antiphospholipid Syndrome.
Thrombosis
Plasma Proteomics of COVID-19 Associated Cardiovascular Complications: Implications for Pathophysiology and Therapeutics.
Thrombosis
Platelet factor 4 inhibits ADAMTS13 activity and regulates the multimeric distribution of von Willebrand factor.
Thrombosis
Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models.
Thrombosis
Predicting pathological von Willebrand factor unraveling in elongational flow.
Thrombosis
Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study.
Thrombosis
Rapid Restoration of Thrombus Formation and High-Molecular-Weight von Willebrand Factor Multimers in Patients with Severe Aortic Stenosis After Valve Replacement.
Thrombosis
Rare Variants in the ADAMTS13 Von Willebrand Factor-Binding Domain Contribute to Pediatric Stroke.
Thrombosis
Recent advances in thrombotic thrombocytopenic purpura.
Thrombosis
Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura.
Thrombosis
Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease.
Thrombosis
Reference range for ADAMTS13 antigen, activity and anti-ADAMTS13 antibody in the healthy adult Singapore population.
Thrombosis
Relative Deficiency of Plasma A Disintegrin and Metalloprotease with Thrombospondin Type 1 Repeats 13 Activity and Elevation of Human Neutrophil Peptides in Patients with Traumatic Brain Injury.
Thrombosis
Secretion of von Willebrand Factor and Suppression of ADAMTS-13 Activity by Markedly High Concentration of Ferritin.
Thrombosis
Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction.
Thrombosis
Serum ADAMTS-13 Levels as an Indicator of Portal Vein Thrombosis.
Thrombosis
Shear stress and platelet-induced tensile forces regulate ADAMTS13-localization within the platelet thrombus.
Thrombosis
Shear stress and von Willebrand factor in health and disease.
Thrombosis
Shear-Induced Unfolding and Enzymatic Cleavage of Full-Length VWF Multimers.
Thrombosis
Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases.
Thrombosis
Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood.
Thrombosis
SNPs in ADAMTS13.
Thrombosis
Structure-function and regulation of ADAMTS-13 protease.
Thrombosis
Systemic antithrombotic effects of ADAMTS13.
Thrombosis
Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).
Thrombosis
The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis.
Thrombosis
The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation.
Thrombosis
The expression of ADAMTS13 in human microvascular endothelial cells.
Thrombosis
The function of ADAMTS13 in thrombogenesis in vivo: insights from mutant mice.
Thrombosis
The kidney in thrombotic thrombocytopenic purpura.
Thrombosis
The Plasma Levels of ADAMTS-13, von Willebrand Factor, VWFpp, and Fibrin-Related Markers in Patients With Systemic Sclerosis Having Thrombosis.
Thrombosis
The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor.
Thrombosis
The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study.
Thrombosis
The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis.
Thrombosis
The Role of von Willebrand Factor, ADAMTS13, and Cerebral Artery Thrombus Composition in Patient Outcome Following Mechanical Thrombectomy for Acute Ischemic Stroke.
Thrombosis
Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura.
Thrombosis
Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13.
Thrombosis
Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway.
Thrombosis
Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor.
Thrombosis
Thrombotic thrombocytopenic purpura presenting with pathologic fracture: a case report.
Thrombosis
Thrombotic thrombocytopenic purpura with unusual 33 recurrences: a case report.
Thrombosis
Thrombotic thrombocytopenic purpura: a moving target.
Thrombosis
Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.
Thrombosis
Update on ADAMTS13 and VWF in cardiovascular and hematological disorders.
Thrombosis
Update on thrombotic thrombocytopenic purpura.
Thrombosis
Use of a mouse model to elucidate the phenotypic effects of the von willebrand factor cleavage mutants, y1605a/m1606a and r1597w.
Thrombosis
Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy.
Thrombosis
Variations among normal individuals in the cleavage of endothelial-derived ultra-large von Willebrand factor under flow.
Thrombosis
Von Willebrand Factor Adhesive Activity and ADAMTS13 Protease Activity in HIV-1-Infected Men.
Thrombosis
Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis.
Thrombosis
Von Willebrand factor and thrombosis.
Thrombosis
von Willebrand Factor, ADAMTS13 Activity, and Decline in Kidney Function: A Population-Based Cohort Study.
Thrombosis
von Willebrand Factor, Shear Stress, and ADAMTS13 in Hemostasis and Thrombosis.
Thrombosis
von Willebrand factor, von Willebrand factor-cleaving protease, and shear stress.
Thrombosis
von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.
Thrombosis
Von Willebrand factor: molecular size and functional activity.
Thrombosis
Von Willebrand factor:antigen and ADAMTS-13 level, but not soluble P-selectin, are risk factors for the first asymptomatic deep vein thrombosis in cancer patients undergoing chemotherapy.
Thrombosis
VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.
Thrombosis
Whole-exome sequencing detects mutations in pediatric patients with atypical hemolytic uremic syndrome in Taiwan.
Thrombosis
[Changes of ADAMTS13 Activity and TSP1 Level in Patients with Hematologic Malignancies].
Thrombosis
[Influence of HSCT Preconditioning on ADAMTS-13 Activity and vWF level and Its Clinical Significance].
Thrombosis
[Stable expression and characterization of the von Willebrand factor cleaving protease]
Thrombosis
[Thrombosis and ADAMTS13 exclusively produced in the liver]
Thrombosis
[Thrombotic microangiopathy]
Thrombosis
[Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
Thrombotic Microangiopathies
A Case of Recurrent Thrombotic Microangiopathy Caused by Hypertensive Urgency.
Thrombotic Microangiopathies
A Case of Thrombotic Thrombocytopenia Purpura Associated with Systemic Lupus Erythematosus: Diagnostic Utility of ADAMTS-13 Activity.
Thrombotic Microangiopathies
A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
A human monoclonal antibody against the distal carboxyl terminus of ADAMTS-13 modulates its susceptibility to an inhibitor in thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome.
Thrombotic Microangiopathies
A mild deficiency of ADAMTS13 is associated with severity in COVID-19: comparison of the coagulation profile in critically and noncritically ill patients.
Thrombotic Microangiopathies
A multi-center evaluation of TECHNOSCREEN® ADAMTS-13 activity assay as a screening tool for detecting deficiency of ADAMTS-13.
Thrombotic Microangiopathies
A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13.
Thrombotic Microangiopathies
A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infection.
Thrombotic Microangiopathies
A Novel Case of Leflunomide-Induced Thrombotic Thrombocytopenic Purpura.
Thrombotic Microangiopathies
A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan.
Thrombotic Microangiopathies
A patient with SLE-associated thrombotic microangiopathy and non-neutralizing antibodies against ADAMTS13.
Thrombotic Microangiopathies
Acquired thrombotic thrombocytopenic purpura due to antibody-mediated ADAMTS13 deficiency precipitated by a localized Castleman's disease: A case report.
Thrombotic Microangiopathies
ADAMTS-13 deficiency: can it cause chronic renal failure?
Thrombotic Microangiopathies
ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies.
Thrombotic Microangiopathies
ADAMTS-13 metalloprotease abnormalities in systemic lupus erythematosus: is there a correlation with disease status?
Thrombotic Microangiopathies
ADAMTS13 activity levels in patients with human immunodeficiency virus-associated thrombotic microangiopathy and profound CD4 deficiency.
Thrombotic Microangiopathies
ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy.
Thrombotic Microangiopathies
ADAMTS13 and TTP.
Thrombotic Microangiopathies
ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.
Thrombotic Microangiopathies
ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.
Thrombotic Microangiopathies
ADAMTS13 missense variants associated with defective activity and secretion of ADAMTS13 in a patient with non-cirrhotic portal hypertension.
Thrombotic Microangiopathies
ADAMTS13 related markers and von Willebrand factor in plasma from patients with thrombotic microangiopathy (TMA).
Thrombotic Microangiopathies
ADAMTS13 test and/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis.
Thrombotic Microangiopathies
ADAMTS13 Testing Methodologies and Thrombotic Thrombocytopenic Purpura (TTP): Conflicting Results Can Pose a Clinical Dilemma.
Thrombotic Microangiopathies
ADAMTS13--more than just TMA and TTP.
Thrombotic Microangiopathies
ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine-induced thrombotic microangiopathy.
Thrombotic Microangiopathies
Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis.
Thrombotic Microangiopathies
Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes.
Thrombotic Microangiopathies
Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension.
Thrombotic Microangiopathies
Attending rounds: microangiopathic hemolytic anemia with renal insufficiency.
Thrombotic Microangiopathies
Atypical Hemolytic Uremic Syndrome Presenting as Acute Heart Failure-A Rare Presentation: Diagnosis Supported by Skin Biopsy.
Thrombotic Microangiopathies
Atypical presentation of hepatic visceral larva migrans mimicking cancer and associated with ADAMTS13 deficiency-mediated thrombotic microangiopathy: A first report from Reunion Island.
Thrombotic Microangiopathies
Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management.
Thrombotic Microangiopathies
Availability of an ADAMTS13 assay with rapid turnaround time may avoid interhospital transfer in patients with thrombotic microangiopathy.
Thrombotic Microangiopathies
Behavior of ADAMTS13 and Von Willebrand factor levels in patients after living donor liver transplantation.
Thrombotic Microangiopathies
Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency.
Thrombotic Microangiopathies
Characteristics and Outcomes of Patients with Systemic Lupus Erythematosus-associated Thrombotic Microangiopathy, and Their Acquired ADAMTS13 Inhibitor Profiles.
Thrombotic Microangiopathies
Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
Thrombotic Microangiopathies
Clinical and laboratory diagnosis of TTP: an integrated approach.
Thrombotic Microangiopathies
Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry.
Thrombotic Microangiopathies
Clinical characteristics and outcomes of thrombotic microangiopathy in Malaysia.
Thrombotic Microangiopathies
Clinical features and outcomes in patients with thrombotic microangiopathy not associated with severe ADAMTS13 deficiency.
Thrombotic Microangiopathies
Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Clinical utility of ADAMTS-13 testing in suspected thrombotic microangiopathy: an audit of ADAMTS-13 activity assay requests in routine practice from a tertiary hospital.
Thrombotic Microangiopathies
Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing.
Thrombotic Microangiopathies
Comparison of Clinical Scoring Systems in the Management of Patients with Microangiopathic Hemolytic Anemia and Thrombocytopenia
Thrombotic Microangiopathies
Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Complement Activation Associated with ADAMTS13 Deficiency in Human and Murine Thrombotic Microangiopathy.
Thrombotic Microangiopathies
Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies.
Thrombotic Microangiopathies
Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies.
Thrombotic Microangiopathies
Complete defect in vWF-cleaving protease activity associated with increased shear-induced platelet aggregation in thrombotic microangiopathy.
Thrombotic Microangiopathies
Congenital thrombotic thrombocytopenic purpura associated with unilateral moyamoya disease.
Thrombotic Microangiopathies
Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the ADAMTS13 gene.
Thrombotic Microangiopathies
Coombs Positive Thrombotic Thrombocytopenic Purpura in a Male Pediatric Patient: An Urgent Diagnostic Challenge.
Thrombotic Microangiopathies
Correlation between ADAMTS13 activity and neurological impairment in acute thrombotic microangiopathy patients.
Thrombotic Microangiopathies
COVID 19 infection associated with thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Decreased ADAMTS13 Levels in Patients after Living Donor Liver Transplantation.
Thrombotic Microangiopathies
Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study.
Thrombotic Microangiopathies
Development and validation of a multivariable prediction rule for detecting a severe acquired ADAMTS13 activity deficiency in patients with thrombotic microangiopathies.
Thrombotic Microangiopathies
Diabetic ketoacidosis presenting with atypical hemolytic uremic syndrome associated with a variant of complement factor B in an adult: a case report.
Thrombotic Microangiopathies
Diagnosis and follow-up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay.
Thrombotic Microangiopathies
Diagnosis of complement alternative pathway disorders.
Thrombotic Microangiopathies
Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies.
Thrombotic Microangiopathies
Disseminated cerebral aspergillosis complicated by thrombotic microangiopathy.
Thrombotic Microangiopathies
Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study.
Thrombotic Microangiopathies
Does severe ADAMTS13 deficiency in thrombotic microangiopathy rule out complement-mediated atypical hemolytic uremic syndrome.
Thrombotic Microangiopathies
Drug-induced thrombotic microangiopathy.
Thrombotic Microangiopathies
Early response to caplacizumab and rituximab after anaphylaxis to Octaplas plasma in a patient with thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy.
Thrombotic Microangiopathies
Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.
Thrombotic Microangiopathies
Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement.
Thrombotic Microangiopathies
Evaluation of a rapid turn-over, fully-automated ADAMTS13 activity assay: a method comparison study.
Thrombotic Microangiopathies
Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies.
Thrombotic Microangiopathies
External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment.
Thrombotic Microangiopathies
Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity.
Thrombotic Microangiopathies
Fatal case of chikungunya and concomitant thrombotic thrombocytopenic purpura in French Guiana during air flight medical evacuation.
Thrombotic Microangiopathies
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.
Thrombotic Microangiopathies
Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura.
Thrombotic Microangiopathies
H1N1 Influenza (Swine Flu)-Associated Thrombotic Microangiopathy with a Markedly High Plasma Ratio of von Willebrand Factor to ADAMTS13.
Thrombotic Microangiopathies
Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment.
Thrombotic Microangiopathies
Heparin cofactor II as a predictor of thrombotic microangiopathy after bone marrow transplantation.
Thrombotic Microangiopathies
Heparin-induced thrombocytopenia antibody and the pathogenesis of thrombotic microangiopathy after stem cell transplantation.
Thrombotic Microangiopathies
Heparin-induced thrombocytopenia as a cause of prolonged low platelet count in a patient with thrombotic thrombocytopenic purpura treated with plasmapheresis.
Thrombotic Microangiopathies
Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases.
Thrombotic Microangiopathies
High titer of ADAMTS13 inhibitor associated with thrombotic microangiopathy of the gut and skeletal muscle after allogeneic hematopoietic stem cell transplantation.
Thrombotic Microangiopathies
How I treat thrombotic thrombocytopenic purpura in pregnancy.
Thrombotic Microangiopathies
Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity.
Thrombotic Microangiopathies
Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies.
Thrombotic Microangiopathies
IL-1? Down-Regulates ADAMTS-13 mRNA Expression in Cells of the Central Nervous System.
Thrombotic Microangiopathies
Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative.
Thrombotic Microangiopathies
Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis.
Thrombotic Microangiopathies
Indicators Differentiating Thrombotic Thrombocytopenic Purpura From Other Thrombotic Microangiopathies in a Canadian Apheresis Referral Center.
Thrombotic Microangiopathies
Inherited thrombotic thrombocytopenic purpura mimicking immune thrombocytopenic purpura during pregnancy: a case report.
Thrombotic Microangiopathies
Inherited Thrombotic Thrombocytopenic Purpura Revealed by Recurrent Strokes in a Male Adult: Case Report and Literature Review.
Thrombotic Microangiopathies
Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient.
Thrombotic Microangiopathies
Insights Into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13.
Thrombotic Microangiopathies
Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure.
Thrombotic Microangiopathies
Intensive plasma exchange increases ADAMTS-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure.
Thrombotic Microangiopathies
International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13.
Thrombotic Microangiopathies
Interplay between ADAMTS13 and von Willebrand factor in inherited and acquired thrombotic microangiopathies.
Thrombotic Microangiopathies
Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency?
Thrombotic Microangiopathies
Is it quinine TTP/HUS or quinine TMA? ADAMTS13 levels and implications for therapy.
Thrombotic Microangiopathies
Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
MED-TMA: A clinical decision support tool for differential diagnosis of TMA with enhanced accuracy using an ensemble method.
Thrombotic Microangiopathies
Methodologies and clinical utility of ADAMTS-13 activity testing.
Thrombotic Microangiopathies
Microangiopathic Anemia of Acute Brucellosis - is it a True TTP?
Thrombotic Microangiopathies
Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome.
Thrombotic Microangiopathies
Multicentric evaluation of the new HemosIL Acustar® chemiluminescence ADAMTS13 activity assay.
Thrombotic Microangiopathies
Multiple centre evaluation study of ADAMTS13 activity and inhibitor assays.
Thrombotic Microangiopathies
Natural history of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Thrombotic Microangiopathies
Neutrophil Protease Cleavage of Von Willebrand Factor in Glomeruli - An Anti-thrombotic Mechanism in the Kidney.
Thrombotic Microangiopathies
Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure.
Thrombotic Microangiopathies
Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity.
Thrombotic Microangiopathies
Novel therapeutic approaches for thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Pathogenesis of Thrombotic Microangiopathies.
Thrombotic Microangiopathies
Pathogenesis of thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease).
Thrombotic Microangiopathies
Performance of Diagnostic Scores in Thrombotic Microangiopathy Patients in the Intensive Care Unit: A Monocentric Study.
Thrombotic Microangiopathies
Plasmapheresis in Sepsis-induced Thrombotic Microangiopathy: A Case Series.
Thrombotic Microangiopathies
Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy.
Thrombotic Microangiopathies
Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia.
Thrombotic Microangiopathies
Post-traumatic thrombotic microangiopathy following pelvic fracture treated with transcatheter arterial embolization: a case report.
Thrombotic Microangiopathies
Potential impact of a delayed ADAMTS13 result in the treatment of thrombotic microangiopathy: an economic analysis.
Thrombotic Microangiopathies
Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience.
Thrombotic Microangiopathies
Presence of ADAMTS13 activity in a patient with metastatic cancer and thrombotic microangiopathy.
Thrombotic Microangiopathies
Prognostic and Long-term Survival of Immune Thrombotic Thrombocytopenic Purpura in older patients.
Thrombotic Microangiopathies
Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity.
Thrombotic Microangiopathies
Prospective evaluation of ADAMTS-13 and von Willebrand factor multimers in cardiac surgery.
Thrombotic Microangiopathies
Rapid quantitative assay of ADAMTS13 activity on an automated coagulation analyzer: clinical applications and comparison with immunoblot method.
Thrombotic Microangiopathies
Recent advances in thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Redefining outcomes in immune TTP: an international working group consensus report.
Thrombotic Microangiopathies
Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases.
Thrombotic Microangiopathies
Reference range for ADAMTS13 antigen, activity and anti-ADAMTS13 antibody in the healthy adult Singapore population.
Thrombotic Microangiopathies
Refractory thrombotic thrombocytopenic purpura associated with oral contraceptives and factor V Leiden: a case report.
Thrombotic Microangiopathies
Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA).
Thrombotic Microangiopathies
Relevance of ADAMTS13 to liver transplantation and surgery.
Thrombotic Microangiopathies
Renal thrombotic microangiopathy and pulmonary arterial hypertension in a patient with late-onset cobalamin C deficiency.
Thrombotic Microangiopathies
Rituximab in a child with autoimmune thrombotic thrombocytopenic purpura refractory to plasma exchange.
Thrombotic Microangiopathies
Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
Thrombotic Microangiopathies
Safety and efficacy of cryoprecipitate-poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: A single center retrospective evaluation.
Thrombotic Microangiopathies
Schistocytic anaemia, severe thrombocytopenia, and renal dysfunction: thrombotic microangiopathy due to severe acquired ADAMTS-13 deficiency. Case 2.
Thrombotic Microangiopathies
Seasonal distribution of severe ADAMTS13 deficient idiopathic thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13).
Thrombotic Microangiopathies
Secondary thrombotic microangiopathy with severely reduced ADAMTS13 activity in a patient with Capnocytophaga canimorsus sepsis: a case report.
Thrombotic Microangiopathies
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.
Thrombotic Microangiopathies
Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients.
Thrombotic Microangiopathies
Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.
Thrombotic Microangiopathies
Structure and Proteolytic Properties of ADAMTS13, A Metalloprotease Involved in the Pathogenesis of Thrombotic Microangiopathies.
Thrombotic Microangiopathies
Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids.
Thrombotic Microangiopathies
Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.
Thrombotic Microangiopathies
Systemic lupus erythematosus presenting as thrombotic thrombocytopaenic purpura in a child: a diagnostic challenge.
Thrombotic Microangiopathies
Systemic lupus erythematosus with ADAMTS13 inhibitor-negative thrombotic microangiopathy treated with combination of mycophenolate mofetil, plasma exchange and steroid.
Thrombotic Microangiopathies
The "cutting" edge: von Willebrand factor-cleaving protease activity in thrombotic microangiopathies.
Thrombotic Microangiopathies
The activity of the von Willebrand factor cleaving protease ADAMTS-13 in newborn infants.
Thrombotic Microangiopathies
The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical andin silico study.
Thrombotic Microangiopathies
The Differential Diagnosis and Treatment of Thrombotic Microangiopathies.
Thrombotic Microangiopathies
The HLA Variant rs6903608 Is Associated with Disease Onset and Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Caucasians.
Thrombotic Microangiopathies
The potential therapeutic benefit of targeting ADAMTS13 activity.
Thrombotic Microangiopathies
The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.
Thrombotic Microangiopathies
The role of ADAMTS-13 in the coagulopathy of sepsis.
Thrombotic Microangiopathies
The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis.
Thrombotic Microangiopathies
The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies.
Thrombotic Microangiopathies
The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry.
Thrombotic Microangiopathies
The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange.
Thrombotic Microangiopathies
Thrombocytopenia in pregnancy.
Thrombotic Microangiopathies
Thrombotic microangiopathic hemolytic anemia with reduction of ADAMTS13 activity: initial manifestation of childhood-onset systemic lupus erythematosus.
Thrombotic Microangiopathies
Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway.
Thrombotic Microangiopathies
Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13.
Thrombotic Microangiopathies
Thrombotic microangiopathies: role of ADAMTS-13.
Thrombotic Microangiopathies
Thrombotic microangiopathy (TTP and HUS): advances in differentiation and diagnosis.
Thrombotic Microangiopathies
Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis.
Thrombotic Microangiopathies
Thrombotic microangiopathy due to malignant hypertension complicated with late-onset bleeding after renal biopsy.
Thrombotic Microangiopathies
Thrombotic microangiopathy in a 17-year-old patient: TTP, HUS or a bit of both?
Thrombotic Microangiopathies
Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/ thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other?
Thrombotic Microangiopathies
Thrombotic microangiopathy with acquired deficiency in ADAMTS 13 activity in lung transplant recipients.
Thrombotic Microangiopathies
Thrombotic Microangiopathy: Current Knowledge and Outcomes With Plasma Exchange.
Thrombotic Microangiopathies
Thrombotic thrombocytopenic purpura as a rare cause of anemia with thrombocytopenia in childhood: report of 2 cases.
Thrombotic Microangiopathies
Thrombotic Thrombocytopenic Purpura in a Child Treated for Acute Lymphoblastic Leukemia: Case Report and Review of Literature.
Thrombotic Microangiopathies
Thrombotic Thrombocytopenic Purpura in a ChildWithSystemic Lupus Erythematosus.
Thrombotic Microangiopathies
Thrombotic thrombocytopenic purpura--a syndrome caused by multiple pathogenetic mechanisms.
Thrombotic Microangiopathies
Thrombotic thrombocytopenic purpura-what is new?
Thrombotic Microangiopathies
Thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine.
Thrombotic Microangiopathies
Treatment of thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Treatment with or without plasma exchange for patients with acquired thrombotic microangiopathy not associated with severe ADAMTS13 deficiency: a propensity score-matched study.
Thrombotic Microangiopathies
Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.
Thrombotic Microangiopathies
Update on ADAMTS13 and VWF in cardiovascular and hematological disorders.
Thrombotic Microangiopathies
Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy.
Thrombotic Microangiopathies
Validation of the PLASMIC score, a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis, in Chinese patients.
Thrombotic Microangiopathies
Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure.
Thrombotic Microangiopathies
von Willebrand factor and thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience.
Thrombotic Microangiopathies
Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory.
Thrombotic Microangiopathies
von Willebrand factor-cleaving protease (ADAMTS13) in the course of stem cell transplantation.
Thrombotic Microangiopathies
Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy.
Thrombotic Microangiopathies
Von Willebrand factor-cleaving protease activity in thrombotic microangiopathy: first report from iran.
Thrombotic Microangiopathies
VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.
Thrombotic Microangiopathies
What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura.
Thrombotic Microangiopathies
[ADAMTS13, von Willebrand factor specific cleaving protease].
Thrombotic Microangiopathies
[Clinical observation of a patient with thrombotic thrombocytopenic purpura with renal and intestinal lesions].
Thrombotic Microangiopathies
[Development of a novel ADAMTS13 activity assay for diagnosis of TMA and criteria for judgment of platelet transfusion]
Thrombotic Microangiopathies
[Diagnosis and treatment of thrombotic thrombocytopenic purpura].
Thrombotic Microangiopathies
[Expression of the metalloproteinase domain of von Willebrand factor-cleaving protease and preparation of its McAb]
Thrombotic Microangiopathies
[Frontline clinical practice for thrombotic thrombocytopenic purpura].
Thrombotic Microangiopathies
[Measurement of plasma von Willebrand factor cleaving protease in patients with varied thrombotic microangiopathy]
Thrombotic Microangiopathies
[Post-transfusion acute lung injury (Trali) after plasma infusion in a patient having a constitutional thrombotic microangiopathy]
Thrombotic Microangiopathies
[Thrombotic microangiopathy after extracorporeal circulation : Important differential diagnosis.]
Thrombotic Microangiopathies
[Thrombotic microangiopathy: thrombocytopenia and hemolytic anemia]
Thrombotic Microangiopathies
[Thrombotic thrombocytopenic purpura: Do not ignore cardiac involvement.]
Thrombotic Microangiopathies
[Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point].
Thyrotoxicosis
Thrombotic thrombocytopenic purpura precipitated by thyrotoxicosis.
Toxoplasmosis
Increased expressions of ADAMTS-13 and apoptosis contribute to neuropathology during Toxoplasma gondii encephalitis in mice.
Transfusion-Related Acute Lung Injury
[Post-transfusion acute lung injury (Trali) after plasma infusion in a patient having a constitutional thrombotic microangiopathy]
Unconsciousness
Acquired thrombotic thrombocytopenic purpura with a smoldering clinical course.
Vascular Diseases
Inverse correlations between serum ADAMTS13 levels and systolic blood pressure, pulse pressure, and serum C-reactive protein levels observed at a general health examination in a Japanese population: A cross-sectional study.
Vascular Diseases
Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation.
Vascular Diseases
Quantitative and qualitative changes of von Willebrand factor and their impact on mortality in patients with end-stage kidney disease.
Vascular System Injuries
ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
Vascular System Injuries
ADAMTS13--more than just TMA and TTP.
Vascular System Injuries
Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis.
Vascular System Injuries
Binding of von Willebrand factor cleaving protease ADAMTS13 to Lys-plasmin(ogen).
Vascular System Injuries
Characterization of the interactions of ADAMTS13 CUB1 domain to WT- and GOF-Spacer domain by molecular dynamics simulation.
Vascular System Injuries
Complement activation associated with ADAMTS13 deficiency may contribute to the characteristic glomerular manifestations in Upshaw-Schulman syndrome.
Vascular System Injuries
Conformational plasticity of ADAMTS13 in hemostasis and autoimmunity.
Vascular System Injuries
Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets.
Vascular System Injuries
Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease.
Vascular System Injuries
Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.
Vascular System Injuries
Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models.
Vascular System Injuries
Proteolytic inactivation of ADAMTS13 by thrombin and plasmin.
Vascular System Injuries
Thrombogenesis and thrombotic disorders based on 'two-path unifying theory of hemostasis': philosophical, physiological, and phenotypical interpretation.
Venous Thromboembolism
ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.
Venous Thromboembolism
Increased ADAMTS13 activity in patients with venous thromboembolism.
Venous Thromboembolism
Verification of the Role of ADAMTS13 in the Cardiovascular Disease Using Two-Sample Mendelian Randomization.
Venous Thrombosis
ADAMTS-13-VWF axis in sickle cell disease patients.
Venous Thrombosis
ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis.
Venous Thrombosis
Changes in von Willebrand factor and ADAMTS-13 in patients following arthroplasty.
Venous Thrombosis
Influence of ADAMTS13 deficiency on venous thrombosis in mice.
Venous Thrombosis
Low ADAMTS13 levels are associated with venous thrombosis risk in women.
Venous Thrombosis
Macrovascular thrombosis in critically ill patients with thrombotic micro-angiopathies.
Venous Thrombosis
Next-Generation Sequencing and In Vitro Expression Study of ADAMTS13 Single Nucleotide Variants in Deep Vein Thrombosis.
Venous Thrombosis
Next-generation sequencing study finds an excess of rare, coding single-nucleotide variants of ADAMTS13 in patients with deep vein thrombosis.
Venous Thrombosis
Polymorphisms and Mutations in vWF and ADAMTS13 Genes and Their Correlation With Plasma Levels of FVIII and vWF in Patients With Deep Venous Thrombosis.
Venous Thrombosis
The role of von Willebrand factor in hemorrhagic and thrombotic disorders.
Venous Thrombosis
Von Willebrand factor:antigen and ADAMTS-13 level, but not soluble P-selectin, are risk factors for the first asymptomatic deep vein thrombosis in cancer patients undergoing chemotherapy.
Virus Diseases
A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infection.
Virus Diseases
ADAMTS13 Levels in Young Patients With ?-Thalassemia Major: Relation to Hepatitis C Virus Infection, Liver Cirrhosis, and Iron Overload.
Virus Diseases
Biomarkers of endothelial activation/dysfunction in infectious diseases.
Virus Diseases
Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review.
von Willebrand Disease, Type 1
An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13.
von Willebrand Disease, Type 1
Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin.
von Willebrand Disease, Type 1
The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype.
von Willebrand Disease, Type 2
A common mechanism by which type 2A von Willebrand disease mutations enhance ADAMTS13 proteolysis revealed with a von Willebrand factor A2 domain FRET construct.
von Willebrand Disease, Type 2
Simultaneous Exposure of Sites in von Willebrand Factor for Glycoprotein Ib Binding and ADAMTS13 Cleavage: Studies With Ristocetin.
von Willebrand Disease, Type 2
The effect of exercise on von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease.
von Willebrand Disease, Type 3
ADAMTS-13 and bleeding phenotype in von Willebrand disease.
von Willebrand Disease, Type 3
Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease.
von Willebrand Diseases
A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE.
von Willebrand Diseases
A common mechanism by which type 2A von Willebrand disease mutations enhance ADAMTS13 proteolysis revealed with a von Willebrand factor A2 domain FRET construct.
von Willebrand Diseases
A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B.
von Willebrand Diseases
ADAMTS-13 activity in von Willebrand disease.
von Willebrand Diseases
ADAMTS-13 and bleeding phenotype in von Willebrand disease.
von Willebrand Diseases
ADAMTS13 unbound to larger von Willebrand factor multimers in cryosupernatant: implications for selection of plasma preparations for thrombotic thrombocytopenic purpura treatment.
von Willebrand Diseases
An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13.
von Willebrand Diseases
Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein.
von Willebrand Diseases
C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand factor.
von Willebrand Diseases
Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin.
von Willebrand Diseases
Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13.
von Willebrand Diseases
Higher and lower active circulating VWF levels: different facets of von Willebrand disease.
von Willebrand Diseases
Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
von Willebrand Diseases
Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease.
von Willebrand Diseases
Platelet-free shear flow assay facilitates analysis of shear-dependent functions of VWF and ADAMTS13.
von Willebrand Diseases
Shear stress and von Willebrand factor in health and disease.
von Willebrand Diseases
Simultaneous Exposure of Sites in von Willebrand Factor for Glycoprotein Ib Binding and ADAMTS13 Cleavage: Studies With Ristocetin.
von Willebrand Diseases
The effect of exercise on von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease.
von Willebrand Diseases
The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype.
von Willebrand Diseases
Type 1 von Willebrand disease: a possible novel mechanism.
von Willebrand Diseases
Type 2 A (group II) von Willebrand disease mutations increase the susceptibility of VWF to ADAMTS-13.
von Willebrand Diseases
Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.
von Willebrand Diseases
von Willebrand factor and von Willebrand disease.
von Willebrand Diseases
[A2 domain of human von Willebrand factor expressed in e. Coli and its biological activity.]
von Willebrand Diseases
[Increased susceptibility of recombinant type 2A von Willebrand factor mutant A1500E to proteolysis by ADAMTS13].
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3.4.24.87 ADAMTS13 endopeptidase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
